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1. The innate immune system 
1.1 The complement system 
 
The complement system forms the first innate defense mechanism against 
pathogens before adaptive immune responses takes place. In this function it helps to 
trigger the opsonization and neutralization of these pathogenic agents (Zundel et al., 
2004). The term “complement” was introduced 1890 by Paul Ehrlich. 
The complement system consists of more than 60 (Zipfel and Skerka, 2009) 
components including recognition molecules with effector or control-function (Krarup 
et al., 2004). Within this system, the molecules are arranged in complexes with 
proteolytic enzymes and non-enzymatic proteins (Wittenborn et al., 2010).  
Three different pathways are able to activate the complement system: (I) the 
classical pathway, (II) the alternative pathway and (III) the lectin pathway. 
All three pathways have in common that they activate the molecule C3 and 
subsequently form the C3 convertase (C4bC2a) (see Fig. 1). 
 
 
 
 
Figure 1: Overview complement pathways.  
Three pathways of protein and proteases cascades are known to activate the complement system. 
These are the classical, the lectin and the alternative pathway of complement activation. All of them 
contribute to the clearing of invading pathogens (Modified after Fujita, 2002. Nature Reviews 
Immunology, 2, 346-353).   
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(I) Classical pathway 
 
The classical pathway is characterized by the involvement of antibodies (adaptive 
immunity). Here an antigen is recognized by an antibody, which in turn is bound by 
the collectin C1q. C1q later activates the associated serine proteases, first C1r, than 
C1s. C1r mediates the internal activation of this new built C1 complex, which starts 
the complement cascade. When C1s is activated, C4 and C2 can be cleaved to 
generate C3 convertase (C4bC2a) (Zundel et al., 2004). This convertase cleaves the 
molecule C3. As a result C3 becomes activated and the resulting C3b fragment 
initiates the formation of the final membrane attack complex, consisting of the 
complement factors C5 to C9.  Besides this function, C3b also acts as an opsonin, 
through directly marking the pathogen itself (Miller et al., 1968; Levinsky et al., 1978; 
Matsushita, 2010). 
Interestingly, C1q also shows binding to C-reactive protein (CRP), which in return is 
bound to the surface of microorganism. Thereby the complement system is also 
activated via the classical pathway. 
The classical pathway is regulated by C1 inhibitor (C1INH), via binding to the serine 
proteases C1s and C1r. This inhibitor also is known to bind to the serine proteases 
of the lectin pathway - MASP-1 and MASP-2 - but not to MASP-3 (Petersen et al., 
2000). 
 
(II) Alternative pathway 
 
The theory of this alternative complement pathway, additional to the classical 
pathway, was proposed by Pillemer (Klein, 1982). 
The alternative pathway of the complement system is characterized by activation in 
the absence of immunoglobulins. 
The molecules of the alternative pathway are C3, properdin, factor B, factor D, and 
proteins for regulation (Matsushita, 2010). So far it seems that MBL and MASPs (e.g. 
MASP-1) activate not only the lectin pathway, but also the alternative pathway. In 
this case C2 is not involved (Selander et al., 2006).  
 
(III) Lectin pathway 
 
The lectin pathway of the complement system is initiated via binding of ficolins 
(lectins) or MBL (collectin) to carbohydrate or other patterns on microorganism. 
Binding of MASPs to these recognition molecules leads to phagocytosis and killing of 
these pathogens by the complement system. This activation is triggered by different 
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complex formations between ficolins or MBL and MASPs (Endo et al., 2010). This 
pathway of the complement activation was first discovered by the interaction of MBL 
with MASPs (Matsushita, 1996; Gadjeva et al., 2001; Fujita, 2002). MBL leads to 
opsonization of the pathogen and thereby initiates further clearance by neutrophils 
(Miller et al., 1968; Levinsky et al., 1978).  
Also, ficolin forms complexes with serine proteases. Binding of ficolin (in human: M-, 
L- and H-ficolin, in other mammalians: Ficolin A and B) to patterns on microbial 
surfaces and subsequent binding of MASPs leads to activation of the protease 
(Schwaeble et al., 2002). Activated MASP further initiates the complement cascade 
of the lectin pathway via binding to complement factor C4. 
Historically, the lectin pathway was discovered later than the classical and alternative 
pathways. The existence of a third pathway was assumed when recognizing that 
pathogens are also detected, when antibodies (classical) were absent, and 
mechanisms unrelated to the alternative pathway were observed (Schwaeble et al., 
2002). Previously, this new complement pathway was called MBL pathway because 
MBL was the first protein discovered to activate this pathway. Later when also 
ficolins were found to interact with MASPs, it was more generally named the lectin 
pathway (Wallis et al., 2010).  
1.2 Activation of the complement system 
 
The classical pathway of complement is activated when C1 proteins bind to an 
antibody-antigen complex. C1 protein is the first molecule to initiate this antibody- 
induced complement pathway. C1 protein consists of the collectin C1q and the 
serine proteases C1s and C1r (Bally et al., 2009). Thereby one C1q molecule is in 
complex with two molecules C1r and two molecules C1s (Basiglio et al., 2009). C1q 
is also able to bind directly to surfaces of pathogens and thereby activating the 
classical pathway independently of antibodies. Also CRP (C-reactive protein), a 
member of the pentraxin family, binds directly to C1q and is therefore also an 
important activator of the classical pathway (Fabian et al., 2006).  
The alternative pathway is activated by the complement factor C3 that is 
spontaneously cleaved into C3a and C3b. C3b acts as an opsonin and binds to the 
surface of pathogenic agents. On this foreign surface C3b stays active and is able to 
bind complement factor B to form the C3 convertase of the alternative pathway. This 
complex is very weak and has to be stabilized by binding through properdin. Binding 
of properdin initiates the alternative pathway, which is therefore also called the 
properdin-pathway of complement activation. The lectin pathway of the complement 
system is activated via binding of MBL or ficolin to one of three serine proteases 
(MASP), that in turn initiate the lectin pathway of the complement system. Each 
  4 
complement pathway contributes to the defense against invading microbes, as well 
as to the clearance of dead cells via building a terminal membrane attack complex 
(MAC). This complex was also formerly known as terminal complement complex 
(TCC), leading to cell lysis. Beyond that complement is involved in other non-
immune functions.  
1.3 Regulation of the complement system 
 
Via complement activation a strong immune response is initiated that needs to be 
tightly regulated and stopped after successful clearance to avoid overreaction and 
cell- and tissue-damage due to inflammation. During complement activation pro-
inflammatory mediators are activated, the anaphylatoxins, that need to be controlled. 
Dysfunctions in complement regulation can lead to diseases. Activation and 
inhibition must be strictly balanced. These regulators and inhibitors engage at 
different stages in the complement cascade (Zipfel and Skerka, 2009) (see Fig. 2).   
The complement system itself is able to regulate its response by adjusting the 
reaction to each appropriate situation. Hence, it is able to modulate the intensity of 
the reaction in a self-controlled manner (Zipfel and Skerka, 2009). One way by which 
the complement can be efficiently regulated are inhibitors that bind directly to the 
component that first initiates the cascade. C4b-binding-protein (C4BP) and factor H 
behave like this (Sjöberg et al., 2008). Some complement activators, like CRP, also 
interact directly with complement regulators. For example CRP is found to cooperate 
with inhibitors like factor H and C4BP (Sjöberg et al., 2008). Factor H and C4BP are 
so called fluid phase inhibitors of the complement system. They are also associated 
with dying host cells and found to bind to apoptotic cells. This is important, because 
these dying cells down-regulate their membrane bound complement inhibitors to 
signal for phagocytosis. Normally, each host-cell expresses more or less membrane-
bound molecules on its surface to inhibit unwanted complement activation. Such a 
molecule is for example CD46. Binding of inhibitors does not totally block the 
complement activity but enables opsonization and dampens the immune response to 
avoid massive complement activation and cell lysis (Sjöberg et al., 2008).  
An important control to avoid destruction of intact host cells by complement is 
managed by a combination of integral proteins, as well as surface attached and fluid-
phase control molecules (Zipfel and Skerka, 2006). Most pathogens however 
prevent detection by the complement system through binding to complement 
inhibitors or they protect themselves by capturing C4BP and factor H (Zipfel and 
Skerka, 2006). Summarized, complement regulators can be divided into three 
groups: (I) fluid-phase, (II) surface-attached and (III) membrane-integral regulators. 
Factor H, FHL1 and properdin (itself also an activator protein) belong to the group of 
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fluid-phase control proteins (Zipfel and Skerka, 2006). Responsible for partly 
inactivation of the anaphylatoxins is Carboxipeptidase N. C1-Inhibitor (C1INH) is a 
regulator protein for the classical- and the lectin pathway. The same is the case for 
C4BP (Zipfel and Skerka, 2006). Regulator proteins that interfere during the terminal 
processes are CFHR1, clusterin and vitronectin (Zipfel and Skerka, 2006). Fluid 
phase regulators are more specific, compared to e.g. the membrane integral proteins 
by controlling either the classical, the alternative, or the lectin pathway. Membrane-
integral proteins are CR1, CR2, CD55 and CD46. These molecules are inhibitors for 
all three complement pathways. CR1 and CD46 for example inactivate C3 and C4. 
Some fluid phase regulators are also shown to act as surface-attached regulators. 
These are factor H, FHL1, C4BP, CFHR1, clusterin, and vitronectin. (Zipfel and 
Skerka, 2006). 
 
 
 
Figure 2: Activation and regulation of the complement system.  
The complement system is a highly specific and strong system to eliminate pathogens. Due to this, 
activation must be strictly regulated by different effector molecules. (Modified after Francis et al., 
2003). 
 
1.4 Complement-dependent diseases 
 
When activation and/or regulation of the complement cascade are disturbed 
complement diseases can occur (see Fig. 3). Many of them occur when one or more 
complement factors are deficient. Many diseases are connected with failures of the 
regulator proteins factor H and C1-inhibitor or with problems concerning the basic 
complement components C2, C3, and C4. Diseases that are often connected with 
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dysfunctional complement components are autoimmune diseases, cancer, or 
problems with infectious pathogens (Zipfel and Skerka, 2006).  
 
 
 
Figure 3: Complement regulators and failures in regulation.  
Failures in complement activation and/or complement regulation often trigger complement diseases. 
(Modified after Zipfel and Skerka, 2009).  
 
1.5 Cell surface receptors 
 
Receptors expressed on the surface of cells, also called membrane or 
transmembrane receptors, are specialized in recognition of pattern-like structures 
and represent a connection between cell-inside and cell-outside.  
 
1.5.1 Scavenger receptors 
 
Scavenger receptors (see Fig. 4), or lipoprotein receptors, are a group of proteins 
that function in recognition of low density lipoprotein (LDL). These receptors are 
widely expressed on surfaces of cells (Dieckmann et al., 2010). They bind to 
molecules with a negative charge or to modified LDLs. They possess a role in 
cleaning (also called “scavenging”) by taking up and removing these molecules. 
These molecules include for example proteases or protease inhibitors from cell 
surfaces or from the environment. In this way they are also important in sensing the 
extracellular environmental situation (Dieckmann et al., 2010). 
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With regard to their structure, they are divided into group A, B-, and C-scavenger 
receptors. They are also distinguished by their uptake or non-uptake of the 
lipoprotein. The first group internalizes the lipoproteins and the second group 
promotes lipid exchange at the plasma, without taking it up (Dieckmann et al., 2010).  
 
 
 
Figure 4: Overview the scavenger receptor family members.  
Molecules of the scavenger receptor family contribute to immune responses against pathogens by 
recognition of patterns associated with these pathogens. (Modified after Moore and Freeman, 2006).    
 
1.5.2 C-type lectin receptors (CLRs) 
 
C-type lectin receptors are a heterogeneous group of molecules, located on the 
membrane of cells (see Fig. 5). Myeloid cells often express these receptors.  
The name “C-type” came up by the characteristics of these proteins to be calcium- 
dependent binding lectins, compared to other lectins, which are Ca2+-independent 
(Zelensky and Gready, 2005). Now the term C-type lectin is more generally used for 
proteins with a carbohydrate recognition domain (CRD) (Cambi et al., 2007), a 
structural feature common for members of these group. Proteins belonging to this 
group of recognition receptors are able to detect carbohydrates in a calcium-
dependent or calcium-independent manner (Cambi et al., 2007). Protein families 
belonging to these receptors are defensins as well as collectins including the well-
known member MBL.  
The first discovered receptors to bind to bacteria, fungi and viruses were molecules 
of the mannan-receptor family (Ley and Kansas, 2004), DEC-205 and Langerin 
(Zelensky and Gready, 2005). Other groups within the C-type lectins are the 
selectins (Ley and Kansas, 2004) and the collectins, with selectins more responsible 
for cell-cell functions and collectins, e.g. MBL, specialized in pathogen recognition.  
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Soluble collectins are structurally characterized by forming trimers, which in turn form 
higher oligomers. This multimerization helps to effectively bind patterns on microbes 
(Cambi et al., 2005). These receptors are able to act as endocytic recognition 
receptors to mediate the uptake of the pathogen or of altered host-cells. Upon this, 
they can initiate destruction of the particle or antigen presentation to T cells (Osorio 
and e Sousa, 2011). C-type lectins were found to sense cell death by binding to 
products from these cells. C-type lectins are localized on the cell membrane or they 
are found as soluble recognition receptors (Cambi and Figdor, 2009). Members of 
the transmembrane receptor group are divided into two subgroups, depending on the 
orientation of their N-terminus. Type-I transmembrane receptor proteins are 
characterized by the N-terminus pointing outwards of the cytoplasm. In the case of 
Type-II transmembrane receptor proteins the N-terminus points inwards in the 
cytoplasm (Cambi and Figdor, 2009).  
With regard to pathogen recognition C-type lectins often collaborate with other 
receptors, such as the Toll-like receptors (TLRs). Besides functioning as a pattern 
recognition receptor C-type lectin receptors are also involved in dampening or 
alterating myeloid cell activation (Osorio and e Sousa, 2011). 
 
 
 
Figure 5: C-type lectin receptors on dendritic cells and Langerhans cells.  
C-type lectin receptors are a group of molecules contributing to pathogen recognition and trigger 
thereby the elimination of microorganisms (modified after Figdor et al., 2002). 
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1.5.3 Toll-like receptors (TLRs) 
 
Toll-like receptors are key molecules of the innate and the adaptive immune system 
recognizing patterns on invading pathogens and thereby initiating signal transduction 
cascades that subsequently lead to the expression of appropriate genes. These 
signaling pathways are regulated by TIR domain-containing adaptors such as 
MyD88, TRIF and TRAM (Takeda and Akira, 2005). The name TIR-domain is based 
on the similarity of the cytoplasmic tail between the members of the TLR- and the IL-
1-family (Takeda and Akira, 2005). The term Toll-like receptor developed from the 
recognition molecule Toll in Drosophila melanogaster (Tukhvatulin et al., 2010), 
which binds to fungi (Lemaitre et al., 1996). Later homologues of this receptor were 
discovered in mammalians and named Toll-like-receptors. This first characterized 
mammalian TLR was termed TLR4 (Takeda and Akira, 2005). The mammalian TLR 
family consists of at least 11 structurally related proteins, with TLR1 to TLR9 rather 
conserved between human and mouse. TLR10 is assumed to be non-functional in 
the mouse and TLR11 seems to be active in the mouse but, due to a stop-codon, 
without function in the human system. Individual TLRs are able to recognize patterns 
on pathogens like bacteria, fungi, protozoa and viruses (Takeda and Akira, 2005).  
TLR1 is expressed on the cell surface and recognizes structures of Gram-positive 
bacteria (Takeuchi et al., 2002; Lien et al., 2002).  
TLR2 binds to lipoproteins from various microbes, as well as peptidoglycan and 
lipoteichoic acid from Gram-positive bacteria (Hirschfeld et al., 2001; Werts et al., 
2001; Smith et al., 2003). It also recognizes LPS from non-enterogenic bacteria. This 
is interesting because this form of polysaccharide differs from the LPS detected by 
TLR4 (Netea et al., 2002). TLR2 is structurally related to TLR1 and TLR6 and forms 
heterophilic dimers with these TLRs but also with others. TLR2 is also expressed on 
the cell surface. 
TLR3, which is expressed in intracellular compartments, recognizes double-stranded 
RNA (dsRNA) and viruses. However, TLR3-independent mechanisms of dsRNA 
recognition exist (Takeda and Akira, 2005).  
Essential for detection of bacterial lipopolysaccharide (LPS) is TLR4 (Poitorak et al., 
1998; Hoshino et al., 1999). Expression of TLR4 is found on cell surfaces.  Due to 
the fact that LPS is a very potent activator of an inflammatory immune reaction, only 
a small amount of LPS is necessary to trigger a response.  
The receptor TLR5 binds to flagellin, which is a monomeric constituent of bacterial 
flagella (Hayashi et al., 2001). TLR5 is expressed by epithelial cells (Gewirtz et al., 
2001; Maaser et al., 2004).  
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TLR7 and human TLR8, both expressed in intracellular compartments, recognize a 
nucleic acid-like structure on viruses, more specific guanoside or uridine-rich single-
stranded RNA (ssRNA), e.g. from human immunodeficiency virus (HIV), vesicular 
stomatitis virus (VSV), and influenza virus (Heil et al., 2004; Diebold et al., 2004; 
Lund et al., 2004). Host-derived ssRNA is not detected because this RNA is not 
transported to the endosome, where both TLRs are expressed. 
TLR9 is a receptor for both, bacterial and viral CpG-rich DNA (Hemmi et al., 2000). 
Due to the recognition of the chromatin structure, TLR9 seems to be involved in 
autoimmune diseases. Also, TLR9 expression is found in intracellular compartments. 
TLR11 is a functional receptor in mice even if its ligand is not identified yet (Takeda 
and Akira, 2005). The human homologue to mouse TLR11 is non-functional and 
became maybe lost during evolution (Zhang et al., 2004). 
TLRs are also able to sense danger signals via recognition of alarmins, e.g. heat 
shock proteins, whose concentration is increased in the intracellular space in this 
situation (Tukhvatulin et al., 2010). Alarmins belong to the group of damage-
associated molecular patterns (DAMPs).  
 
1.5.4 Soluble pattern recognition receptors (PRR) 
 
Soluble or secreted pattern recognition receptors are molecules that do not remain 
associated with the cell expressing them. 
1.5.4.1 MBL and MASPs 
 
1.5.4.1.1 Human MBL 
 
Mannan binding lectin (MBL, see Fig. 6 and 7) is an archetypical molecule for 
recognition of invading pathogens (Jensenius et al., 2009). It is named Mannan- (or 
also Mannose-) binding lectin, because the protein was first discovered through its 
interaction with this yeast polysaccharide (Kawasaki et al., 1978; Kawasaki et al., 
1983). Mannan is a polymer of the sugar mannose. But MBL is not particular 
selective for this sugar (Jensenius et al., 2002); it also binds to D-mannose, N-acetyl-
D-glucosamine, D-glucose, L-fucose, but not to D-galactose (Weis et al., 1992; 
Wallis, 2002).  
In humans, two MBL genes are known: MBL-1 and MBL-2, where active MBL is 
encoded by MBL-2 gene and MBL-1 is a pseudo gene. Additionally MBL protein is 
divided in two classes respective to its oligomerization: a lower-oligomer (MBL-I) and 
a higher oligomeric form (MBL-II). MBL belongs to the acute phase proteins, but the 
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increase in this phase is not more than threefold compared to normal MBL-
concentrations (Holmskov et al., 2003). Further, MBL belongs to the family of 
collectins due to its collagen domain, while ficolins are lectins.  
Other collectins are the surfactant proteins SP-A and SP-D, CL-P1, CL-K1, Cl-L1 
and conglutinin (Kilpatrick, 2007). All collectins recognize cell wall components in 
bacteria: lipoteichic acid in Gram-positive and lipopolysaccharide in Gram-negative 
bacteria (Polotsky et al., 1996; Holmskov et al., 2003). 
MBL reacts with pathogens like bacteria, fungi, viruses, and protozoa (Turner and 
Hamwas, 2000). Some bacteria seem to avoid their recognition by MBL or lectins 
with the help of their capsule (Holmskov et al., 2003). 
The broad binding specificity of MBL is due to the fact that it binds to repeating sugar 
structures found on these pathogens (Miller et al., 1968; Levinsky et al., 1978) but 
not on mammalian cells (Eisen and Minchinton, 2003; Sorenson et al., 2005). MBL is 
also able to detect viruses like HIV-1 and HIV-2  (Haurum et al., 1993) and binds to 
parasites like leishmania promastigotes (Green et al., 1994). Oligomerization of MBL 
is crucial for its biological function and activation of the complement system (Larsen 
et al., 2004; Jensen et al., 2005; Teillet et al., 2005). MBL-II in humans is the higher 
oligomeric form of MBL, which seems to mainly interact with MASP-2 and activates 
thereby the complement (Dahl et al., 2001).  
 
 
 
Figure 6: CRDs and MBL structure. 
(modified after Jensenius et al., 2009) 
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Figure 7: Tetrameric strcuture of human MBL. 
(Modified after Turner, 2002) 
 
1.5.4.1.2 Mouse MBL 
 
In contrast to the human system, in mice two forms of MBL exist, namely MBL-A and 
MBL-C (Ihara et al., 1991; Hansen and Holmskov, 1998). Both proteins are 
distinguished by their distribution: MBL-A is found in serum, while MBL-C is found in 
the liver (Oka et al., 1998). In the year 2000, Hansen et al. described that both forms 
are detectable in serum (Hansen et al 2000). Structurally it is assumed that mouse 
MBL-C forms higher oligomeric forms compared to MBL-A (Liu et al., 2001). Human 
MBL was shown to be an acute phase protein. Investigations in the mouse system 
revealed that mouse MBL-A shows a mild acute phase response, whereas mouse 
MBL-C had no effect (Liu et al., 2001). MBL-C is highly sensitive to proteolytic 
degradation (Hansen et al., 2000). Both forms of mouse MBL are able to activate 
complement factor C4 to mediate complement activation via the lectin pathway 
(Hansen et al., 2000). 
 
1.5.4.1.3 MBL-associated serine proteases (MASPs) 
 
Because only discovered in 1992 (Matsushita and Fujita, 1992) together with MBL 
these proteases are called MBL-associated serine proteases (MASPs) (Schwaeble 
et al., 2002). The MASP family consists of MASP-1, MASP-2, MASP-3 and 
additionally MAp19. MAp19 is a non-enzymatic protein of 19kDa, also called sMAP. 
All members of the MASP family show a domain structure similar to other factors of 
the complement system: C1r and C1s. MASP-1 and MASP-3 originate from a 
common MASP-1/-3 gene and are produced by alternative splicing. In the same 
manner, MASP-2 and MAp19 evolved as different splice-products from the MASP-2 
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gene. All MASPs exist circulating in serum in two forms: in their inactive and their 
active form. The pro-enzymes, also named “Zymogens”, are proteolytically inactive 
until they are bound to recognition components. After this, they convert to the active 
forms. The site of their enzymatic activity is found in the β-chain of the serine 
proteases (Schwaeble et al., 2002). Pro-enzymes appear in Western blot analysis as 
one polypeptide chain (one band) compared to the active form with two polypeptide 
chains (two bands). The zymogens are mainly found in complexes with MBL or 
ficolins. Complexes between MASPs and ficolins are more often seen than MASP-
MBL connections. It is discussed that MASPs are more bound to low MBL oligomers 
(Sorensen et al., 2005). The MBL-MASP-complex seems to be analogous to the C1-
immune-complexes (interaction with Fc-part of IgG or IgM), but it differs in function 
as well as in composition.  
In solution MASPs dimerize and this formation is calcium-dependent (Sorensen et 
al., 2005). MASPs of humans, mice and rats are structurally related proteins.  
 
1.5.4.1.3.1 Human MASP-1  
 
Human MASP-1 was first isolated from human serum complexed with MBL by affinity 
chromatography. A mannan-sepharose column was used under calcium-containing 
conditions, based on the fact that MASP dimerization is dependent on the presence 
of calcium (Sorensen et al., 2005). Human MASP-1 is encoded by a 680aa 
polypeptide chain and a leader peptide of 19aa. The protein is generated by 
alternative splicing from a common MASP-1/-3 gene (see Fig. 8). The calculated 
molecular weight of the MASP-1 zymogen is 76kDa. 
MASP-1 in the human system possesses four N-linked glycosylation sites. 
Regarding to its protease activity, it seems to cleave C2 but not C4. However, it also 
cleaves C3 even though with lower efficiency, and thereby may activate C3 directly. 
MASP-1, therefore, also activates the alternative pathway of complement activation. 
Recombinant human MASP-1 was demonstrated to activate and cleave C3 only 
marginally (Rossi et al., 2001; Ambrus et al., 2003). Beside this, MASP-1 is able to 
activate MASP-2 within a MASP-2/MBL-complex (Takahashi et al., 2008). The 
production of recombinant human MASP-1 from plasma is described by Thielens et 
al. in 2001 (Thielens et al., 2001).  
  14 
 
 
 
Figure 8.: Exon structure of human MASP-1 protein. 
(Modified after Schwaeble et al., 2002) 
 
1.5.4.1.3.2 Human MASP-2 
 
The exon of the second human MASP, MASP-2, encodes a polypeptide of 671aa 
and a leader peptide of 15aa (see Fig. 9). The only mRNA expression site in human 
as well as in mice is the liver, like in the case of MAp19 (Knittel et al., 1997). The 
observed mass in immunoblot analysis is 74kDa, which is consistent to the 
calculated molecular weight. Compared to MASP-1, human MASP-2 offers no 
putative N-linked glycosylation site.  
In contrast to MASP-1, human MASP-2 cleaves C2 and also C4 (Matsushita et al., 
2001) and so performs as a monomer the same function as C1q and C1s in the 
classical complement pathway (Sorensen et al., 2005; Vorup-Jensen et al., 2000). 
This proteolytic activity is inhibited by C1-inhibitor (Matsushita et al., 2000; Petersen 
et al., 2000). So far it seems that only MASP-2 protein is required for activation of the 
lectin pathway. This is assumed because the lack of both MASP-1 and MASP-3 
showed no difference for complement activation in mouse studies (Takahashi et al., 
2000). MASP-2 is not only able to cleave C4 but also C2 to form C3 convertase 
(Rossi et al., 2001). The enzymatic activity for C2 is comparable to C1s, but MASP-2 
is 40 times more efficient in cleaving C4. C1s is a component of the classical 
complement pathway and forms complexes with C1r (Rossi et al., 2001).  
Beside this, MASP-2 might also show proteolytic activity within the coagulation 
system. It is assumed to participate in activation of the blood coagulation system 
through binding and inducing cleavage of pro-thrombin (Krarup et al., 2007). 
Nevertheless, MASP-2 also reveals auto-activation (Sorensen et al., 2005). 
Production of recombinant MASP-2 is described by Cseh et al., 2002; Rossi et al., 
2001). 
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Figure 9: Exon structure of human MASP-2 protein.  
(Modified after Schwaeble et al., 2002) 
 
1.5.4.1.3.3 Human MASP-3 
 
The exon of human MASP-3 encodes a polypeptide chain of 709aa, excluding a 
leader sequence of 19aa (see Fig. 10). The calculated molecular weight of the pro-
enzyme is 81kDa. There are seven putative N-linked glycosylation sites in MASP-3. 
A common MASP-1/-3 gene encodes MASP-3 and the protein is produced by 
alternative splicing (Dahl et al., 2001; Endo et al., 2003).  
Human MASP-3 mRNA expression is found in the liver and in non-hepatic tissues, 
including spleen, lung, and brain. The question came up, whether human astrocytes 
are a source of MASP-3 mRNA (Kuraya et al., 2003). Expression is also found in the 
small intestine and thymus (Lynch et al., 2005). So far, no substrate for human 
MASP-3 is known and, therefore, a synthetic substrate was used to investigate its 
proteolytic activity (Zundel et al., 2004). In contrast to the other two MASPs, 
activated MASP-3 exhibits no proteolytic activity towards either C2, C3, or C4 
(Zundel et al., 2004). 
Unlike MASP-2 (Vorup-Jensen et al., 2000; Rossi et al., 2001) and also MASP-1 
(Zundel et al., 2004), human MASP-3 does not auto-activate spontaneously or self- 
activates in experiments using recombinant MASP-3 (Zundel et al., 2004). Also in 
difference to the other MASPs, human MASP-3 is not associated with C1-inhibitor, 
so its activation and regulation seems to differ from MASP-1 and MASP-2 (Zundel et 
al., 2004). Interestingly, MASP-3 shows down-regulatory activity for MASP-2 (Dahl et 
al., 2001). Recombinant, in Insect cells produced human MASP-3 by Zundel et al. 
(Zundel et al., 2004) exists as a homodimer in the presence of calcium and as a 
monomer in the presence of EDTA (Zundel et al., 2004). 
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Figure 10: Exon structure of human MASP-3 protein.  
(Modified after Schwaeble et al., 2002) 
 
1.5.4.1.3.4 Human MAp19 
 
Human MAp19, also named sMAP (small MBL-associated protein), is a truncated 
version of MASP-2 and is generated from the MASP-2/-MAp19 gene by alternative 
splicing (see Fig. 11). The protein polypeptide consists of 185aa with a molecular 
weight of 19kDA. Expression is found in the liver. The protein is more often found 
associated with lower-molecular weight MBL (MBL-I), than with higher oligomers 
(Sorensen et al., 2005). 
 
 
Figure 11: Structure of the common human MAAP-2/Map19 gene.  
(Modified after Endo et al., 2011) 
 
1.5.4.1.3.5 Human MAp44 
 
Human MAp44 is, like MASP-3, also a splice variant of the MASP-1/-3 gene (Degn 
et al., 2010). Expression of MAp44 mRNA is found in high amounts in the heart 
(Degn et al., 2009). Further mRNA expression is detected in the liver, in bladder, 
brain, cervix, colon, and prostate (Degn et al., 2009). MAp44 is found to inhibit 
complement activation via competing with MASP-2 for binding to MBL or ficolins 
(Degn et al., 2009). So it seems, that MAp44 acts as a control molecule in 
complement activation.  
  17 
 
1.5.4.2 Ficolins 
 
Ficolins are proteins that also serve as soluble pattern recognition molecules. They 
are able to recognize pathogens and sense danger signals derived from the host 
(Thielens et al., 2007). The first identified and biochemical characterized ficolin was 
TGFβ-1 by Ichijo in the year 1991 as a protein from porcine uterus (Ichijo et al., 
1991; Ichijo et al., 1993). The Interaction of ficolins with porcine TGF-1 still remains 
unclear (Endo et al., 2005). In the year 1993 pig ficolin-α and ficolin-β were 
characterized also by the group of Ichijo (Ichijo et al., 1993). Since 1991 and the first 
identification and characterization of ficolins (Ichijo et al., 1991), these molecules are 
under investigation by different groups all over the world. Evolution and genetic 
aspects of ficolins are discussed by the English group of Peter Garred (Garred et al., 
2010). Garlatti et al. discuss structural and functional aspects of ficolins (Garlatti et 
al., 2010). The same field is also investigated by Matsushita and his group in Japan 
(Matsushita, 2010). In addition to this, Endo et al. are interested in the interaction of 
ficolins and MBL within the lectin pathway of the complement system and they also 
demonstrate interaction of those lectins with both fibrinogen and fibrin (Endo et al., 
2010). All ficolins and MBL have their structure and some binding specificities in 
common, but they are expressed and distributed in different tissues. Due to that fact 
they may also have tissue-specific functions (Matsushita et al., 2010). Concerning 
their structure, all ficolins consists of a collagen-like and a fibrinogen-like domain 
(see Fig. 12). Thereby the collagen region is responsible for association and binding 
with MASPs. The counterpart to the fibrinogen-like domain in ficolins is the typical C-
type lectin domain in MBL (Le et al., 1998; Sugimoto et al., 1998). 
All so far tested ficolins bind to acetylated groups such as GlcNAc and GalNAc 
(Thiel, 2007). These groups are found on microbes. 
Beside this, ficolins were demonstrated to bind to apoptotic cells (Karaya et al., 
2005; Jensen et al., 2007). 
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Figure 12: Schematically structure of ficolin.  
(Modified after Fujita, 2002). 
 
1.5.4.2.1 Human ficolins 
 
In contrast to other mammalians, in humans three forms of ficolin, instead of two, 
exists. They are named M-ficolin, L-ficolin and H-ficolin. The last one turned out as a 
pseudo-gene in other mammalians (see Fig. 13).  
 
 
 
Figure 13: Overview of the exon structure of human ficolins.  
(Modified after Takahashi, 2008) 
 
1.5.4.2.1.1 Human M-ficolin 
 
Mainly called M-ficolin this ficolin is also known as ficolin 1 or L-ficolin/p35-related 
protein. Human M-ficolin was first identified by genomic DNA and cDNA cloning as a 
by-product during human L-ficolin characterization in 1996 (Endo et al., 1996; Lu et 
al., 1996a). The gene of M-ficolin is FCN1 and it is located on the same chromosome 
as the L-ficolin gene (Endo et al., 1996). M-ficolin mRNA expression was found in 
monocytes, in lung and in spleen (Endo et al., 1996; Lu et al., 1996a; Lu et al., 
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1996b; Teh et al., 2000). However, mRNA was not detectable in macrophages (Lu et 
al., 1996a) or monocytic-derived dendritic cells (Hashimoto et al., 1999). 
On the protein level M-ficolin is found on the surface of blood monocytes and pro-
monocytic U937 cells (Teh et al., 2000). Tu et al. and Endo et al. confirmed 
expression in peripheral blood leucocytes in general and additionally demonstrated 
expression in the lung (Lu et al., 1996a; Endo et al., 1996). Overall, ficolins exists in 
two forms: a serum-type and a cell-associated form. Recent results showed that this 
classification is not that strict, especially with regard to human M-ficolin. M-ficolin 
was believed to be not in the serum. It was found to be a cell-associated lectin (Lu et 
al., 1996a; Endo et al., 1996). Recently however, it also was found in serum although 
in lower concentration compared to the „true“ serum-type lectins H- and L-ficolin 
(Honore et al., 2008; Wittenborn et al., 2010). Nowadays it is possible to identify 
lower protein concentrations with more specific and more sensitive reagents and 
instruments. 
Liu et al. showed in 2005 that human M-ficolin is also a secretory protein (Liu et al., 
2005b). Functionally recombinant human M-ficolin was shown to bind to substrates 
such as N-acetylglucosamine, N-acetylgalactosamine and sialic acid (Liu et al., 
2005b; Frederiksen et al., 2005). 
Human M-ficolin recognizes also sialic acid, like its mouse orthologue Ficolin B (Liu 
et al., 2005b). This is an interesting finding, because sialic acid acts as a receptor for 
molecules involved in regulation of cellular growth, differentiation, cell-cell-interaction 
and adhesion (Sotiropoulou et al., 2002; Holmskov et al., 2003). 
In 2005, different groups were also able to identify binding of M-ficolin to bacteria 
such as Group B Streptococcus (GBS), Staphylococcus aureus or Staphylococcus 
typhimurium (Kjaer et al., 2011; Liu et al., 2005b; Frederiksen et al., 2005). So it is 
also under investigation whether M-ficolin serves as a lectin-like phagocytic receptor 
for pathogens (Teh et al., 2000). Responsible for the binding activity of ficolins is 
their fibrinogen-like domain. The other structural part of ficolin, its collagen like 
region, is necessary for interactions with MASPs in the complement cascade of the 
immune system. Human M-ficolin forms complexes with MASP-1 and MASP-2 and 
thereby activates the lectin pathway (Liu et al., 2005b). M-ficolin is also found 
associated in complexes with MAp19 (Matsushita et al., 2000; Matsushita et al., 
2002; Liu et al., 2005b; Endo et al., 2005). 
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1.5.4.2.1.2 Human L-ficolin 
 
A typical serum-type ficolin is the human L-ficolin encoded by the FCN2 gene. Other 
names are Ficolin-2, P35, EBP-37 or hucolin (Edgar, 1995; Endo et al., 2011). 
Human L-ficolin was first purified from serum by Matsushita et al. (Matsushita et al., 
1996).  
As a humoral factor, L-ficolin is synthesized by hepatocytes and secreted into the 
blood circulation (Sorensen et al., 2005; Matsushita et al., 1996; Akaiwa et al., 1999; 
Yae et al., 1991). In the liver, L-ficolin has three splicing variants (Endo et al., 1996). 
Its smallest subunit is the monomer with a molecular weight of 35kDa (Matsushita et 
al., 1996) and its proposed structure is a tetramer consisting of four triple helices and 
12 subunits (Hummelshoj et al., 2007). Each subunit contains a collagen-like strand 
(N-terminal) consisting of three L-ficolin chains and three C-terminal fibrinogen-like 
regions. These C-terminal recognition domains are necessary for binding to e.g. 
acetylated groups on microbial surfaces (Matsushita et al., 2002; Thiel, 2007). 
L-ficolin is able to recognize acetylated groups, which is common to all ficolins 
(Kraruo et al., 2004; Faro et al., 2008; Krarup et al., 2008). More precise, substrates 
of L-ficolin are GlcNAc (Matsushita et al., 1996), β-1-3-D-glucan (Ma et al., 2004) 
and DNA (Kuraya et al., 2005; Jensen et al., 2007), both found on bacteria. For this 
reason bacterial targets for human L-ficolin were investigated. L-ficolin shows 
binding affinity towards Salmonella typhimurium TV119 (contains a 
lipopolysaccharide with a GlcNAc residue at the non-reducing terminus), Escherichia 
coli, and several serotypes of capsulated Staphylococci or Staphylococcus 
pneumoniae. So far it does not detect strains without a capsule, indicating that L-
ficolin recognizes a pattern within this structure (Matsushita, 2010). Through its 
binding to the pathogen surface, L-ficolin leads to the activation of the lectin 
complement pathway. L-ficolin is also discussed to act as an opsonin to help to 
destroy invading pathogens (Matsushita et al., 1996). 
Additionally to this lectin activity, human L-ficolin has been reported to be able to 
recognize elastin (Harumiya et al., 1995) and corticosteroids (Edgar, 2005).        
L-ficolin shows a broad range of different substrates. Its binding ability is provided by 
four different binding sites, discovered and characterized by Garlatti et al. (Garlatti et 
al., 2007). Human L-ficolin forms complexes with MASPs and also MAp19 
(Matsushita et al., 2000; Matsushita et al., 2002; Liu et al., 2005b; Endo et al., 2005). 
Besides activating the lectin pathway of the complement system by complex 
formation with MASPs, it was shown that human L-ficolin interacts also with C-
reactive protein (CRP) and thereby activates the complement via the classical 
pathway in the absence of immunoglobulins. To do so special conditions of local 
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infection and inflammations are crucial (Zhang et al., 2009). During the last years 
studies revealed a correlation of L-ficolin deficiency with premature, low birth weight 
neonates and prenatal infections (Swierzko et al., 2009). 
  
1.5.4.2.1.3 Human H-ficolin 
 
Additional to the former two ficolins, in humans a third ficolin was characterized, 
which was found to be a pseudo-gene in other mammalians. Like human L-ficolin it 
is also a typical serum-type ficolin. H-ficolin was the first ficolin that was recovered 
already in 1978 by Inaba and Okochi (Inaba and Okochi, 1978). Human H-ficolin is 
also found under following names: ficolin 3, Hakata-Antigen or β2-thermolabile 
Macro glycoprotein. This protein was first observed during a reaction with an 
autoantibody in patients with systemic lupus erythematodes (SLE). Finally, 1998 
human H-ficolin was cloned and characterized (Sugimoto et al., 1998). 
Like all ficolins, also H-ficolins forms higher oligomers and the smallest subunit, 
called a monomer, appears at a size of 34kDa. The FCN3 gene encodes the protein 
and mRNA is expressed in the lung (Akaiwa, 1999) and in the liver (Kuraya, 2003). 
Like all the other ficolins H-ficolin binds to GlcNAc, even if this association is very 
weak compared to the other serum lectin L-ficolin (Garlatti et al., 2007). D-fucose, 
galactose (Girija et al., 2011) and GalNAc are also substrates, but H-ficolin failed to 
bind to mannan or lactose (Sugimoto et al., 1998). Interestingly, the only bacterium 
found to be a target of human H-ficolin is Aerococcus viridians (Tsujimura et al., 
2002). 
Sugimoto et al. could show that H-ficolin is able to agglutinate human erythrocytes 
coated with lipopolysaccharide from different bacterias e.g. Staphylococcus 
typhimurium, Salmonella Minnesota and Escherichia coli (O111) (Sugimoto et al., 
1998). H-ficolin activates the lectin pathway of complement by forming complexes 
with MASPs and with MAp19 (Matsushita et al., 2000, Matsushita et al., 2002, Liu et 
al., 2005b, Endo et al., 2005). 
 
1.5.4.2.2 Mouse ficolins 
 
In the mouse immune system, two ficolins help the body to destroy invading 
pathogens by the recognition of patterns on the microorganisms. In contrast to 
humans, in other mammalians only two ficolins exists named ficolin-A and ficolin-B. 
The orthologue to human H-ficolin was found to be a pseudo-gene. 
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1.5.4.2.2.1 Mouse ficolin-A 
 
The orthologue to the human L-ficolin is mouse ficolin-A. This protein is also found in 
the serum and acts as a serum-type lectin, with mRNA expression in spleen and 
liver, but mainly in liver (Endo et al., 2004). Preferentially mouse ficolin-A protein 
exists in higher oligomers, mainly tetramers, consisting of 12 subunits (Ohashi and 
Erickson, 1998). Like all ficolins it has the capacity for binding to acetylated 
compounds such as GlcNAc (Fujimori et al., 1998, Endo et al., 2004). Due to the 
assumption that ficolin-A in mice is the counterpart to L-ficolin in humans, it is not 
remarkable that also the mouse lectin binds to elastin (Ohashi et al., 1998). Two 
forms of ficolin-A exist: ficolin-A and a variant form that is generated from the ficolin-
A gene by alternative splicing. This variant form consists of a shorter collagen-like 
region and possesses a longer gap sequence (Endo et al., 2005). 
Mouse ficolin-A acts as soluble pattern recognition molecule in serum by recognizing 
structures on pathogens and subsequently forms complexes with MASPs. This 
combination contributes to the activation of the complement lectin pathway. 
Endo et al. demonstrate that also the variant form of mouse ficolin-A binds to MASP-
2 and MAp19 (Endo et al., 2005). Endo et al. also shows that also ficolin-A, and its 
variant form exists in complexes with MASP-2 and MAp19 and is therefore also able 
to activate the complement system (Endo et al., 2005). 
 
1.5.4.2.2.2 Mouse ficolin-B 
 
The second ficolin in the mouse system is ficolin-B (FcnB). Like its human 
orthologue FcnB is also a more cell associated than a serum-type lectin. So far it has 
not been detected in serum. 
The main expression site of mouse FcnB is the bone marrow. Even though the site 
of localization is identified, nearly nothing is known about this lectin and its function 
in the immune system remains unclear (Endo et al., 2005; Endo et al., 2004). Unlike 
its human orthologue M-ficolin, mouse FcnB expression is not found in peripheral 
leucocytes (Ohashi et al., 1998). Beside bone marrow, FcnB mRNA is also detected 
in the spleen. More precise, Endo et al. showed that FcnB production is mainly found 
in cells of the myeloid cell lineage in the bone marrow (Liu et al., 2005a). Runza et 
al. demonstrated in 2006 that FcnB protein is co-localized with LAMP-1 in lysosomes 
of activated macrophages (Runza et al., 2006). 
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Recombinant FcnB is able to recognize sialic acid, which it has in common with its 
human homologue M-ficolin. Only the non-serum-type ficolins (human M-ficolin and 
ficolin-B in other mammalians, e.g. mouse FcnB) possess this binding specificity.  
Furthermore, mouse FcnB was reported to recognize and subsequently aggregate 
Staphylococcus aureus leading to enhanced phagocytosis by macrophages 
(Matsushita, 2010; Endo et al., 2007). 
Even though a common function of all ficolins is their lectin activity and activation of 
the complement system through complex formation with MASPs, mouse FcnB does 
not seem to bind to MASP-2 (Endo et al., 2005). Comparing the collagen-like regions 
of MBL and the ficolins, it seems that mouse FcnB should be able to associate with 
MASPs. The mouse lectin is endowed with the necessary residues for this binding 
(Endo et al., 2005) because it has the MASP-2 binding motif. Endo et al. investigate 
in 2005 possible interactions between recombinant mouse FcnB and MASPs or 
MAp19. No complexes could be detected in their studies.   
 
1.5.4.2.2.3 Mouse ficolin H 
 
Like in other mammalians, with the exception of humans, the third ficolin turned out 
to be a pseudo-gene (Endo et al., 2004). The homologue genomic region to human 
H-ficolin in mouse is located on chromosome 4 (Endo et al., 2004). Until know, a 
functional protein has only been identified in humans (Endo et al., 2004). 
 
1.3.1.3 Other lectins and collectins 
 
One major group of soluble recognition proteins are the C-type lectins. A subgroup of 
these lectins are innate immune collectins or collagenous lectins. Collectins consists 
not only of a collagenous region but also of a carbohydrate-binding domain, which is 
calcium-dependent (Litvack and Palaniyar, 2010). This carbohydrate-binding domain 
is also called carbohydrate-recognition domain or CRD. They are further 
characterized by their multimerization.  
Two well-examined collectins, beside MBL, are SP-A and SP-D. From their isolation 
from lung surfactant they received their names, surfactant protein A and D. 
Structurally SP-A consists of six units of a homotrimer (each of 35kDa) and thereby 
generates an octodecamer (“bouquet”). SP-D in contrast is much larger. Four units 
of homotrimers (43kDa) together form an X- or asterisk-shaped multimer (Litvack 
and Palaniyar, 2010). 
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Both surfactant proteins contribute also to the clearance of dying host cells (Wright 
2005; Stuart et al., 2006; Thiel, 2007; Palaniyar et al., 2008). More precise: SP-A 
acts in binding to bacteria, viruses and apoptotic cells and enhances their 
phagocytosis by lung alveolar macrophages (Schagat et al., 2001; Vandivier et al., 
2002; Gardai et al., 2003; Janssen et al., 2008). SP-D binds to apoptotic cells and it 
was shown that a further ligand of SP-D is genomic DNA. Binding is also observed to 
fatty acids and phospholipids (Ogasawara et al., 1992; DeSilva et al., 2003). SP-D 
also connects the innate immunity with the adaptive immunity via binding to the 
immunoglobulins IgG, IgE, secretory IgA and IgM (Kim et al., 2002; Nadesalingam et 
al., 2005). Sp-A and SP-D are, in contrast to MBL, not able to activate the 
complement system (Litvack and Palaniyar, 2010).   
Some other collectins that have been studied are CL-P1, CL-L1 and CL-K1 (also 
named CL-11). They received their names because of their main expression site: in 
placenta (CL-P1), liver (CL-L1) and kidney (CL-K1) (Keshi et al., 2006, Thiel, 2007, 
Palaniyar et al., 2008).  
Further collectins, typically found in bovine serum, are conglutinin, CL-43 and CL-46 
(Thiel, 2007, Litvack and Palaniyar, 2010).   
 
1.6 Aim of work 
 
The aim of this doctoral thesis project was the characterization and functional 
analysis of mouse FcnB as a pathogen-recognition lectin.  
Human ficolins are well characterized and also some functions could be identified. It 
has been shown that human L- and H-ficolin help in the clearance of dead cells by 
binding to apoptotic or necrotic cells and the initiation of their removal (Jensen et al., 
2007; Kuraya et al., 2005). The most important role of ficolins is the activation of the 
complement system via the lectin pathway by binding to MASPs (Endo et., 2010; 
Endo et a., 2011; Matsushita 2010).  
Since FcnB has not been studied extensively, the aim of this thesis was to identify 
the producer cells of FcnB and structurally and functionally characterize the FcnB 
protein. 
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2. Material and Methods 
 
2.1 Materials  
 
2.1.1 Chemicals and reagents 
 
Chemical/reagent Manufacturer 
6 x DNA-Loading buffer New England Biolabs 
β-Estradiol  Sigma 
β-Mercaptoethanol for Molecularbiology Sigma 
β-Mercaptoethanol for Cell culture  Gibco 
Agarose, LE for gel-electrophoresis Biozym 
AcBSA Sigma 
AcLDL Biomedical Technologies  
Biotin, NHS Sigma 
BSA (Fraction V) Sigma 
Chitin beads New England Biolabs 
CpG Metabion 
DAPI  Sigma 
DEPC  Sigma 
DMSO, steril Merck 
DMSO, non sterile Sigma 
DNA-Molecular weight-Standard 100bp  New England Biolabs 
DNA- Molecular weight-Standard 1kb New England Biolabs 
EDTA Sigma 
Ethanol Roth 
Ethidium bromide solution  Promega 
FCS Sigma / PAN 
Ficoll-Histopaque 1077 Sigma 
Ficoll-Histopaque 1119 Sigma 
fMLP  Sigma 
Formaldehyd  Sigma 
Glacial acid  Merck 
Glutamin  PAN 
Glycerin  Merck 
Glycin USB 
HAT PAN Biotech GmbH 
HT PAN Biotech GmbH 
HEPES  Sigma 
Hygromycin PAN 
IgG, rat Sigma 
IgG, mouse Sigma 
Imidazol Sigma 
Immersion Oil Zeiss 
Ionomycin Sigma 
Kaliumhydrogenphosphat  Merck 
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Chemical/reagent Manufacturer 
Kanamycin Gibco 
Labtek chamber II, Chamber slide Nalge Nunc International 
LPS Escherichia coli strain 0127:B8 Sigma 
LPS Salmonella abortus equi  Prof. M. Freudenberg 
Methanol Merck 
Milk powder Real 
Ni-NTA-Agarose Qiagen 
Nitrocellulose membrane 0.45µm (Dot Blot) BioRad 
NOWA solution A and B MoBiTec 
Nuclease-free Water Marchery Nagel 
Opti-MEM® mit GlutaMAXTM  Gibco 
PCR-Cycler, MyCycler thermal Cycler BioRad 
PCR-Cycler, ICycler thermal Cycler BioRad 
PBS  PAN 
Penicillin/ Streptomycin  PAN 
Paraformaldehyde Merck 
PMA Sigma 
Ponceau S Concentrate Sigma 
Power Pac 300 (Power Supply) BioRad 
Power Pac 1000 (Power Supply) BioRad 
Power Pac Basis (Power Supply) BioRad 
Precision Plus protein standard marker BioRad 
Protein marker VI Applichem 
Proteinase inhibitor Roche 
Protein-G-Agarose Roche 
RPMI-1640 medium PAN 
Rotiphorese Gel 30 (37;5:1) Roth 
Sodium acid  Merck 
Streptavidin-HRP R&D Systems 
Streptavidin-HRP ultra sensitive Sigma 
Tetenal Roentoroll AC Fischer Solutions 
Tetenal Superfix Part 2 Fischer Solutions 
Tetenal Superfix MRP Fischer Solutions 
Transfer-membrane Western Blot, 0.45µm Immobilon miilipore 
TRIS base/ultra Applichem 
TRIS-HCl Merck 
Trypan Blue Sigma 
Trypsin  PAN 
Tween 20  Fluka 
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2.1.2 Consumables and equipment 
 
Consumables/ equipment Manufacturer 
Accu-jet pro  Brand 
Accuracy weighing machine, Iso 9001 CP2245 Sartorius 
Agarose-Gel casting chamber BioRad 
Agarose-Gel-Electrophoresis Chamber Sub cell 
GT 
BioRad 
Agarose-Gel-Electrophoresis Chamber Mini Sub 
cell GT 
BioRad 
Agarose-Gel-Electrophoresis Chamber Wide Mini 
Sub cell GT 
BioRad 
Balance Mettler PJ400 
Balance, Kern EMB 200-1 Kern 
Bio Photometer Eppendorf Eppendorf 
Bio Rad Econo System device BioRad 
Cell culture flasks  BD  
Cell culture dishes  BD  
Cell Counter, AC-12, Assistant Assistant 
Cell Safe Digitalkamera ColorView I  Zeiss 
Cell strainer BD  
Cell scraper Sarstedt 
Centrifuge, Eppendorf 5417 R Eppendorf 
Centrifuge, Eppendorf 5415 D Eppendorf 
Centrifuge, Eppendorf, 5418  Eppendorf 
Centrifuge, Eppendorf, Cooling, 5810 R Eppendorf 
Color View, Soft Imaging System Leitz, Diaplan, 
Leica-Microscope 
Leitz, Diaplan 
Confocal Microscope, FluoView FV1000  Olympus 
Cuvette 10x4x45mm, Polystyrol/ Polystyrene Sarstedt 
Cytospin 4, Shandon Thermo 
Digital graphic printer UP-D895 VWR international / Sony 
Dry Block Heating Thermostat, Bio TDB-100 Hartenstein 
E-cups Eppendorf 
FACS LSR II Flow Cytometer  BD 
FACS tubes BD  
Falcon tubes flat bottom 50ml Sarstedt 
Falcon tubes round bottom 50ml Sarstedt 
Falcon tubes 15ml Sarstedt 
Gel-documentation, Bio Imaging System,  Gene Genius Syngene 
Microplate Reader Molecular Devices, 
MWG-biotech Emax  
Image Quant, LAS 4000 mini GE Healthcare 
Incubator, Heraeus BBD 6220 Heraeus 
iCycler BioRad 
iQ5 Multicolor Real Time PCR Detection System  BioRad 
Laminar Flow, Cell Safe Integra Bioscience 
Laminar Flow, Hera Safe Thermo 
MaxQ shaker Thermo Scientific 
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Consumables/ equipment Manufacturer 
Microwave Inverter Panasonic 
Microscope Olympus CK 2, ULW LD 3.0 Olympus 
Mithras, Multicolor Plate Reader LB940 Berthold technologies 
Multi channel pipette 100µl Eppendorf 
Multi channel pipette 300µl Eppendorf 
MyCycler  BioRad 
Nanophotometer IMPLEN 
Needle 20G ½, 0.9x40mm BD 
Needle 27G ¾, 0.4x19mm BD 
Neubauer Zählkammer  HBG 
PCR Thermocycler BioRad 
pH-meter Inolab 
Pipette 0.5-10µl Eppendorf 
Pipette 2-20µl Eppendorf 
Pipette 10-100µl Eppendorf 
Pipette 100-1000µl Eppendorf 
Photometer, BioPhotometer  Eppendorf 
Pipette tips (with filter)  Biozym 
Pipette tips (without filter)  Sarstedt 
Pipette 5, 10, 25 ml  Sarstedt 
Refrigerator Liebherr Gastroline 
Polyporylen tubes for bacterial cultures Sarstedt 
Power Supply, Power Pack P25 T Biometra 
Power Supply, Microcomputer electrophoresis, 
Consort E425 
Consort 
Rotator Mixer, programmable, Multi RS-60 Talron Biotech 
Syringe 1ml BD 
Syringe 5ml BD 
Syringe 10ml BD 
Thermal printer DPU-414 Eppendorf 
Ultrasonic-waterbath SONOREX Bandelin 
Vortexer REAX 2000 Heidolph 
Vortexer, Minishaker MS-2 IKA 
Vortexer, Vortex Genie 2 Bender & Hobein AG 
Waterbath, mini Thermo Mix Bk Braun 
Waterbath, Julabo TW20 Julabo 
Whatman Paper Hartenstein 
X-ray film processor Optimax Protec Medicine 
technique  
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2.1.3 Buffer and solutions 
 
2.1.3.1 Buffer 
 
1x Towbin/ SDS transfer buffer, pH 8.3 
 
Tris                                                                                                                  25 mM 
SDS                                                                                                                   0.02% 
Glycine                                                                                                              192 mM 
Methanol                                                                                                                 20% 
H20                                                                                                               ad 1000 ml 
 
 
5x Running buffer, pH 8.3  
 
Tris base                                                                                      120 mM 
Glycine                                                                                    950 mM 
SDS                                                                                              0.5% 
H20                                                                                         ad 2500 ml  
  
The Running buffer was stored at RT and diluted to 1x Running buffer with Millipore 
water before running the SDS-PAGE.  
 
 
5x Sample buffer  
 
Tris-HCl pH 6.8                                                                                              312.5 mM 
SDS                                                                                            10% (w/v) 
DTT                                                                                                                   250 mM 
Glycerol                                                                                       50% 
Bromophenol blue                                                                                    0.05% (w/v) 
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10x TBS buffer, pH 7.3 
 
Tris Base                                        3g 
NaCl                                   8g 
KCl                                                            0.2g 
H20                                            ad 1000ml 
 
 
Blocking buffer (Western blot/ Dot blot/ ELISA): 
  
10% skim milk powder was diluted in TBS/ 0.05% Tween 20 with or without 5 mM 
Ca++ according to the experiment. 
  
 
Blocking buffer (Confocal-microscopy) 
 
Cold water fish gelatin                                     3% 
Goat serum (heat inactivated)                         5% 
BSA                          1% 
Tween 20                                                 0.25% 
 
Reagents were diluted final in 1x PBS. 
 
 
C4 buffer 
 
Veronal Buffer Saline (VBS)                                             pH 7.4 
CaCl2                                                                                  2 mM  
MgCl2                                                                                    1 mM 
 
 
Coating buffer pH 9.6 
 
Na2CO3                                                                                 15 mM 
NaHCO3                       35 mM  
H2O                      ad 1000 ml 
 
 
  31 
Enhancement buffer 
 
CH3COOH                                                 0.57% 
Triton X-100                                                  0.1% 
PEG-6000                                 1% 
NTA                 15 µM 
TOPO                   50 µM 
 
 
FACS buffer 
 
1x PBS 
2% FCS 
 
 
Lämmli sample buffer  
 
4x Lämmli buffer                                                                 20 ml 
Tris-HCl pH 6.8                                                  250 mM 
Glycerol                                             40%  
SDS                                  5% 
Bromophenol blue                              0.005% 
H2O                                                                                 1.9 ml 
 
Lämmli sample buffer was stored for long term at -20ºC. Right before use for sample 
preparation, 10% β-ME was added. 
 
 
MASP-2 buffer 
 
Tween 20               0.05% 
EDTA                10 mM 
NaCl                      885 mM 
Human IgG                         100 µg/ml 
 
Dilution was performed in 1x TBS. 
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Ponceau S red solution 
 
A 5x Ponceau S red stock solution was obtained from Sigma (P7767). The solution 
was diluted 1:5 with millipore water and stored at RT. 
 
 
RIPA-cell-lysis-buffer 
 
Tris-HCl pH 7.5                          50 mM 
NaCl                                                 150 mM 
Nonidet P40                                             1% 
Sodiumdesoxycholat                           0.5% 
SDS                                                        10% 
 
RIPA-buffer for cell-lysis was stored at RT. In general, 1x 106 cells are resuspended 
in 50µl RIPA-buffer. Before storage of the lysates at -80°C, a protease inhibitor was 
added at a final concentration 1:7. 
 
 
SDS-PAGE-buffers 
 
1 M Tris-HCl pH 8.8                       250 ml   30.28g 
1 M Tris-HCl pH 6.8                        100 ml   12.11g  
 
 
Stripping buffer 
 
SDS                                                 10% 
Tris pH 6.8                                    12 M    
H20                              ad 500 ml 
 
 
Streptavidin-Europium buffer 
 
Tween 20                0.05% 
EDTA                          25 µM 
 
Dilution was performed in 1x TBS. 
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Veronal buffer Saline (VBS), pH 7.4 
 
Barbital                                    4 mM 
NaCl                                 145 mM 
NaN3                                    0.02% 
H20                          ad 500 ml 
 
 
2.1.3.2 Solutions 
 
2x Freezing medium 
 
DMSO                               20% 
FCS                                   80% 
 
 
50-fold HAT  
 
Hypoxanthine                                         5 mM 
Aminopterin            0.02 mM 
Thymidine                                      0.8 mM 
 
50-fold HAT was diluted in RPMI 1640 medium, 10% FCS, 100 U/ml 
Penicillin/Streptomycin and 50 µM β-ME.  
 
 
50-fold HT  
 
Hypoxanthine                               5 mM 
Thymidine                0.8 mM 
 
50-fold HT was diluted in RPMI 1640 medium, 10% FCS, 100 U/ml 
Penicillin/Streptomycin and 50 µM β-ME.  
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Coomassie-staining solution 
 
Glacial acetic acid                               10% 
Methanol                               40% 
Coomassie Brilliant blue R250                   0.2 % 
Millipore water                           49.8 % 
 
 
Coomassie-destaining solution 
 
Glacial acetic acid                   10% 
Ethanol                                       40% 
Millipore water                 50% 
 
 
Trypan-blue solution, pH 7.4 
 
Trypan-blue                                     0.16% (w/v) 
NaCl                                        150 mM 
H20                                                   ad 1000 ml 
 
 
 
2.1.4 Molecular weight markers   
 
(I) Precision Plus Protein All Blue Standard from BioRad.  Representative lot of blue 
pre-stained Precision Plus Protein standard on a 4–20% Gel ™ Tris-HCl Criterion.  
 
(II) Protein marker VI (10-245) pre-stained from Applichem (product code: A8889).  
Representative lot of dual-color Protein standard is shown on a 4–20% Gel ™ Tris-
Glycine, in a Bis-Tris 10% MOPS buffer or in Bis-Tris 10% MES buffer. 
 
 
 
 
 
 
  35 
2.1.5 Kits 
 
Diff-Quick Differential staining Set (Dade Behring, Eschborn) 
 
Performed for differential morphological cellular analysis by light microscopy (Leica 
Microscope, Leitz). 
 
 
DOTAP liposomal transfection reagent (Roche) 
 
Used for liposome-mediated DNA transfer into eukaryotic cells (e.g. insect cells). In 
this case, it is a transfection mediated by cationic liposomes.  
 
 
BCA Protein Assay Kit (Pierce/Thermo Scientific) 
 
For determination of protein concentrations after affinity chromatography purification, 
of monoclonal antibodies or recombinant proteins. For the protein quantification a 
BSA standard curve was used. This assay is based on the reduction of Cu2+ to Cu+ 
in an alkaline environment and the ability of bicinchoninic acid (BCA) to detect Cu+ 
(Smith et al., 1985).  
 
 
“Pure yield TM Plasmid Miniprep DNA Purification” Kit (Promega) 
 
Used for DNA isolation and purification from E. coli cultures. 
 
 
RNA Isolation-Kit NucleoSpin ® RNA I Kit (Marchery-Nagel) 
 
Used for RNA isolation from Hoxb8-neutrophils, PMN, BMDM, BMDC, and spleen 
cells. RNA is very sensitive to degradation. This has to be prevented during the 
isolation process. During the isolation the cells are lysed by incubation in a solution, 
containing large amounts of chaotropic ions. The advantage of this lysis buffer is that 
RNases are immediately inactivated. An rDNase digestion removes contaminating 
DNA, which is bound to the silica membrane. Finally pure RNA is eluted with RNase-
free water and the eluate is stored at -80° C for long-term-storage.  
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2.1.6 Nucleic acids: Oligonucleotides 
 
All primers were purchased from Metabion at a concentration of 100 pmol (100µM), 
and stored at -20°C in aliquots of 10 pmol until use. The primers used in this work 
are listed below: 
 
Name Sequence Amplicon 
RT-PCR FcnB Forward 
RT-PCR FcnB Reverse 
5’- TCA TAC AAG AGG GGC TTT GG-3’ 
5’- GCC GTC ATT GTC TTG GTC -3’ 
230 bp 
18S Primer Forward 
18S Primer Reverse 
5’- GTA ACC CGT TGA ACC CCA TT -3’ 
5’- CCA TCC AAT CGG TAG TAG CG -3’ 
180 bp 
Oligo dT18-Primer  5’- TTT TTT TTT TTT TTT TTT -3’ - 
 
Tab. 1: Overview RT-PCR primers.  
 
2.1.7 Antibodies 
2.1.7.1 Primary antibodies for Western blot/ Dot blot/ ELISA 
 
Name Clone Species Modification Producer 
Anti-V5 - Mouse Unlabeled Invitrogen 
Anti-V5-HRP - Mouse HRP Invitrogen 
Anti-mouse FcnB moAb  2F1B6B6 Rat Unlabeled This work 
Anti-mouse FcnB moAb  2F1B6B6 Rat Biotinylated This work 
Anti-mouse FcnB moAb  2F1B6E2 Rat Unlabeled This work 
Anti-mouse FcnB moAb  2F1B6E2 Rat Biotinylated This work 
Anti-mouse FcnB moAb  2F1C7G4 Rat Unlabeled This work 
Anti-mouse FcnB moAb  2F1C7G4 Rat Biotinylated This work 
Anti-mouse FcnB moAb  16D3D6 Rat Unlabeled This work 
Anti-mouse FcnB moAb  16D3D6 Rat Biotinylated This work 
Anti-mouse FcnB moAb  16G3C2 Rat Unlabeled This work 
Anti-mouse FcnB moAb  16G3C2 Rat Biotinylated This work 
Anti-mouse FcnB moAb  11A1A10 Rat Unlabeled This work 
Anti-mouse FcnB moAb  11A1A10 Rat Biotinylated This work 
Anti-mouse FcnB moAb  11A1B11 Rat Unlabeled This work 
Anti-mouse FcnB moAb  11A1B11 Rat Biotinylated This work 
Anti-mouse FcnB moAb  11A1C7A5 Rat Unlabeled This work 
Anti-mouse FcnB moAb  11A1C7A5 Rat Biotinylated This work 
Anti-mouse FcnB moAb  IA4 Rat Unlabeled Institute of 
Immunology 
Regensburg (Dr. 
V. Runza) 
Anti-mouse FcnB moAb  IA4 Rat Biotinylated Dr. V. Runza 
Anti-mouse FcnB PoAb - Chicken Unlabeled Davids Biotech. 
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Name Clone Species Modification Producer 
Anti-human MASP-2 6G12 Rat Unlabeled Hycult 
Anti-human C4b 161-1 Mouse Biotinylated Immunolex 
Anti-human C4b 161-2 Mouse Biotinylated Immunolex 
 
2.1.7.2 Primary antibodies for FACS 
 
Name Clone Species Modification Producer 
Anti-mouse CD11b M1/70 Mouse PE BD 
Anti-mouse B220 RA3-6B2 Mouse PerCP eBioScience 
Anti-mouse Ly6C AL-21 Mouse FITC BD 
Anti-mouse Ly6G 1A8 Mouse eFluor450 BD 
 
2.1.7.3 Primary antibodies for confocal microscopy 
 
Name Species Modification Producer 
Lamp-1 Mouse FITC BD Pharmingen 
Isotype-Lamp-1 Mouse FITC BD Pharmingen 
Phalloidin Mouse RED Invitrogen 
Anti-elastase Rabbit - Calbiochem 
Anti-nucleosome Mouse - BD Pharmingen 
Lysotracker Mouse RED Invitrogen 
 
2.1.7.4 Secondary antibodies 
 
Name Epitope Species Modification Producer 
DyLight 488 anti-rabbit Rabbit IgG - DyLight 488 Jackson 
ImmunoRe
search 
DyLight 549 anti-mouse Mouse IgG - DyLight 549 Jackson 
ImmunoRe
search 
Goat anti rat IgG (WM)-HRP Rat IgG Goat HRP Sigma 
Goat anti-rat IgG (y-chain)-
HRP 
Rat IgG Goat HRP Biolegend 
Goat anti-mouse IgG-HRP Mouse IgG Goat HRP Biozol 
Sheep anti-rat IgG1 Rat IgG1 Sheep - Serotec 
Sheep anti-rat IgG2a Rat IgG2a Sheep - Serotec 
Sheep anti-rat IgG2b Rat IgG2b Sheep - Serotec 
Sheep anti-rat IgG2c Rat IgG2c Sheep - Serotec 
Sheep anti-rat IgM-HRP Rat IgM Sheep HRP Serotec 
Goat anti-chicken-HRP Chicken IgY Goat HRP Abnova 
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2.1.7.5 Secondary detection reagents 
 
Name Modification Producer 
Streptavidin-Alexa 488 AF488 Invitrogen 
Streptavidin-Alexa 546 AF546 Invitrogen 
Streptavidin-HRP HRP R&D Systems 
Streptavidin-HRP 
ultrasensitive 
HRP Sigma 
Streptavidin-Europium Eu3+ Perkin Elmer 
ToPro3 - Invitrogen 
 
2.1.7.6 Blocking antibodies 
 
(I) Fc receptor Blocking: Rat anti mouse FcyR II/III (clone 2.4G2)  
 
2.1.8 Bacteria 
 
2.1.8.1 Pseudomonas aeruginosa 
 
Name Producer 
Pseudomonas aeruginosa,  
PAO-1, GFP-tagged 
Kindly provided by Dr. Analia Trevani (Academia 
Nacional de Medicina, Buenos Aires, Argentinien) 
 
Bacteria were routinely grown at 37°C in Luria-Bertani (LB) broth or on LB agar. 
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2.1.8.2 Staphylococcus aureus 
 
All Staphylococcus aureus strains were grown in Todd-Hewitt broth medium at 37°C 
for O/N. Bacteria were spun down at 2000g for 15min at 5°C and washed three 
times with PBS. The bacteria were fixed in 1% PFA for O/N or longer at 4°C. 
Residual aldehyde groups were blocked for 1h at RT with 0.1 M ethanolamine. 
Bacteria were again centrifuged at 2000g, 15min at 5°C. Washing was performed 
three times with TBS and 0.9% NaN3 and stored at 4°C. Bacterial concentration was 
determined by reading the optical density at 600 nm. An optical density of 1 
corresponds to 1.8 x 109 bacteria/ml (Krarup et al., 2005). 
 
Serotype ATCC number Producer 
T-1 12598 Inst. of Microbiology, University of Aarhus, Denmark 
T-2 49519 Inst. of Microbiology, University of Aarhus, Denmark 
T-3 12600 Inst. of Microbiology, University of Aarhus, Denmark 
T-4 49520 Inst. of Microbiology, University of Aarhus, Denmark 
T-5 49521 Inst. of Microbiology, University of Aarhus, Denmark 
T-6 12603 Inst. of Microbiology, University of Aarhus, Denmark 
T-7 49525 Inst. of Microbiology, University of Aarhus, Denmark 
T-8 12604 Inst. of Microbiology, University of Aarhus, Denmark 
T-9 12606 Inst. of Microbiology, University of Aarhus, Denmark 
T-10 12607 Inst. of Microbiology, University of Aarhus, Denmark 
T-11 12608 Inst. of Microbiology, University of Aarhus, Denmark 
T-12 12609 Inst. of Microbiology, University of Aarhus, Denmark 
T-13 12610 Inst. of Microbiology, University of Aarhus, Denmark 
 
Tab. 2: Overview serotypes of S. aureus used for binding studies. 
 
2.1.8.3 Group B Streptococcus (GBS or Streptococcus Agalactiae) 
 
All Group B Streptococcus strains were grown in Todd-Hewitt broth medium at 37°C 
for O/N. Then the bacteria were spun down at 2000g for 15min at 5°C and washed 
three times with PBS. The bacteria were fixed in 1% PFA for O/N or longer at 4°C. 
Residual aldehyde groups were blocked for 1h at RT with 0.1 M ethanolamine. The 
Bacteria were again centrifuged at 2000g, for 15min at 5°C. Washing was performed 
three times with TBS and 0.9% NaN3 and stored at 4°C. Bacterial concentration was 
determined by reading the optical density at 600 nm. An optical density of 1 
corresponds to 1.8 x 109 bacteria/ml (Krarup et al., 2005). 
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Serotype Strain Producer 
1a 090 Inst. of Microbiology, University of Aarhus, Denmark 
1b ss618 Inst. of Microbiology, University of Aarhus, Denmark 
II 18 RS 21 Inst. of Microbiology, University of Aarhus, Denmark 
III 3782 Inst. of Microbiology, University of Aarhus, Denmark 
IV 3139 Inst. of Microbiology, University of Aarhus, Denmark 
V 1169 Inst. of Microbiology, University of Aarhus, Denmark 
VI 10214 Inst. of Microbiology, University of Aarhus, Denmark 
VII 7271 Inst. of Microbiology, University of Aarhus, Denmark 
VIII 22634/86 Inst. of Microbiology, University of Aarhus, Denmark 
IX 534/04 Inst. of Microbiology, University of Aarhus, Denmark 
(non-capsulated) B848/64 Inst. of Microbiology, University of Aarhus, Denmark 
 
Tab. 3: Overview serotypes of GBS used for binding studies. 
 
2.1.9 Eukaryotic cell lines 
 
2.1.9.1 Drosophila Schneider-2 (DS-2) cell line 
 
For recombinant expression of mouse FcnB, the Drosophila Schneider 2 cell 
expression system from Invitrogen was used. This cell line was used for the 
overexpression of FcnB.  
 
2.1.9.2 SP2/O-Ag14 myeloma cell line 
 
As myeloma cells for the fusion with antibody producing plasma-B-cells, SP2/O-
Ag14 myeloma cells were used (ATCC No. CRL 1581). 
 
2.1.9.3 ERHoxb8 cells 
 
This cell line was kindly provided by Dr. H. Häcker (Wang, G. G. et al 2006). The 
ERHoxb8 cells are progenitor cells when cultivated in estradiol-containing medium. 
After withdrawal of estradiol (also oestradiol), the cells differentiate within 3-4 days to 
mouse neutrophils.  
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2.1.9.4 RAW macrophages 264.7 
 
These RAW cells (ATCC number; TIB-71™) are mouse macrophages which grow 
adherent in RPMI medium containing 10% FCS. 
2.1.10 Animals 
 
C57BL/6 mice and female rats (ACI, Wistar and Fischer 344) both aged 8-12 weeks 
were also obtained from Charles River. The animals were kept under conventional 
conditions with food and water ad libitum in the animal facilities of the University of 
Regensburg and treated in accordance with institutional guidelines and the German 
Federal Regulations of Animal Experimentation. 
 
2.1.11 Software and Database                   Company 
 
Cell^F Imaging Software                                                                              OLYMPUS 
FACS software: BD FACSDiva software and FlowJo software                                BD 
Graph Pad Prism version 4                                                                Graph Pad Prism 
iCycler Analysis Software, IQ5TMOptical System Software 2.0                        BioRad 
Image Quant Tl 7.0 Image Analysis Software                                        GE Healthcare 
Microsoft Office 2008          Microsoft Office 
MicroWin 2000 (Mithras)                                                                                  Berthold 
Software Fluoview 1000                OLYMPUS 
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2.2 Methods 
 
2.2.1 DNA and RNA-based techniques  
 
2.2.1.1 Isolation of genomic DNA from E. coli 
 
For DNA isolation and purification “Pure yield TM Plasmid Miniprep System” from 
Promega was used according to the manufactures instructions. 
Briefly, one day before the DNA isolation, bacterial cultures in LB-medium were 
prepared and inoculated with material of E. coli colonies. 600µl of bacterial culture 
were added to a 1.5ml microcentrifuge tube. To lyse the cells, 100µl of cell lysis 
buffer was added and the tube was mixed by inverting. Then 350µl of cold 
neutralization buffer were added and the suspension was centrifuged at maximum 
speed for 3min. The supernatant was transferred to a “Pure yield TM” mini column. 
The column was placed into a collection tube and centrifuged at maximum speed for 
15sec. The flow-through was discarded and the column was placed back into the 
same collection tube. Then the column was washed: first with 200µl of Endotoxin 
Removal Wash (ERW) and centrifuged for 15sec and second with 400µl of Column 
Wash Solution (CWC) and 30sec centrifuged at maximum speed. For elution of 
DNA, column was placed into a clean 1.5 ml tube. 30µl of nuclease free water was 
added directly to the column matrix and incubated for 1min at RT. To finally elute 
DNA, column was centrifuged for 15 sec at maximum speed. DNA concentration was 
measured (see 2.2.1.2) and DNA stored at -20°C.  
 
2.2.1.2 Quantification of nucleic acids 
 
Purified DNA samples were measured at a wavelenght of 260nm (“BIO-photometer”, 
Eppendorf). In general, samples were diluted in a 1:50 ratio, with 2µl of probe to 98µl 
water. As a blank-control 100µl of water was used. A dilution was prepared in an 
eppendorf tube and then transferred to a photometer cuvette (10x4x45mm, 
Sarstedt). The DNA concentration was calculated according to the Lambert-Beer’s 
law where an optical density of 1 (OD260=1) corresponds to 50 μg of dsDNA/ml. 
The concentrations of RNA samples were measured at 280nm. 
 
  43 
2.2.1.3 Polymerase chain reaction  
 
The polymerase chain reaction (PCR) is a technique used to enzymatically amplify a 
defined DNA sequence in vitro (Mullis, 1990). PCR reactions were carried out in a 
programmable thermocycler (BioRad iQ5 Thermo Cycler). In order to avoid DNA 
contamination, the different components of the reaction were pipetted with filtered 
tips. 
2.2.1.4 Agarose gel electrophoresis  
 
Agarose gel electrophoresis was performed to analyse the PCR products after RT-
PCR. In general, 1% agarose gels were prepared by dissolving agarose in 1xTAE 
buffer. RT-PCR products were diluted in 6x DNA loading buffer and loaded on the 
gels. Samples were separated according to their size at 100 Volts for 1h. Finally 
DNA bands were visualized by ethidium bromide staining under a 366 nm UV light.  
 
2.2.1.5 RNA isolation  
 
RNA isolation was performed with the NucleoSpin ® RNA I- Kit from Marchery-Nagel 
(Düren, Germany) according to the manufacture´s instructions. 
The total RNA-isolation protocol in detail is as follows: 
 
(I) Lyse cells by adding 350 µl of Buffer RA1, containing fresh added 3.5µl β-ME 
to the pellet and gently mix or vortex the tube.  
(II) Filtrate lysate by filtration through a NucleoSpin ® Filter (violet ring). The filter 
is placed in a 2 ml collection tube and centrifuged for 1min at 11.000g. 
(III) After centrifugation the filter is discarded and flow through is homogenized by 
adding 350µl of 70% and mixed by pipetting 5 times up and down.  
(IV) Each sample is than loaded to a NucleoSpin ® RNA II Column (light blue ring) 
and placed in a 2 ml collection Tube.  
(V) Columns are centrifuged for 30s at 11.000g. Column is afterwards placed in a 
new 2 ml collection tube.  
(VI) Membrane is desalted by adding 350µl MDB (Membrane Desalting Buffer) 
and for 1min centrifuged at 11.000g to dry the membrane. Desalting step is 
important to make the following rDNase digestion step more efficient.  
(VII) For DNA digestion first a mixture has to be prepared containing for each 
sample: 10µl rDNase and 90µl rDNase Reaction Buffer.  
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(VIII) Solution is mixed and 95µl is directly applied to the center of the silica 
membrane of the column. Incubation is performed at RT for 15min. 
(IX) Membrane washes (3 times): first with 200µl Buffer RA2 to inactivate the 
rDNAse. Column is centrifuged for 30sec at 11.000x g and placed into a new 
2 ml collection Tube.  
(X) The second washing step is performed by adding 600µl of Buffer RA3 
followed by a centrifugation step for 30s at 11.000g. The flow through is 
discarded and column is placed back into the collection tube. 
(XI) Finally, 250µl Buffer RA3 are applied to the column and centrifuged at 
11.000g for 2min. This step is recommended to dry the membrane 
completely. After centrifugation column is put into a nuclease-free 1.5 ml 
collection tube.  
(XII) Isolated RNA is eluted in 60µl RNase-free water (or 40µl, if higher 
concentrations are desired) and centrifuged at 11.000g for 1min.  
(XIII) RNA is stored at -80°C to keep it stable. 
 
2.2.1.6 cDNA synthesis 
 
Before performing RT-PCR analysis, isolated RNA has to be transcribed into cDNA 
(„complementary DNA“). Reverse transcription is accomplished using the standard 
first-strand synthesis protocol from Promega (see 2.1.5).  
In general, 500ng of RNA were transcribed to single-stranded cDNA. The maximum 
volume, however, is 15.75µl, in case that the concentration of RNA is not high 
enough. First appropriate amounts of RNA were mixed with 2µl of Oligo dT primer 
(Fermentas, Oligo dT 18) and filled up to 17.75µl with water. The samples were 
heated up for 5min at 70°C (denaturation and primer hybridization/annealing) and 
then cooled down on ice. 5µl of 5x MLV-buffer (Promega, M531A) were added to the 
reaction, 1µl of MLV enzyme (200 Units) and 1.25µl of dNTP-Mix (each 10µM). MLV-
enzyme is a reverse trancriptase from murine leukemia virus. Samples were 
incubated for 1h at 40°C (elongation) and the reaction was stopped and enzymes 
were finally inactivated at 70°C for 15min. Finally, cDNA was placed on ice when 
directly used for RT-PCR analysis or stored at -20°C for long-term-storage.  
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2.2.1.7 RT-PCR 
 
Real time PCR (RT-PCR) is a useful technique to amplify a gene of interest without 
introns. It is a good method to analyze specific mRNA transcript expression in a 
particular tissue or different cell types. Therefore, first RNA must be reverse 
transcribed into cDNA (“complementary DNA”).  
For mRNA expression analysis the thermocycler iQ5 multicolor real-time PCR 
detection system from Bio-Rad was used. 
 
RT-PCR-reaction: 
 
cDNA 1:5 dilution 5µl 
RT-PCR Primer For (100µM) 0.1µl 
RT-PCR-Primer Rev (100µM) 0.1µl 
2x Sensi Mix* 12.5µl 
Millipore water 7.3µl 
25µl 
 
Tab. 4. Overview RT-PCR reaction mix. 
 
* The 2x SensiMix Plus SYBR Kit & Fluorescein Kit from Quantace is a ready to use 
mix for Real time PCR, including the hot start Taq-polymerase, the fluorescein SYBR 
green I as an internal reference, dNTPs, magnesium chloride and stabilizers. The 
SYBR green mix was stored at -20°C. The RT-PCR-program is listed below. 
 
 
 
 
 
 
 
Tab. 5. Overview RT-PCR program. 
Temperature Time Cycles Procedure 
95°C 7min  
95°C 15sec 
60°C 30sec 
45x 
 
 
Realtime 
95°C 1min  
55°C 1min  
55°C 30sec  
 
 
Meltcurve 
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2.2.2 Cell culture techniques 
 
2.2.2.1 Eukaryotic cells 
 
2.2.2.1.1 Drosophila Schneider-2 cells (DS-2)  
 
The Drosophila Schneider 2 (DS-2) cell line (Invitrogen; Catalog no. R690-07, 
Version F) is derived from a primary culture of late stage (20h to 24h) Drosophila 
melanogaster embryos (Schneider, 1972). Cells grow at 28°C without CO2 in an 
incubator. In tissue culture flasks they build a semi-adherent monolayer, compared 
to a growth in suspension in shaking flasks.   
DS-2 cells are used to produce recombinant proteins and therefore these cells are a 
good expression system.  
Culture medium for DS-2 cells is commercially available (for example the “Insect 
Express Prime” from PAA (Catalogue no. E21-895), with 10% FCS and 100µg/ml 
kanamycin). The selection medium during transfection is as the culture medium, but 
with additional Hygromycin-B at a concentration of 300µg/ml. The induction medium 
for protein expression is as the selection medium, with 500µM final concentration of 
CuSO4, but without FCS. 
 
2.2.2.1.1.1 Thawing of DS-2 cells 
 
When initiating the cell culture of DS-2 cells, a cryotube from the liquid nitrogen tank 
was quickly thawed and the cells were transferred to a 15 ml falcon tube, containing 
9 ml pre-warmed (room temperature) culture medium. Cells were centrifuged at 
1000g for 3min, supernatant discarded to remove the DMSO and the cells were 
resuspended in 5 ml culture medium and plated in a 6 well or a flask.  
DS-2 cells were incubated at 28°C for 4 to 5 days, until they were 100% confluent. 
 
2.2.2.1.1.2 Passaging of DS-2 cells 
 
In general, the cell density is between 6x 106 to 20x 106 cells per ml. When 
passaging the cells, cells were collected by carefully pipetting them up and down to 
break up cell clumps and were then centrifuged at 1000g for 3min. Cells were split 
twice a week in a dilution of 1:5 or depending on cell growth. Hereby, the conditioned 
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medium was mixed with freshly prepared medium. Cells were always split into new 
wells or flasks.  
 
2.2.2.1.1.3 Freezing of DS-2 cells 
 
Before starting the freezing of DS-2 cells, cryotubes were kept on ice and labeled. 
Freezing medium contains 40% conditioned medium, 40% fresh culture medium, 
10% DMSO and 10% FCS. In general 1x 107 cells are frozen per cryotube. Before 
freezing, cells were counted and the cell viability was determined. Cells were 
centrifuged at 1000g for 3min; the pellet was resuspended in fresh culture medium 
and the cell number was determined. Conditioned medium was saved after the 
centrifugation to prepare the freezing medium. Appropriate cell numbers were diluted 
in freezing medium and 1 ml suspension was transferred to each vial.  
Cells were first slowly frozen down, by transferring the cryotubes to the -80°C freezer 
and 2 days later to the liquid nitrogen tank for long-term storage. 
 
2.2.2.1.1.4 Transfection of DS-2 cells 
 
For stable transfection of DS-2 insect cells, the liposomal transfection reagent 
DOTAP from Roche was used. Transfection of eukaryotic cells was mediated by 
cationic liposomes. For transfection, the DNA used for transfection should be of high 
purity and the cells to be transfected should proliferate well. It is recommended to 
passage cells the day before transfection. The cell density should be around 60-80% 
at time of transfection. For transfection, 5µg of DNA were diluted in HEPES-buffered-
saline (HBS) buffer to a final volume of 50µl. In parallel, 30µl DOTAP were diluted in 
HBS to a final volume of 100µl. DNA and DOTAP solutions were mixed together and 
incubated 10-15min at RT. Meanwhile, the DS-2 cells were centrifuged for 3min at 
1000g and resuspended in fresh culture medium. Then, the DNA-DOTAP-mixture 
was added directly to the cells to be transfected and incubated up to 72h. The 
transfection medium was replaced by the selection medium. The selection medium 
consists of normal culture medium, containing 0.3mg/ml antibiotic Hygromycin B. 
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2.2.2.1.1.5 Induction of protein expression 
 
Protein expression was induced with 500µM CuSO4, added to the culture medium. 
Normally, cells were induced for 5 to 7 days. Supernatants from differently 
transfected DS-2 cell clones can be tested in Dot blot or ELISA. If recombinant 
protein is produced, the expression can be detected with antibodies against the 
respective recombinant protein or against the V5-His-Tag. Also cells can be lysed in 
lysis buffer and the cell lysates checked in Western blot analysis. For collection of 
recombinant protein, DS-2 cells were centrifuged at 3000g for 5min and the 
supernatant was sterile-filtered and stored in flasks for later protein purification. 
 
2.2.2.1.2 SP2/O-Ag14 myeloma cells 
 
Myeloma cells (SP2/O-Ag14, ATCC No. CRL 1581) are used as fusion partner for 
plasma B cells to generate hybridomas for the production of monoclonal antibodies. 
This myeloma cell line is a non-light chain-immunoglobulin-secreting line derived 
from a cell line created by the fusion of Balb/C mouse spleen cells with the mouse 
myeloma P3X63Ag8. These cells are resistant to 8-azaguanine (20 g/ml) and do 
not survive in media containing HAT. B-cells in contrast, are able to grow in HAT-
medium, but they are not long-living cells. So, only fused cells with the capacity of an 
immortal myeloma cell and a cell able to grow in HAT will survive after fusion and 
during selection in HAT. Myeloma cells were cultured in RPMI medium, containing 
10% FCS, 2 mM L-glutamine and were incubated at 37°C and 5% CO2. For the 
culture, the cell density should be between 5x104 and 5x105 viable cells/ml. Some 
cells may attach, but in general SP2/O-Ag14 myeloma cells are suspension cells. 
Medium was changed every 2 to 4 days, depending on the cell density. 
 
2.2.2.1.3 ERHoxb8 cells 
 
ERHoxb8 cells are kept in a precursor state when cultured in medium containing β-
estradiol. After withdrawal of estradiol the cells differentiate within 3 to 4 days to 
neutrophils. For culture the cells were grown in OPTIMEM medium from Gibco/ 
Invitrogen, supplemented with heat-inactivated 10% FCS, 1% Penicillin/ 
Streptomycin (Pen/Strep) and 30µM β-ME. Stem Cell factor was always added fresh 
(SCF; supernatant from transfected CHO-cells, produced in our laboratory) in a 1:25 
dilution containing either 1µM estradiol (precursor cells) or not. 
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2.2.2.1.3.1 Thawing of ERHoxb8 cells 
 
Before thawing of ERHoxb8 cells, complete medium was prepared and warmed up 
to 37°C temperature. Cells were thawn quickly in a water bath and cell suspension 
was transferred to a 15 ml falcon and slowly 9 ml of medium were added dropwise. 
After centrifugation for 5min at 300g, at 4°C, cells were resuspended in 3 ml medium 
and placed into a 6 well. On the next day 1 ml fresh medium was added. One day 
later, the cells were centrifuged again at 300g for 5min at 4°C and resuspended in 6 
ml medium and seeded in two 6 wells.  
 
2.2.2.1.3.2 Passaging of ERHoxb8 cells 
 
ERHoxb8 cells were cultivated in 6 well plates and split every second day. The cell 
number was adjusted to 5x105 cells per well. For differentiation, cells were 
centrifuged, washed two times in 1x PBS with 10% FCS and resuspended in 
medium without estradiol. Cells were counted and adjusted to the required cell 
number for the experiment.  
 
2.2.2.1.3.3 Freezing of ERHoxb8 cells 
 
Before freezing, the ERHoxb8 cells were split the previous day. Cells were 
centrifuged at 300g, 5min at 4°C, resuspended in medium and placed on ice. In 
general, 5x106 cells were prepared for one cryotube. Cells were diluted in an equal 
volume of 2-fold freezing medium (20% DMSO, 80% FCS, SCF 1:25 and 1µM 
estradiol). Normally cells were first placed at -80°C for at least one day, before 
storage at -190°C in the liquid nitrogen tank.   
 
2.2.2.1.4 RAW macrophages 264.7 
 
RAW 264.7 cells are a mouse macrophage-like cell line. The culture medium was 
RPMI medium with 10% FCS and 0.1% gentamicin. RAW macrophages are 
adherent cells, cultivated at 37°C, 5% CO2 in T75-flasks. Every 2 to 3 days, the cells 
had been split 1:20 into new T75 flasks. For passaging, the old medium was 
removed and the cell layer washed once with 10ml cold PBS, by rinsing carefully the 
cell layer. The PBS was removed and the cells were detached by adding 1ml trypsin 
directly to the cells. The trypsin step was performed for 1-2min at RT and afterwards 
the trypsin was removed. Now, the detached cells were resuspended in 20ml RPMI 
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10% FCS medium. Cells were centrifuged at 300g, 8min at 4°C and the pellet was 
resuspended in 10ml medium. The cell number was determined and cells were 
distributed to new flasks when passaging or adjusted to the required cell number for 
the experiment. If cells were used in experiments, the detachment step with trypsin 
can be replaced by scraping the cells off.  
 
2.2.2 Primary cells 
2.2.2.1 Generation of BMDM 
 
Bone marrow derived macrophages were generated according to the protocol by 
Lutz and Schuler, 1999 (Lutz and Schuler et al, 1999).  
Briefly, mice were anesthetized with ether and killed. The skin was wetted with 70% 
ethanol and femura and tibia were isolated and cleaned from tissue. Bones were first 
incubated for 2min in 70% ethanol and then washed in PBS. The epiphysis was 
opened on both sides and the bone marrow was flushed out with 10 ml cold and 
sterile PBS, until the bone marrow was fully washed out (Syringe. Needle: 27G ¾, 
0.4x19mm). The cell suspension was transferred to a falcon tube with cold 50 ml 
medium. Cells were filtered through a cell strainer, centrifuged for 10min at 300g and 
4°C and washed once with culture medium (RPMI medium with 10% FCS, 1% 
Pen/Strep). After resuspension in culture medium, cells were counted and cultured in 
square plates (BD). In general, 1x107 cells were seeded in one square plate with 20 
ml medium.  
 
Culture protocol for BMDM: 
 
(I) d0: Cells were seed in a square plate with 1x107 cells in 20 ml medium 
(II) d5: The medium was removed and exchanged against fresh medium (thereby 
non-adherent cells were removed) 
(III) d6: square plates were placed on ice. Medium was collected in a 50 ml falcon. 
The cell layer was washed with 10ml cold PBS and after a short incubation, 
the cells were carefully detached with a cell scraper. Cells were resuspended 
in the medium collected before. Afterwards, the cells were pelleted by 
centrifugation at 300g, 8min at 4°C. The supernatant was discarded and the 
pellet was resuspended in RPMI medium without FCS. 
(IV) Cell numbers were determined and cells were cultured several days or the 
cells were prepared for experiments.   
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2.2.2.2 Generation of BMDC 
 
Bone marrow derived macrophages were generated according to the protocol by 
Lutz and Schuler, 1999. Bone marrow cells were isolated as described previously. 
 
Culture protocol for BMDC: 
 
(I) d0: Cells were seed in a petri dish with 2x106 cells per 10 ml medium 
(II) d3: 10 ml fresh culture medium were added directly to the dishes 
(III) d6: The medium was removed and exchanged against fresh medium (thereby 
non-adherent cells were removed)  
(IV) d8: The plates were placed on ice and the medium was collected into a 50 ml 
falcon tube. The cell layer was washed with 10 ml cold PBS and after a short 
incubation the cells were carefully detached with a cell scraper. Cells were 
resuspended in the medium collected before. Afterwards, the cells were 
pelleted by centrifugation at 300g, 8min at 4°C. The supernatant was 
discarded and the pellet was resuspended in RPMI medium without FCS. 
(V) Cell numbers were determined and cells were cultured several days or the 
cells were prepared for experiments.   
 
2.2.2.3 Generation of peritoneal exudate macrophages (PEC) 
 
Peritoneal exudate cells (PEC) were generated to use them as “feeder cells” after 
the fusion during the generation of hybridomas. “Feeder cells” were used because 
they provide conditioned medium for the hybridoma cells. They also phagocytose 
dead cells and particles after the fusion and stabilizes the hybridoma cells. 
In general, the evening before the isolation of PEC, 1 ml sterile PBS was injected 
into mice with a 1 ml syringe and a needle size 27G ¾, 0.4x19mm. The next morning 
mice were killed and the peritoneum was flushed with 10ml cold RPMI medium 
containing 10% FCS pro mouse (needle: 20G ½, 0.9x40mm, yellow). The medium 
was recovered again with the syringe (needle: 20G ½, 0.9x40mm, yellow) and 
transferred into a 50 ml tube. Cells were centrifuged for 10min at 300g, washed twice 
with PBS/10% FCS and resuspended in an appropriate volume of medium. If cells 
were used for fusion they were resuspended in HAT medium. Cells were counted 
and the cell numbers were adjusted. For cell analysis, the cells were centrifuged 
onto a cytospin-slide at 600rpm, for 6min with low acceleration. Normally the yield of 
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isolated PEC was around 1x 106 cells per mouse. The next day sterility was checked 
before adding the hybridoma cells. 
 
2.2.2.4 Generation of PMN from bone marrow  
 
Neutrophils from mouse bone marrow were isolated according to the protocol by 
Ermert et al 2009 (Ermert et al 2009). 
 
2.2.2.4.1 Ficoll-purification of PMNs 
 
Polymorphonuclear neutrophils (PMNs) from Balb/c bone marrow were isolated over 
a Histopaque gradient. Thereby cell types were separated regarding to their size and 
density. 
First, bone marrow cells were isolated and each cell preparation was resuspended in 
3 ml RPMI-medium without FCS. In general, bone marrow cells from one mouse 
were loaded on one gradient.  
Gradients were prepared as follows: (I) apply 3 ml of Ficoll-Histopaque (density 
1.119; Sigma-Aldrich) into a 15ml tube. Slowly add 3 ml of Ficoll-Histopaque (density 
1.077; Sigma-Aldrich) and then 3 ml cell suspension was carefully overlayed on the 
gradient. The gradient was centrifuged for 30min and 700g (without brake) at 4°C. 
After centrifugation, cell populations will be separated and distributed in two layers. 
The upper layer contained the mononuclear-enriched fraction and the lower layer 
contained the neutrophil-enriched population. This lower layer should be localized in 
the interface of the two Ficoll-Histopaque layers. The upper layer was aspirated with 
a glass pipette and the cells in the lower phase were carefully collected and 
transferred into a new 50 ml tube. Cells were washed two times with 10-20ml RPMI 
medium and centrifuged for 10min and 400g at 4°C. Afterwards, the cell pellet was 
resuspended in complete medium, e.g. RPMI medium with 10% FCS, for the 
experiment. For analysis and determination of purity of the isolated neutrophils, a 
cytospin and FACS-analysis were performed. Normally nearly 80% pure neutrophils 
are obtained. 
 
2.2.2.4.2 Percoll-purification of PMNs 
 
For PMN isolation and purification from Balb/c bone marrow, cells were isolated in 
the same way as with Ficoll-purification, However, the cell suspension was 
separated over a Percoll gradient. The gradient consisted of 3 layers differing in their 
Percoll-densities.  In brief, cells were resuspended in RPMI medium with 5% FCS 
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and further given over a cell strainer and resuspended in HBSS (Hanks Balanced 
Salt Solution) medium. Cell purification was performed with the following gradient:  
 
(I) 3ml of 78% Percoll solution (lowest layer) 
(II) 3ml of 69% Percoll solution and /middle layer) 
(III) 3ml of 52% Percoll solution (upper layer)  
 
100% Percoll solution was prepared with 18 ml Percoll and 2 ml of 10x PBS. After 
centrifugation for 30min at 1500g without brake, the cells in the interphase of 69% 
and 79% Percoll were collected and washed with PBS and again centrifuged for 
10min, 400g at 4°C. PMN purity was determined by FACS analysis staining for the 
neutrophil-specific marker Gr1. 
 
2.2.2.4.3 FACS staining protocol for PMN analysis 
 
Quality and purity of isolated PMNs were determined by FACS-analysis. After 
isolation, the cell number was determined and adjusted so that between 5x105 to 
1x106 cells were transferred into a FACS-tube and pelleted for 5min at 300g at 4°C. 
Before the specific antibody staining, Fcy-receptors were blocked with rat anti mouse 
FcyR II/III, clone 2.4G2. One µl of antibody was diluted in 200µl FACS-buffer (1x 
PBS with 2% FCS). Blocking was performed for 30min, 4°C in the dark. Then the 
cells were washed once with FACS-buffer and centrifuged for 5min at 300g. 
Antibodies were diluted in FACS-buffer and staining was done for 30min, 4°C in the 
dark. After a final washing step, cells were resuspended in 200µl FACS buffer and 
directly analyzed or fixed with 2% PFA (paraformaldehyde), diluted in FACS-buffer. 
Fixed cells were stored at 4°C and analyzed within 1 week. 
 
FACS staining protocol for PMN analysis 
 
Antibodies: 
 
CD11b-PE                              diluted 1/200 
B220-PerCP                           diluted 1/600 
Ly6 C-FITC                             diluted 1/200 
Ly6 G-V450                            diluted 1/400 
 
Antibodies were diluted in FACS buffer. 
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2.2.3 Mycoplasma test 
 
Every eukaryotic cell line used in this work was periodically controlled for 
mycoplasma contamination. Cytospins from cells were stained with DAPI (1:100 
dilution) and analyzed under the fluorescence microscope. Mycoplasma appeared 
under the microscope as small blue-fluorescent dots. 
 
2.2.4 Generation of monoclonal rat anti mouse FcnB antibodies 
 
2.2.4.1 Preparation of rat splenocytes for fusion 
 
For isolation of rat spleen, rats were bled and killed. The spleen was removed under 
sterile conditions and cut into pieces with a scissor. Then the spleen pieces were 
gently strained through a metal strainer by using the stamp of a 5ml syringe. 
Flushing was performed with around 30 ml of RPMI-medium without FCS. After 
filtration, cells were centrifuged for 5min at 300g at 4°C. After two washing steps with 
25ml RPMI medium, the cells were resuspended in RPMI medium and ¼ of the cells 
was used for the fusion. The rest was kept frozen in liquid nitrogen. In general, the 
ratio of spleen cells to myeloma cells was 3:1. 
2.2.4.2 Fusion 
 
The fusion was done to combine the characteristics of immortal myeloma cells with 
antibody-producing spleen cells to generate hybridoma cells. During fusion 
splenocytes were together with myeloma cells in a ratio 3:1. In this thesis, SP2/O-
Ag14 myeloma cells (ATCC No. CRL 1581) were used. Both cell types were merged 
in a 15 ml tube and centrifuged at 300g, for 5min at 4°C. The following fusion steps 
include: 
 
(I) Supernatant after centrifugation was removed thoroughly by aspiration 
(II) Cells were incubated in a 37°C water bath, while rotating 
(III) 1 ml of 37°C-prewarmed PEG was added to the cells, while rotating 
(IV) Cells were incubated at 37°C for 1min while rotating 
(V) 10ml RPMI-medium without FCS was added drop-wise within 5min at RT 
           while gently shaking 
(VI) The cell suspension was diluted with RPMI-HAT medium up to 30 ml 
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(VII) The cell suspension was distributed on 3x 50 ml tubes and filled-up with RPMI 
           HAT medium to 50 ml total volume each 
(VIII) Fused cells were carefully transferred to 15x 96 well microtiter plates, 
           containing PEC as “feeder cells” 
 
Additional, one row contained 5x104 SP2/O myeloma cells as a negative control. 
These cells should die within a few days, because they are not able to grow in HAT-
medium. 
 
2.2.4.3 Maintenance and expansion of hybridomas 
 
Hybridomas were tested in ELISA for specific antibody production. Positive clones 
were sub-cloned and further tested. When clones remained positive in ELISA, they 
were cultured and transferred from 96-well plates to larger vessels and later to 
flasks. For antibody production and collection, the FCS percentage in the culture 
medium was reduced from 10% to 2%. After a few days, the conditioned medium 
was collected by centrifugation (300g, 8min, 4°C) and sterile-filtered into flasks until 
the antibody purification on protein G sepharose. 
2.2.4.4 Sub-cloning by dilution 
 
This technique was used for the isolation of single cell clones of the hybridomas. 
Sub-cloning should be repeated several times, until the arising clones are likely to 
originate from one single antibody-producing cell. Sub-cloning was performed in a 
96-well microtiter-plate. First, 100µl of culture medium was transferred in every well, 
except the first well (A1) by using a multichannel-pipette. Then, 200µl cell 
suspension of positive clone was pipetted to well A1. In general, the cell number of 
the hybridomas that should be subcloned was adjusted to about 100 cells. Dilution 
serie was performed from A1 to H1, while gently pipetting each step log 2. Second 
log 2 dilution series was performed with an 8-channel-pipette from row 1 to row 12. 
Finally, each well should contained total volume of 100µl. The plate was kept at 
37°C, 5% CO2. On the next day, cells were fed by adding 100µl/well culture 
medium. After 4 to 5 days, clones growing should be visible under the microscope. 
Supernatants of clones should be tested for example in ELISA for specific antibody 
production. 
Subcloning should be repeated with positive candidates until monoclonality is 
reached. 
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2.2.4.5 Freezing hybridomas 
 
Hybridoma cells and corresponding subclones were frozen for long-time storage in 
liquid nitrogen. For this, first the cell number was determined by counting them with 
trypan-blue staining. Then, 0.5 - 1x 107 cells/ml were resuspended in fresh medium 
(RPMI medium with 10% FCS) and diluted 1:2 in 2x freezing medium. Sample 
preparation was performed on ice. 
 
2.2.5 Bacterial binding studies 
 
To test whether recombinant mouse FcnB binds to bacteria, different serotypes from 
Group B Streptococcus and Staphylococcus aureus were tested.  
109 bacteria per 100µl TBS/ 0.05%Tw/ 5 mM Ca++ buffer were incubated with 5µg 
recombinant mouse FcnB-V5-His protein in a final volume of 200μl. Samples were 
incubated for 4h at RT while rotating. After centrifugation (10.000g, 10min, 4°C), 
unbound recombinant FcnB in the supernatants was quantified with a TRIFMA 
assays. A five-step tenfold dilution of 109 to 105 bacteria was made for each bacteria 
type. The bacteria were tested as described above. Additionally, 5µg recombinant 
FcnB protein was treated in the same way, but without adding bacteria, to serve as a 
positive control (= 100% unbound recombinant FcnB). 
 
2.2.6 Cytospin 
 
A simple method to analyze cells (for example after isolation from mouse) was the 
cytospin analysis by "May-Grünwald-Giemsa-staining". Here, a cell suspension was 
centrifuged onto a slide and further analyzed under the microscope. First, the cell 
number was adjusted to around 6x105 cells/ml suspension in medium containing 
50% FCS. For each slide, a total volume of 100µl was used. Slides were centrifuged 
for 6min at 600 rpm (low acceleration) and than air-dried before staining. Steps of 
Diff-Quick-staining were performed as following: (I) 5 times in the fixation solution, 
(II) 8 to 10 times in the eosin solution, (III) 5 times in methylen blue and (IV) slides 
were briefly and carefully rinsed with water and dried again. Cell analysis was 
performed on a Leica microscope under immersion oil (Leitz, Diaplan). 
 
 
 
  57 
2.2.7 Protein-biochemical techniques 
 
2.2.7.1 Protein purification  
 
2.2.7.1.1 Purification of recombinant FcnB by chelating sepharose 
 
In a previous work, mouse FcnB was cloned into a vector for expression in insect 
cells (pMTA/BiP/V5/His-A) after transfection of DS-2 cells. This vector contains the 
protein under regulation of a cupper-inducible promotor, in addition also a vector for 
later selection was co-transfected. After transfection and selection, clones positive 
for the expression of recombinant FcnB-V5-His protein were cultured. Afterwards, 
protein expression was induced by addition of copper (0.5 mM CuSO4) to the 
medium. Induced supernatant, containing the recombinant protein is collected and 
sterile filtered. The supernatant is then transferred to a chelating sepharose fast flow 
column (GE Healthcare GmbH). After binding of the protein in the supernatant to the 
column, washing steps were performed: (I) three times with washing buffer 1 (0.02 M 
Na2HPO4, 0.5 M NaCl, pH 7.5) and (II) three times with washing buffer 2, to remove 
unspecifically bound proteins (10 mM Imidazol, 0.02 M Na2HPO4, 0.5 M NaCl, pH 
7.5). Elution of bound protein is performed with increasing concentrations of 
imidazole (ranging from 10 mM to 250 mM) in the elution buffer. Elution fractions 
were collected in 0.5 ml aliquots and analyzed by SDS-PAGE for the presence of the 
recombinant protein. Equivalent fractions were pooled and dialyzed O/N against 1x 
TBS buffer. Protein concentrations are measured with PIERCE BCA Kit.  
 
2.2.7.1.2 Purification of monoclonal antibodies by protein-G sepharose 
 
In general, antibodies were purified using 2 ml protein-G sepharose, packed into a 
column and attached to the Bio Rad Econo System device. Before loading the 
column with the antibody solution, the resin was pre-equilibrated. A four-fold volume 
of binding buffer was passed through the column with a flow rate of 0.5 ml/min. Then 
the antibody solution was loaded onto the protein G sepharose column at the same 
flow rate. Non-specifically bound proteins were washed off with binding buffer until a 
baseline UV absorbance was reached monitored at 280 nm.  
Elution was performed at 0.5 ml/min with elution buffer (0.1 M glycine pH 3.1) and 
samples were collected in 1.5 ml Eppendorf tubes, in 1 ml fractions. Immediately 
after elution, samples were neutralized with 1M Tris pH 11. Afterwards, purified 
antibody fractions were analyzed on SDS-PAGE. Corresponding fractions were 
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pooled and dialyzed against TBS O/N at 4°C, while swirling. Protein concentrations 
of dialyzed samples were determined using a PIERCE BCA kit. Aliquots of 
antibodies were stored for long term at -20°C. To re-use the protein-G sepharose 
column, the resin was regenerated by washing first with 6 M Urea, washing and 
flushing with 20% ethanol and stored. 
 
 
 
 
Figure 14: Protein purification of one monoclonal rat-anti-mouse FcnB antibody.  
Representative, the elution profile of the purification of the antibody 2F1 B6 E2 is shown. Elution 
fractions were loaded on a SDS-PAGE gel and stained with Coomassie blue. 
 
2.2.7.2 Preparation of the protein lysates 
 
For preparation of protein lysates from cells, the cells were collected and washed by 
a centrifugation step at 300g, for 8min at 4°C. The supernatant was discarded and 
the cells were resuspended in 2 ml PBS. The cell number was determined by trypan 
blue exclusion staining. The cell suspension was transferred to a microcentrifuge 
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tube and centrifuged for 5min and 14.000 rpm at 4°C. For cell lysis, 1x106 cells were 
resuspended in 50µl RIPA buffer (containing protease inhibitor). The lysates were 
stored at -80 °C. Before application, the protein concentrations of the lysates were 
determined with Pierce BCA kit. 
 
2.2.7.3 Determination of the protein concentration 
 
For determination of the protein concentrations, the protein Assay Kit “BCA Protein 
Assay Reagent (bicinchoninic acid)“ from Pierce was used. First, 10µl of each 
standard (BSA standard curve) or unknown sample were pipetted in duplicates into a 
96 well microtiter plate. Then 200µL of the WR (working ratio: 50 parts solution A to 
1 part solution B) was added to each well and carefully mixed by pipetting before the 
plate was incubated at 37°C for 30min. After incubation, the plate was cooled down 
to RT. Finally the absorbance was measured at 562 nm wavelength on a plate 
reader and the protein concentration was calculated with the BSA standard curve. 
 
2.2.7.4 SDS-PAGE 
 
10% Separation gel (10 ml total: for 2 mini gels, each 1mm or one large gel) 
  
Substance Volume [ml] 
1M Tris-HCl pH 8.8 3.75 
30% Acrylamide 3.33 
Glycerol 0.574 
H2O 2.2 
10% SDS 0.1 
10% APS 0.05 
Temed 0.01 
  
4% Concentration gel (5 ml total: for 2 mini gels, each 1 mm)  
 
Substance Volume [ml] 
1 M Tris-HCl pH 6.8 0.625 
30% Acrylamide 0.65 
H2O 3.65 
10% SDS 0.050 
10% APS 0.025 
Temed 0.005 
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2.2.7.5 Coomassie staining 
 
SDS-PAGE and membranes after western blotting were stained with brilliant blue 
Coomassie staining solution. In general, the gel or membrane was incubated in 
Coomassie-solution for 1h at RT, then de-stained and finally dried under vacuum 
conditions. This method is useful for checking of the protein loading.  
 
2.2.7.6 Biotinylation of antibodies 
 
To enhance the detection signals of antibodies, the strong binding of biotin to 
Streptavidin was used. Thereby, biotinylated antibodies are detected with an HRP-
coupled-Streptavidin reagent. First, antibodies were diluted in PBS. Around 200µg of 
the antibodies were diluted in a total amount of 500µl PBS and dialyzed against PBS 
O/N at 4°C under rotation. Then the antibodies were dialyzed against PBS pH 8.5 
(adjusted with 0.4 M KH2PO4) to provide binding conditions for biotin. A second 
dialysis was performed for 2h at RT, while rotating. 
The antibody solutions were placed from the dialysis pipe to blocked microcentrifuge 
tubes. These tubes were normally blocked with 1x TBS/Tw and later washed 3 times 
before using. In blocked microcentrifuge tubes, the antibodies were incubated with 
biotin (NHS, Sigma) for 4h at RT. For this purpose 33.4µl NHS-Biotin in DMSO were 
adjusted to 200µg antibody. After biotinylation, the biotinylated antibodies were 
dialyzed against 1x TBS with 0.1% (15mM) azide. The first dialysis was performed 
O/N at 4°C and the next day the dialysis was repeated against TBS two times for 
shorter time intervals. The concentration of the biotinylated antibodies was 
determined and then the biotinylated antibodies were stored at 4°C. 
 
2.2.8 Immunoassays  
 
2.2.8.1 Western blot 
 
Blotting: 
 
For Western blot analysis first the proteins were separated according to their 
molecular sizes on SDS-PAGE. Blotting materials were prepared: (I) PVDF 
membrane 6x8.5 cm, (II) 3x3 whatman paper (7x9cm) and (III) the stacking gel from 
SDS-PAGE was cut off and the gel was incubated in transfer buffer. To activate the 
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membrane, transfer-membrane from Immobilon was incubated for 3min in methanol. 
The activated membrane, the gel and the whatman papers were soaked in transfer 
buffer for 10 to 15min at RT. The blotting order was as shown in Fig. 15. 
 
 
 
Figure 15: Schematically arrangement for Western blot analysis. 
 
Blot conditions: 1h with 25 Volt constant in 1x transfer buffer. After blotting, efficiency 
was tested with Ponceau S red staining. Additionally, the SDS-PAGE was stained 
with Coomassie after blotting to check transfer efficiency. 
 
Ponceau S red staining: 
 
After blotting, the membrane was incubated for 2min in Ponceau red dilution (1:5 in 
water). For this the protein-covered membrane site was placed upside down into 
staining solution. Afterwards, the membrane was successively de-stained with 
distilled water. Protein loading was checked and then the membrane was blocked 
before incubation with the antibody.  
 
Blocking: 
 
Membrane blocking was normally performed at RT for 1h in 10% skim-milk powder, 
1xTBS/ 0.05% Tw/ 5 mM Ca++. Non-specific binding sites were blocked. 
 
Antibody staining: 
 
After blocking, the membrane was exposed to the antibody diluted in 3% skim-milk 
powder/TBS/Tw/Ca++ for 1h at RT or O/N at 4°C. The membrane was washed 3 
times with TBS/Tw. Each washing step was performed for 10min. The secondary 
antibody-HRP was diluted in 3% skim-milk powder/TBS/Tw/Ca++ and the membrane 
was incubated for 45min at RT with the secondary antibody solution. In the case that 
the primary antibody was biotinylated, the secondary Streptavidin-HRP was diluted 
in PBS/ 1% BSA and incubated for 30min at RT. Washing steps were performed 
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between both antibody-exposures and afterwards (TBS/Tw, 3 times, each 10min, at 
RT). For development, ECL-Substrate from NOWA Solution A and B (MoBiTec) was 
used at a ratio 1:1. Incubation was performed for 1min at RT, while shaking.  
Exposure was done for 1-10min, depending on the signal obtained.  
 
Membrane stripping: 
 
For western blot analysis, the membrane can be developed successively with 
different antibodies. Therefore, antibodies used first have to be removed. This 
process is called “membrane stripping”.  
First, the membrane was incubated in 99% ethanol for 15min under rocking 
conditions. Then, the membrane was incubated for 35min at 57°C in a water bath in 
the stripping buffer. Afterwards the membrane was washed 3 times for 5min with 
TBS/Tw and blocked again with milk powder, before the membrane was incubated 
with the next antibody. 
 
Membrane staining: 
 
After the western blot was developed, the membrane was stained with brilliant blue 
Coomassie staining solution. In general, the membrane was incubated in 
Coomassie-solution for 1h at RT. Then the membrane was de-stained. When 
successfully de-stained and when the background was clear, the membrane was 
washed in water before drying it.  
 
2.2.8.2 Dot blot 
 
Dot blot is a method for detection of proteins by antibodies in their native (not 
denatured) form on a nitrocellulose membrane. For this, the samples were dotted on 
the membrane and dried. If the protein sample contains the specific antigen, 
recognition by the antibody results in a detectable signal. For more detailed analysis 
of the antigen, concerning the size, a western blot analysis is indispensable. 
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2.2.8.3 Enzyme-linked immunosorbent assay (ELISA)  
 
This method is also based on the binding between antigens and antibodies. The 
interaction is detected by an enzymatic color reaction. Three different kinds of 
ELISA-application are known: 
 
(I) Antibody capture assay, where an antibody is coated to „fish“ appropriate 
antigen from a protein solution 
(II) Antigen capture assay, for example to test antibodies regarding to their 
specificity and quality 
(III) Sandwich assay, based on two antibodies: one capture- and one detection 
antibody, to make the ELISA system more sensitive 
 
In general, ELISAs were performed in 96-well microtiter plates. Samples were 
directly (coating) or indirectly added to the plate. Unbound protein was washed away 
and an enzymatic color switch, induced by binding of enzyme-linked secondary 
antibodies, determined bound protein. Mainly, these secondary antibodies were 
coupled to horseradish-peroxidase.  
  
2.2.8.3.1 Antigen-capture-ELISA for determination of serum titers and for 
hybridoma selection 
 
(I) Coating of recombinant mouse FcnB in Coating buffer is performed O/N, 4°C 
(II) Unspecific binding sites are blocked with 10% skim-milk powder in TBS/Tw for 
1h at RT 
(III) Samples (e.g. serum or supernatant) are transferred at different dilutions to 
the plate and incubated O/N at 4°C 
(IV) Wells are washed 3 times with TBS/Tw 
(V) Secondary goat anti rat IgG-HRP is added for detection 1h, RT 
(VI) Wells are washed 3 times with TBS/Tw 
(VII) ECL-solution is added (NOWA solution A and B (ratio 1:1) for development 
(VIII) Reaction is stopped with 2N H2SO4 
(IX) Plates are measured at 450nm 
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2.2.8.3.2 AcBSA-binding assay 
 
Microtiter wells were coated with 10µg/ml AcBSA in Coating buffer O/N at 4°C. After 
blocking residual binding sites, serial dilutions of recombinant FcnB diluted in 
TBS/Tw/Ca or TBS/Tw/EDTA buffer were added and incubated O/N at 4°C. After 
washing with TBS/Tw, the wells were incubated O/N at 4°C with the monoclonal rat 
anti-FcnB antibody IA4 (3µg/ml, TBS/Tw/Ca), washed with TBS/Tw, and the 
secondary antibody goat-anti-rat IgG (Y-chain-specific)-HRP (1:3000 diluted in 
TBS/Tw) was added for 1 h. After washing, HRP substrate (1:1 diluted, NOWA 
Solution A and NOWA Solution B from Mo Bi Tec) was added, the reaction was 
stopped with 2N H2SO4, and the absorption was measured at a wavelength of 450 
nm. 
To assess whether FcnB exhibits calcium-dependent binding to AcBSA, the FcnB 
samples were diluted in TBS/Tw buffer with 10 mM of calcium chloride or 50 mM 
EDTA and tested in the ELISA. 
To analyze whether binding of recombinant FcnB to AcBSA is inhibited by DNA, the 
ELISA was performed with FcnB samples pre-incubated with or without genomic 
DNA from E. coli as described above (10 or 25 µg/ml in TBS/ 0.05% Tw/ 5 mM 
Ca++). 
 
2.2.8.4 Time-resolved immunofluorometric assay (TRIFMA) 
 
The TRIFMA assay is based on europium bound to streptavidin. When the 
immunometric assay has been completed the europium is dissociated from the 
streptavidin at low pH (by adding the Enhancement buffer) and measured by time-
resolved fluorescence (TRF). 
First, microtiter wells were coated with 10µg/ml AcBSA in coating buffer O/N at 4 °C. 
After blocking residual binding sites, protein samples were diluted in TBS/Tw buffer 
and incubated O/N at 4 °C. After washing with TBS/Tw, wells were incubated O/N at 
4°C with primary antibody. For this, the primary antibody was biotinylated and can be 
detected with streptavidin-conjugated Europium (1:1000; 100ng/ml). Europium-
streptavidin was incubated for 1h at RT, and washing steps follow. Before the 
measurement, 200µl of the enhancement-solution were added and incubated for 
5min at RT, while shaking. Signals were measured with the DELFIA fluorometer 
multilabel counter (Victor 3 1420, Perkin Elmer) as Counts/sec.  
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2.2.8.4.1 Sandwich TRIFMA 
 
Microtiter wells were coated with the primary antibody („capture“ antibody) in Coating 
buffer O/N at 4 °C. After blocking of residual binding sites, the antigen was added in 
serial dilutions in TBS/Tw buffer and incubated O/N at 4 °C. After washing with 
TBS/Tw, the wells were incubated O/N at 4°C with another antibody („detection“ 
antibody). The „detection“ antibody was biotinylated and can be detected with 
streptavidin-conjugated Europium (1:1000, 100ng/ml). Europium-streptavidin was 
incubated for 1h at RT and washing steps follow. Before the measurement, 200µl of 
the enhancement-solution were added and incubated for 5min at RT, while shaking. 
Signals were measured with a fluorometer (Victor 3 1420 Multilabel Counter, Perkin 
Elmer) as Counts/sec.  
 
2.2.8.4.2 MASP-2 binding Assay 
 
(I) Coating 10µg/ml AcBSA with 100µl/well of a 96-well microtiter-plate in coating 
           buffer, O/N at 4°C 
(II) Blocking was performed with TBS/Tw, 1h at RT 
(III) The (recombinant) ficolin was added in TBS/Tw/Ca++ to plate and binding to 
           AcBSA was allowed O/N at 4°C 
(IV) The plate was washed 3 times with TBS/Tw/Ca++ 
(V) Recombinant human MASP-2 was added (500ng/ml) and incubated O/N, 4°C 
(VI) The plate was washed 3 times with TBS/Tw/Ca++ 
(VII) The biotinylated anti-MASP-2 antibody (8B5) was added and incubation was 
           performed O/N at 4°C 
(VIII) Washing 3 times with TBS/Tw/Ca++ 
(IX) Streptavidin-Eu3+, diluted 1:1000 in Europium-buffer was added for 1h at RT 
(X) The plate was washed 3 times with TBS/Tw/Ca++ 
(XI) 200µl of the enhancement buffer was pipetted to each well and the plate was         
           shaken 5min at RT 
(XII) Measure the plate by TRF (Ex: F340nm, Em: 615nm) 
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2.2.8.4.3 C4-deposition Assay 
 
Binding of ficolins to MASPs leads to complement activation. Complement activity 
was measureable by the detection of the complement factor C4b. C4b was only 
cleaved when complement activity was induced. 
 
C4-deposition Assay: 
 
(I) Coating 10µg/ml AcBSA with 100µl/well of a 96-well microtiter-plate in 
           coating buffer, O/N at 4°C 
(II) Blocking was performed with TBS/Tw, 1h at RT 
(III) (Recombinant) ficolin/MASP-mixture was added in TBS/Tw/Ca++ to plate and 
           binding to AcBSA was allowed O/N at 4°C 
(IV) Plate was washed 3 times with TBS/Tw/Ca++ 
(V) Recombinant human C4 was added (1:1000) and incubated for 2h at 37°C 
(VI) Plate was washed 3 times with TBS/Tw/Ca++ 
(VII) Anti-C4-biotinylated antibody mix was added and incubation is performed for 
           1h at 37°C 
(VIII) Washing 3 times with TBS/Tw/Ca++ 
(IX) Streptavidin-Eu3+ was added 1:1000 in Europium-buffer for 1h at RT 
(X) Plate was washed 3 times with TBS/Tw/Ca++ 
(XI) 200µl enhancement buffer was pipetted to each well and plate was shaken 
           2min at RT 
(XII) Measure the plate by TRF (Ex: F340nm, Em: F615nm) 
 
2.2.9 Confocal microscopy with PMNs 
 
For functional analysis of mouse FcnB, PMNs isolated from Balb/c bone marrow 
were studied by confocal microscopy. First PMNs were isolated following general an 
isolation protocol. 
 
2.2.9.1 Pre-treatment of labtek chambers or cover slips with poly-L-lysine 
 
For better attachment of isolated bone marrow-derived PMNs, the wells or slides 
were covered with a poly-L-lysine layer. The labtek chamber (Nalge Nunc) can 
directly be covered with 0.01% poly-L-lysine (PLL). 250 µl of the PLL-solution were 
added and incubated for 20min at RT, and washing steps with 500µl distillated water 
  67 
follows. The labtek chamber was air-dried, before the cells were added. Drying is 
arranged for at least 1h under the sterile hood. In the case of the cover slips, first an 
sterilization is performed. The cover slips were first incubated in 250µl ethanol for 
20min at RT. After washing 2 times with 500µl water, 250 µl of PLL were added and 
incubated for 20min at RT. An additionally washing step was done with 500µl 
distilled water. The cover slips were dried before the cells were transferred to them. 
 
2.2.9.2 Seeding of PMNs and stimulation 
 
After isolation and FACS analysis for purity, 5x105 PMNs were seeded in 200 µl 
medium, in a labtek chamber pre-treated with poly-L-lysine for 1h at 37°C. Then, the 
cells were stimulated. 200µl of RPMI/10% FCS medium was added containing a 
vehicle (DMSO) or 120ng/ml PMA (PMA is diluted in DMSO suspension). The cells 
were cultured for 16h at 37°C and 5% CO2 in an incubator.  
 
2.2.9.3 Preparation of PMNs for confocal microscopy  
 
(I) After the incubation of PMNs for 16h at 37°C, the supernatant was 
removed and the wells were washed with PBS 
(II) Cells were fixed for 30min in 1% (final) PFA, dissolved in PBS 
(III) Cells were washed with PBS 3 times for 5min 
(IV) Cells were permeabilized with 50µl 0.5 % Triton X-100 (in PBS) for 1min at 
RT 
(V) Cells were washed 3 times in PBS for 1min 
(VI) 100 µl of blocking buffer was added and incubated for 30min at 37°C   
(VII) Blocking buffer was removed from the wells 
(VIII) 50µl primary antibody solution was added, diluted in blocking buffer and 
incubated for 1h at 37°C 
(IX) Washing was performed 3 times for 5min with PBS 
(X) 50µl of the secondary antibody diluted in blocking buffer was added for 1h at 
37°C  
(XI) Cells were washed 3 times in PBS for 1min  
(XII) DNA staining with ToPro3 (1:1000 final, light sensitive!) for 15min  
(XIII) Washing was performed 2 times for 5min with distilled water 
(XIV) 5µl of Fluoromont were added 
(XV) Neutrophils were analyzed under the confocal microscope 
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2.2.10 Animal experiments 
 
Female rats (ACI, Wistar and Fischer 344) were purchased from Charles River.  
Primary cells were isolated from C57BL/6 mice, aged between 8 and 10 weeks. 
Animals were kept under conventional conditions with food and water ad libitum in 
the animal facilities of the University of Regensburg and handled in accordance with 
institutional guidelines and the German Federal Regulations of Animal 
Experimentation. 
 
2.2.10.1 Immunization of rats 
 
For generation of monoclonal rat-anti-mouse FcnB antibodies, three rats were 
immunized with the Drosophila Schneider S2 cell-produced-recombinant-mouse 
FcnB. Three different rat strains were chosen, to enhance the likelihood to generate 
monoclonal antibodies.  
Three female rats (strains: Wistar, ACI and F344) were immunized with 100μg/ml of 
the purified recombinant FcnB-V5-His protein in CFA s. c. and boosted in four-week 
intervals each time with 100μg/ml recombinant FcnB-V5-His protein s.c. (first boost 
with IFA, other boosts without adjuvant). Before the immunization (pre-immune), 1 
week after the immunization and 1 week after each boost, the animals were 
anesthetized (8 mg xylazine + 37 mg ketamine/body weight in 0.2 ml PBS). The 
blood was drawn from the retroorbital plexus and the antibody titer was determined 
by ELISA. When a good response was observed, the corresponding animal was 
boosted for a last time and sacrificed three days afterwards. The spleen cells were 
used for fusion with SP2/O cells. 
 
Immunization protocol: 
 
For generation of monoclonal rat anti mouse FcnB antibodies, three rats were 
immunized in parallel with recombinant mouse FcnB produced in DS-2 cells. This 
recombinant protein is tagged with a V5 Tag and a His-Tag. Both tags enable easy 
purification over corresponding columns, but also increase the risk to generate 
antibodies during immunization, raised against a tag. Following, the steps of each rat 
immunization are listed. 
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Species Rat 
Strain Agouti, ACI 
Gender Female 
Age at beginning ≈ 7 weeks 
Arrival date/ birth date ∗ 15.06.2009, EZ (selfishness) 
Immunized antigen Recombinant DS-2 FcnB-V5-His, Pool B, 
purification from 19.06.2009, conc. Of 0.710 
mg/ml, supplemented with Ectoin for protein 
stabilization 
Start immunization 04.08.2009 
 
Date Bleeding Immunization Serum 
04.08.2009 Yes Immunization i.p. (100µg/ml in TBS + 
1.2 ml CFA) 
1ml (-20°C) 
25.08.2009 No 1. Boost i.p. (100µg/ml + 1.2ml IFA)  
02.09.2009 Yes  1ml (-20°C) 
21.09.2009 No 2. Boost i.p. (100µg/ml)  
24.09.2009 Yes KILL + FUSION with ¼ spleen  2ml (-20°C) 
 
Tab. 6: Overview immunization ACI rat. 
 
100µg/ml of protein was diluted in TBS-buffer and injected i.p. with CFA or later IFA. 
After second boost and killing of the rat, spleen cells were prepared according to the 
protocol for fusion. One day before, PEC were seeded as “feeder” cells. For fusion ¼ 
spleen was fused with SP2/0 myeloma cells in a ratio of 3:1.  
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Species Rat 
Strain Wistar 
Gender Female 
Age at beginning ≈ 5 weeks 
Arrival date/ birth date ∗ 05.07.2003, EZ (selfishness) 
Immunized antigen recombinant DS-2 FcnB-V5-His, Pool B, 
purification 19.06.2009, 0.710 mg/ml, 
supplemented with Ectoin  
Start immunization 04.08.2009 
 
Date Bleeding Immunization Serum  
04.08.2009 Yes Immunization i.p. (100µg/ml + 1.2 ml 
CFA) 
1ml (-20°C) 
25.08.2009 No 1. Boost i.p. (100µg/ml + 1.2 ml IFA)  
02.09.2009 Yes  1ml (-20°C) 
21.09.2009 No 2. Boost i.p. (100µg/ml + 1.2 ml IFA)  
29.09.2009 Yes  1ml (-20°C) 
26.10.2009 No 3. Boost i.p. (100µg/ml)  
29.10.2009 Yes KILL + FUSION with 1/5 spleen 3ml (-20°C) 
 
Tab. 7: Overview immunization Wistar rat. 
 
100µg/ml of protein was diluted in TBS-buffer and injected i.p. with CFA or later IFA. 
After second Boost and killing of the rat, spleen cells were prepared according to the 
protocol for fusion. One day before, PEC were seeded as “feeder” cells. For fusion 
1/5 spleen was fused with SP2/0 myeloma cells in a ratio of 3:1. Spleen size was 
obviously very big, compared to normal spleen. Also spleen cell number was higher 
than normally obtained. 
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Species Rat 
Strain Fisher 344, F344 
Gender Female 
Age at beginning ≈ 7 weeks 
Arrival date/ birth date ∗ 13.06.2003, EZ (selfishness) 
Immunized antigen Recombinant DS-2 FcnB-V5-His, Pool B, 
purification from 19.06.2009, conc. Of 0.710 
mg/ml, supplemented with Ectoin for protein 
stabilization 
Start immunization 04.08.2009 
 
Date Bleeding Immunization Serum  
04.08.2009 Yes Immunization (100µg/ml + 1.2ml 
CFA) 
1ml (-20°C) 
25.08.2009 No 1. Boost i.p. (100µg/ml + 1.2 ml IFA)  
02.09.2009 Yes  1ml (-20°C) 
21.09.2009 No 2. Boost i.p. (100µg/ml + 1.2 ml IFA)  
29.09.2009 Yes  1ml (-20°C) 
26.10.2009 No 3. Boost i.p. (100µg/ml + 1.2 ml IFA)  
02.11.2009 Yes  1ml (-20°C) 
15.12.2009 No 4. Boost i.p. (100µg/ml + 1.2 ml IFA)  
05.01.2010 Yes  2ml (-20°C) 
19.01.2010 Yes KILL, store spleen at -80°C 2ml (-20°C) 
 
Tab. 8: Overview immunization F344 rat. 
 
Rat was not used for fusion so far, because the titer was not that high, compared to 
both other immunized rats. Therefore, spleen cells were isolated and stored at -80°C 
for later fusion, if necessary.  
 
2.2.10.2 Collection of blood and serum preparation 
 
Before and after the immunization and also after the booster injections with 
recombinant FcnB-V5-His protein, blood from all three rats was collected in a 15 ml 
falcon and stored O/N at 4°C to allow blood clotting. On the next day, the clotted 
blood was carefully separated from the wall of the falcon, the samples were 
centrifuged at 3000g for 10min and afterwards the supernatant was transferred into a 
new eppendorf tube and centrifuged again. Then, the serum was transferred again to 
a new tube and stored at -20°C.  
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2.2.11 Statistical calculations 
 
Experimental data represent mean values ± standard deviation (SD). The statistical 
analyses were performed using the One-way ANOVA by GraphPad Prism4.  
Values with p < 0.05 were accepted as statistically significant and indicated with *, 
values with p < 0.001 were indicated with ** and values with p < 0.0001 were 
indicated with ***. 
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3. Results 
3.1 Recombinant FcnB expressed in DS-2 insect cells 
 
For the characterization of FcnB the protein was recombinantly expressed in 
Drosophila Schneider 2 cells (DS-2). The protein was tagged with a V5-His protein to 
enable purification and detection. Different fractions after purification were analyzed 
on SDS-PAGE (Fig. 16, left) and the protein concentrations were determined. 
Further, 5µg/ml of the recombinant protein were loaded onto SDS-PAGE and blotted 
to nitrocellulose and characterized using the monoclonal rat anti-mouse FcnB 
antibody IA4 for detection. In Western blot analysis under non-reducing conditions 
the FcnB monomer appeared at a molecular weight of ∼ 35 kDa, but higher 
oligomers were also observed (Fig. 16, right).  
 
 
 
Figure 16: Gel-analysis of recombinant FcnB-V5-His protein.  
The protein was loaded at different concentrations on SDS-PAGE, separated under reducing 
conditions and stained with Coomassie-blue (left). Further, the recombinant protein (5µg/ml) after a 
SDS-PAGE run was blotted and detected with the monoclonal rat anti-mouse FcnB antibody IA4 
(right). The molecular weight standard (Std) is indicated in kDa. 
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3.2. Expression of FcnB 
3.2.1 Expression of FcnB in Hoxb8-neutrophils 
 
RT-PCR analyses were performed to determine sources for mRNA expression of 
FcnB. The expression was analyzed in a neutrophil-like cell line: The ERHoxb8 cell 
line was kindly provided by G. and H. Häcker. ERHoxb8 cells provide a good source 
for the analysis of mouse neutrophils in vivo (McDonald et al., 2011). These cells 
represent progenitor cells of neutrophils and are able to stay in a progenitor status 
when cultured in estradiol-containing medium. After withdrawal of estradiol, the cells 
differentiate within 3 to 4 days to neutrophils. 
RT-PCR was performed to test whether these cells are a source of FcnB. The 
expression of FcnB was analyzed using transcribed RNA samples from Hoxb8-
neutrophils during their differentiation, starting from the progenitors. Fig. 17 shows 
the expression of FcnB depending on the day of culture in the absence of estradiol. 
The expression profile reveals an increase from day 2 (d2) on with a maximum 
expression level achieved on day 3 (d3). During the cultivation of Hoxb8-neutrophils, 
the expression decreased to basal expression levels. This demonstrated expression 
of FcnB without stimulation.  
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Figure 17: Analysis of FcnB expression in Hoxb8-neutrophils. 
Hoxb8-neutrophils were generated from the progenitor cells and analyzed by RT-PCR at indicated 
time-points during cell culture for FcnB expression. The data represent mean ± SD of 5 independent 
cultures. The experiment was repeated at least 3 times.  
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3.2.1.1 Stimulation of Hoxb8-neutrophils with LPS E. coli  
 
Besides non-stimulated Hoxb8-neutrophils, the stimulation effect of different 
reagents was investigated. Therefore, the cells were differentiated and adjusted to a 
defined cell number before starting the stimulation experiment. The cells were left 
untreated for 6h after seeding into wells and stimulated afterwards with LPS from E. 
coli. After different time-points the cells were lysed, the RNA was isolated, reverse 
transcribed, and RT-PCR was performed. As shown in Fig. 18, the FcnB expression 
of non-stimulated Hoxb8-neutrophils on day 3 (d3) was enhanced by stimulation with 
LPS. The cells responded to LPS with increased expression levels within 30min. 
Longer stimulation times did not lead to further enhanced expression and the 
expression started to declined after 1h of stimulation. 
 
NS 30 min 1h 2h
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Figure 18: FcnB expression of LPS-stimulated Hoxb8-neutrophils (day 3).  
Hoxb8-neutrophils were generated from progenitor cells and stimulated on day 3 of differentiation with 
LPS from E. coli (100ng/ml) for the indicated times and FcnB expression was analyzed by RT-PCR. 
The results are given as mean ± SD from 6 independent cultures. The experiment has been repeated 
at least 2 times.  
 
Since longer stimulation times with LPS seemed to reduce FcnB expression 
stimulation with LPS was performed for 24, 48 and 72h. Strong expression levels in 
Hoxb8-neutrophils of day 3 of culture without stimulation were observed. Longer 
incubations with LPS had a reducing effect on FcnB mRNA levels (see Fig. 19).  
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Figure 19: FcnB expression in Hoxb8-neutrophils after long-time exposure to LPS.  
Hoxb8-neutrophils were generated from progenitor cells and stimulated on day 3 of culture for 
indicated times with LPS from E. coli (100ng/ml) and FcnB expression was analyzed by RT-PCR. 
Results are given as mean ± SD from 3 independent cultures.  
 
To investigate whether the induction of expression was possible at a later time point 
of differentiation, stimulation experiments with LPS from E. coli were repeated with 
Hoxb8-neutrophils on day 5 of differentiation. A similar increase in FcnB expression 
was obtained within only 30min of stimulation. This shows that FcnB is not only 
rapidly induced, but also inducible independently of the differentiation state of 
neutrophils derived from ERHoxb8 cells (see Fig. 20).  
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Figure 20: FcnB expression of LPS-stimulated Hoxb8-neutrophils (day 5).  
Hoxb8-neutrophils were generated from progenitor cells and stimulated on day 5 of differentiation with 
LPS from E. coli (100ng/ml) for the indicated times and FcnB expression was analyzed by RT-PCR. 
The results are given as mean ± SD from 4 independent cultures. The experiment has been repeated 
at least 2 times.  
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3.2.1.2 Stimulation of Hoxb8-neutrophils with PMA/Ionomycine 
 
Hoxb8-neutrophils were stimulated with a mixture of PMA and Ionomycine for 
different times. As seen for LPS, mRNA expression showed a rapid increase after 
30min of stimulation with PMA and Ionomycine compared to non-stimulated control 
samples. The expression decreased after 2h of stimulation (see Fig. 21).   
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Figure 21: FcnB expression of PMA/Ionomycine-stimulated Hoxb8-neutrophils.  
Hoxb8-neutrophils were generated from progenitor cells and stimulated on day 5 of culture for the 
indicated times with PMA/Ionomycine (PMA: 15ng/ml and Ionomycine: 1µM) and FcnB expression 
was analyzed by RT-PCR. Results are given as mean and SD from 5 independent cultures. 
 
3.2.1.3 Stimulation of Hoxb8-neutrophils with CpG 
 
Hoxb8-neutrophils were stimulated with CpG for different times. In contrast to LPS 
and PMA/Ionomycine, CpG had no effect on FcnB mRNA expression. The 
experiment was repeated 4 times independently with similar results. CpG did neither 
increase nor affect the expression of FcnB otherwise (see Fig. 22).  
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Figure 22: FcnB expression of CpG-stimulated Hoxb8-neutrophils.  
Hoxb8-neutrophils on day 5 of differentiation were stimulated for indicated time points with CpG 
(5µg/ml) and FcnB expression was analyzed by RT-PCR. Data represent mean ± SD from 4 
independent cultures. 
 
3.2.1.4 Stimulation of Hoxb8-neutrophils with aggregated IgG 
 
Hoxb8-neutrophils were stimulated with aggregated rat IgG for different times. 
Aggregated immunoglobulins were used to stimulate Fc-receptors by agglutinating 
them. Aggregated IgG had no significant effect on mRNA expression of FcnB. 
Aggregated IgG did neither increase nor affect otherwise the expression of FcnB. 
The experiment was repeated 5 times independently (see Fig. 23). 
 
NS 30 min 1h 2h 4h
0
1
2
3
Aggr. IgG stimulation
 
  
Figure 23: FcnB expression of Hoxb8-neutrophils stimulated with aggregated IgG.  
Hoxb8-neutrophils were generated from progenitor cells and stimulated on day 5 for indicated times 
with aggregated mouse IgG (20µg/ml) and the FcnB expression was analyzed by RT-PCR. Results 
are given in mean ± SD from 5 independent cultures.  
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Taken together, FcnB mRNA is expressed by Hoxb8-neutrophils. During the 
differentiation to neutrophils, the expression peaks around d3 and decreases 
afterwards to basal levels. RT-PCR analysis and stimulation experiments indicated a 
rapid mRNA expression after stimulation, performed at d3 and also on d5 of 
differentiation to neutrophils. LPS and PMA/Ionomycine resulted in an increase of 
the expression, whereas reagents like CpG or aggregated IgG did not affect the 
FcnB expression. 
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3.2.2 Expression of mouse FcnB in primary PMN 
3.2.2.1 Stimulation of PMN with LPS E. coli 
 
PMN isolated from bone marrow were either left non-stimulated or were stimulated 
for 30min with LPS. Results demonstrated that PMNs from the bone marrow 
expressed FcnB and the expression was enhanced up to three-fold within 30min by 
LPS stimulation (see Fig. 24). 
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Figure 24: FcnB expression in PMN.  
The expression of FcnB mRNA was investigated in PMN isolated from the bone marrow without 
stimulation or after stimulation with LPS E. coli (100ng/ml). Results are given in mean from 6 
independent cultures. Statistical analysis was performed using an unpaired t-test.  
3.2.2.2 Expression of FcnB in sorted PMN 
 
Primary polymorph nuclear neutrophils (PMN) from bone marrow and spleen were 
isolated from C57BL/6 mice. To separate the immature PMN subpopulations PMN-
MDSC (polymorph nuclear neutrophil-myeloid derived suppressor cells) and MO-
MDSC (mononuclear neutrophil-myeloid derived suppressor cells) first a negative 
depletion by MACS (by anti-CD4, anti-CD8, anti-B220, anti-NK1, and anti CD11c) 
was performed to enrich CD11b+ cells. Second, PMN-MDSC (CD11b+ Ly6G+ Ly6C+) 
and MO-MDSC (CD11b+ Ly6G- Ly6C+) were separated by a positive selection for 
Ly6G+ cells.  
FcnB mRNA was exclusively expressed by PMN-MDSC, which had a purity of 
around 90 %. Expression of FcnB by PMN was found in the spleen, as well as the in 
bone marrow (see Fig. 25). In contrast, no expression of FcnB was found in MO-
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MDSC, which had a purity of around 60 % when isolated from the spleen and only 
31% when isolated from the bone marrow. Cell isolations and MACS experiments 
were performed by Dominic Schmidt. 
 
0.00
0.05
0.10
0.15
0.20
0.25
*
 
 
Figure 25: FcnB expression of subpopulations of PMN from bone marrow and spleen.  
Purified PMN-MDSC (CD11b+ Ly6G+ Ly6C+) and MO-MDSC (CD11b+ Ly6G- Ly6C+) from bone 
marrow and spleen were used for FcnB expression analysis by RT-PCR. Results are given in mean ± 
SD from 3 independent technical replicates. 
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3.2.3 Expression of FcnB in bone marrow-derived macrophages (BMDM) 
 
To investigate FcnB expression in macrophages, cells from bone marrow were 
isolated and cultured in M-CSF containing medium for differentiation into 
macrophages. At each day of cell culture, cells were isolated and FcnB expression 
was determined by RT-PCR. The FcnB expression was high during the first days of 
differentiation in M-CSF-containing medium and decreased during differentiation 
steadily (see Fig. 26). 
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Figure 26: FcnB expression in BMDM.  
In vitro generated macrophages from the bone marrow were analyzed at indicated times for FcnB 
expression by RT-PCR. Data represent mean ± SD from 3 independent cultures. The experiments 
were repeated at least 3 times. 
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3.2.4 Expression of FcnB in bone marrow-derived dendritic cells (BMDC) 
3.2.4.1 Expression of FcnB in BMDC from wild type mice 
 
To investigate FcnB expression in dendritic cells, bone marrow cells were cultured in 
GM-CSF-containing medium to differentiate precursor cells into dendritic cells. At 
each day of cell culture, cells were isolated and the FcnB expression was 
determined by RT-PCR. During the dendritic cell development, FcnB expression 
peaked on d4 (see Fig. 27).  
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Figure 27: FcnB expression in BMDC.  
In vitro generated dendritic cells from the bone marrow were analyzed at indicated times for FcnB 
expression by RT-PCR. Data represent mean ± SD from 3 independent cultures. The experiments 
were repeated at least 2 times.  
 
To investigate whether FcnB expression is inducible during differentiation of BMDC, 
cells were stimulated at different times with a mixture of LPS and IFNγ or left non-
stimulated. When BMDC after 4 days of culture in GM-SCF containing-medium were 
used FcnB was expressed by non-stimulated dendritic cells and the expression was 
only slightly enhanced when these cells were additionally stimulated with a mixture 
of LPS and IFNγ (see Fig. 28).  
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Figure 28: FcnB expression in non-stimulated and stimulated BMDC (d4).  
In vitro generated dendritic cells on day 4 of culture were stimulated with LPS from E. coli (100ng/ml) 
and IFNγ (50 ng/ml) for 1h or left untreated. Data represent mean ± SD of 4 independent cultures.  
 
BMDC from d4 of culture in GM-CSF were sorted using the markers CD11b+ Ly6G+ 
and Ly6Cint and these immature BMDC were isolated. These cells were seeded and 
stimulated with LPS and IFNγ or left non-stimulated for 30min. In contrast to BMDC 
from d4 of culture in GM-CSF the FcnB expression was significantly higher in the 
non-stimulated sorted immature BMDC and slightly enhanced after 30min of 
stimulation (see Fig. 29). 
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Figure 29: FcnB expression in sorted immature BMDC (d4).  
In vitro generated BMDC on day 4 of culture were sorted for CD11b+ Ly6G+ and Ly6Cint and 
stimulated with LPS (100 ng/ml) and IFNγ (50 ng/ml) for 30min or left non-stimulated. FcnB 
expression was analyzed by RT-PCR. Results are given in mean ± SD from 3 independent cultures.  
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BMDC taken on day 6 of culture in GM-SCF-containing medium were tested for 
FcnB expression. The expression of FcnB in non-stimulated BMDC was comparable 
to the expression seen in BMDC from day 4 of culture. Stimulation with LPS and 
IFNy had no enhancing but rather a reducing effect in FcnB expression (see Fig. 30). 
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Figure 30: FcnB expression in non-stimulated and stimulated BMDC (d6). 
 In vitro generated dendritic cells on day 6 of culture were stimulated with LPS from E. coli (100ng/ml) 
and IFNγ (50 ng/ml) for 1h or left untreated. FcnB expression was analyzed by RT-PCR. Data 
represent mean ± SD of 4 independent cultures. 
 
The expression of FcnB by BMDC from day 8 of cell culture in GM-CSF-containing 
medium seemed enhanced after 30min stimulation with LPS but unchanged after 1 h 
of stimulation (see Fig. 31). 
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Figure 31: FcnB expression in non-stimulated and stimulated BMDC (d8).  
In vitro generated dendritic cells on day 8 of culture were stimulated with LPS from E. coli (100ng/ml) 
and IFNγ (50 ng/ml) for 30min, 1h or left untreated. FcnB expression was analyzed by RT-PCR. Data 
represent mean ± SD of 3 independent cultures. 
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FcnB expression by BMDC analyzed on day 10 of culture in GM-CSF-containing 
medium was lower compared to the expression of cells from day 4, day 6, or day 8 
(see Fig. 32). 
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Figure 32: FcnB expression in non-stimulated and stimulated BMDC (d10).  
In vitro generated dendritic cells on day 4 of culture were stimulated with LPS from E. coli (100ng/ml) 
and IFNγ (50 ng/ml) for 6h or left untreated. FcnB expression was analyzed by RT-PCR. Data 
represent mean ± SD of 4 independent cultures. 
 
3.2.4.2 Expression of FcnB in BMDC from wild type and TNFR2-deficient mice 
 
The expression of FcnB by BMDC of wild type mice was compared to FcnB 
expression by BMDC of TNFR2-deficient mice. Cells of these mice lacking TNFR2, 
an inhibitor of TNF, experience a continuously inflammatory environment. FcnB 
expression from non-stimulated BMDC (day 4 of culture) and after 1h stimulation 
with LPS (S. abortus equi) and IFNγ showed slightly increased expression levels in 
the TNFR2-deficient BMDC compared to wild type BMDC (see Fig. 33). 
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Figure 33: FcnB expression in BMDC (d4) from wild type and TNFR2-deficient mice. 
 In vitro generated BMDC on day 4 of culture in GM-CSF from wild type (black) and TNFR2-deficient 
mice (white) were stimulated with LPS from S. abortus equi (100 ng/ml) and IFNγ (50 ng/ml) for 1h or 
left non-stimulated. FcnB expression was analyzed by RT-PCR. Results are given as mean ± SD of 4 
independent mice. Results are statistically not significant.  
 
Additional, BMDC from wild type and TNFR2-deficient mice on day 4 of culture were 
sorted using the markers CD11b+ Ly6G+ and Ly6Cint. After sorting, the immature 
BMDC were seeded and stimulated with LPS (S. abortus equi) and IFNγ or left non-
stimulated for different times. Slightly higher FcnB expression levels were found in 
non-stimulated immature BMDC as seen before, however, the expression was 
higher compared to the non-sorted BMDC from day 4 of culture in GM-CSF (see Fig. 
34). 
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Figure 34: FcnB expression in sorted immature BMDC from wild type and TNFR2-deficient 
mice.  
BMDC were generated from wild type and TNFR2-deficient mice and sorted on day 4 of culture for 
CD11b+ Ly6G+ Ly6Cint and stimulated for different times with LPS from S. abortus equi (100ng/ml) 
and IFNγ (50ng/ml) for 30min, 1h or left non-stimulated. FcnB expression was analyzed by RT-PCR. 
Results are given as mean ± SD of 3 independent mice.  
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FcnB mRNA expression from non-stimulated BMDC (day 6 of culture) and BMDC 
stimulated for 1h with LPS (S. abortus equi) and IFNγ showed again slightly 
increased expression levels in the TNFR2-deficient BMDC compared to BMDC from 
the wild type BMDC (see Fig. 35). 
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Figure 35: FcnB expression in BMDC (d6) from wild type and TNFR2-deficient mice.  
BMDC from wild type (black) and TNFR2-deficient mice (white) were generated in vitro and analyzed 
on day 6 of culture in GM-CSF for FcnB expression. Cells were stimulated for 1h with LPS from S. 
abortus equi (100ng/ml) and IFNγ (50ng/ml) or left non-stimulated. FcnB expression was analyzed by 
RT-PCR. by RT-PCR. Data are present as mean ± SD of 4 independent mice.  
 
FcnB expression from non-stimulated BMDC (day 8 of culture) and BMDC stimulated 
for 30min or 1h with LPS (S. abortus equi) and IFNγ showed again slightly increased 
expression levels in the TNFR2-deficient BMDC compared to wild type BMDC (see 
Fig. 36).  
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Figure 36: FcnB expression in BMDC (d8) from wild type and TNFR2-deficient mice.  
BMDC from wild type (black) and TNFR2-deficient mice (white) were generated in vitro and analyzed 
on day 8 of culture in GM-CSF for FcnB expression. Cells were stimulated with LPS from S. abortus 
equi (100ng/ml) and IFNγ (50ng/ml) for 30min, 1h or left non-stimulated. FcnB expression was 
analyzed by RT-PCR.  Data are present as mean ± SD of 4 independent mice.  
 
BMDC on day 10 of cell culture from TNFR2-deficient mice showed no higher FcnB 
expression levels compared to BMDC of wild type mice (see Fig. 37).  
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Figure 37: FcnB expression in BMDC (d10) from wild type and TNFR2-deficient mice.  
BMDC from wild type (black) and TNFR2-deficient mice (white) were generated in vitro and analyzed 
on day 10 of culture in GM-CSF for FcnB expression. Cells were stimulated for 6h with LPS from S. 
abortus equi (100ng/ml) and IFNγ (50ng/ml) or left non-stimulated. FcnB expression was analyzed by 
RT-PCR. Data are present as mean ± SD of 4 independent mice.  
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3.2.4.3 Expression of FcnB in spleen cells from wild type and TNFR2-deficient 
mice 
 
Spleen cells from wild type and TNFR2-deficient mice were isolated and analyzed for 
FcnB expression. Splenic cells were stimulated with LPS and IFNγ for different times 
or left non-stimulated. Spleen cells from TNFR2-deficient mice had significantly 
higher FcnB expression levels compared to spleen cells from wild type mice and the 
FcnB expression was further enhanced after stimulation (see Fig. 38). 
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Figure 38: FcnB expression in spleen cells isolated from wild type and TNFR2-deficient mice.  
Splenic cells from wild type (black) and TNFR2-deficient mice (white) were isolated and stimulated 
with LPS from E. coli and IFNγ for 30min or 1h or left non-stimulated. FcnB expression was analyzed 
by RT-PCR. Results are given as mean ± SD from 3 independent mice.  
 
In summary a comparison of FcnB expression levels in wild type and TNFR2-
deficient mice revealed higher expression levels of FcnB even in non-stimulated 
BMDC and also in non-stimulated spleen cells isolated from TNFR2-deficient mice. 
Nevertheless, it has to be considered that the RT-PCR values that were obtained 
from BMDC on day 4, day 6, day 8 and day 10 isolated from wild type and TNFR2-
deficient mice are not comparable among the experiments because they were not 
measured in the same experiment.  
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3.3 Binding specificity of recombinant FcnB 
 
3.3.1 Binding to BSA  
 
Binding of recombinant FcnB to BSA was analyzed in ELISA. BSA was coated onto 
plastic at a concentration of 10 µg/ml and recombinant FcnB was added at different 
concentrations. The binding of FcnB to BSA was quantified using a specific antibody 
against FcnB (monoclonal rat anti-mouse FcnB antibody IA4). 
Binding signals were all in the same range indicating that there was no binding of 
recombinant FcnB to BSA (see Fig. 39). 
 
 
 
Figure 39: Binding of recombinant FcnB to BSA.  
Recombinant FcnB at different concentrations was analyzed for binding to coated BSA using the 
monoclonal rat ant-mouse FcnB antibody IA4. Data are given was OD measured at 450 nm 
wavelength and represent mean ± SD of 3 independent technical values. The experiment was 
repeated more than 5 times. 
 
3.3.2 Binding to AcBSA  
 
To test whether recombinant FcnB binds to acetylated BSA (AcBSA), AcBSA was 
coated onto plates and binding of FcnB was determined by ELISA. The assay was 
performed in a calcium-containing buffer. Binding of FcnB to AcBSA was found to be 
dose-dependent. In addition, binding of FcnB to AcBSA was found to be calcium-
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dependent since binding was inhibited by the presence of EDTA in the binding buffer 
(see Fig. 40).  
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Figure 40: Binding of recombinant FcnB to AcBSA.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated AcBSA by using 
the monoclonal rat anti-mouse FcnB antibody IA4 (black bar). Binding was abolished by the presence 
of EDTA in the binding buffer (white bar). Data represent OD values measured at 450 nm and are 
given as mean ± SD of 3 independent technical replicates. The binding experiment was repeated 
more than 5 times.  
 
To test further whether recombinant FcnB binding to AcBSA is specific AcBSA and 
BSA as a negative control were coated onto plates. Recombinant FcnB was added 
at different concentrations and the binding of FcnB was determined by ELISA. The 
assay was performed in a calcium-containing buffer. Binding of FcnB to AcBSA was 
found to be dose-dependent. No binding of FcnB to BSA was observed (see Fig. 41). 
 
 
 
 
  93 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Coating AcBSA
Coating BSA
rec FcnB
*
 
 
Figure 41: Binding of recombinant FcnB to AcBSA and BSA.  
Binding of recombinant FcnB to either BSA or AcBSA coated plastic was compared by ELISA. OD 
values are measured at 450 nm and data represent mean ± SD of 3 independent technical replicates. 
Using the unpaired t-test FcnB binding on coated AcBSA compared to BSA was found to be 
significant with p < 0.01. 
 
Binding of recombinant FcnB to AcBSA was also tested in a Dot blot assay. The 
results demonstrate that recombinant FcnB bound to nitrocellulose-bound-AcBSA, 
but not to nitrocellulose-bound-BSA (see Fig. 42). These results confirmed AcBSA 
as a ligand for FcnB, as for all other ficolins. 
 
 
 
Figure 42: Binding of recombinant FcnB to nitrocellulose-bound AcBSA.  
Nitrocellulose-membrane was coated with two different concentrations of either BSA or AcBSA before 
adding recombinant FcnB (5µg/ml). The binding of FcnB was detected with an anti-mouse V5-tag 
antibody. 
 
The results shown in Fig. X demonstrate that the binding of recombinant FcnB to 
AcBSA was clearly inhibited when EDTA was present in the buffer while binding.  
To test whether this inhibition of EDTA could be enhanced by the addition of acetate, 
ELISA was performed in binding-buffer containing either calcium, EDTA, or EDTA 
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plus acetate. Results in Fig. 43 show that the inhibition of FcnB binding to coated 
AcBSA was even stronger when additionally acetate was added.  
 
 
 
Figure 43: Binding inhibition of recombinant FcnB to AcBSA.  
Recombinant FcnB binding to AcBSA was performed in three different buffers, containing either 
calcium, EDTA, or a mixture of EDTA plus acetate. The binding of FcnB was calcium-dependent and 
was abolished by the presence of EDTA or EDTA/acetate in the binding buffer.. Results are given as 
mean ± SD of 3 independent technical replicates.  
3.3.3 Binding to acetylated low-density lipoprotein (AcLDL) 
 
Another acetylated ligand was tested for binding to FcnB. AcLDL was used for 
coating and binding of recombinant FcnB was tested by ELISA. The results 
demonstrate that recombinant FcnB bound to AcLDL (see Fig. 44). These data 
revealed AcLDL as another ligand of recombinant mouse FcnB.  
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Figure 44: Binding of recombinant FcnB to AcLDL.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated AcLDL by using 
the monoclonal rat anti-mouse FcnB antibody IA4 (black bar). Binding was abolished by the presence 
of EDTA plus acetate in the binding buffer (white bar). Data are given as mean ± SD of 3 independent 
technical replicates. Using the unpaired t-test the inhibition by EDTA was found to be significant with p 
< 0.001. 
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3.3.4 Binding to GlcNAc 
 
Another commonly used ligand of ficolins is N-acetylglucosamine (GlcNAc).The 
binding of recombinant FcnB to GlcNAc was tested by coating GlcNAc to plastic and 
determining binding of FcnB by ELISA.  
Fig. 45 shows that binding of FcnB to GlcNAc occurred in a calcium-dependent 
manner. When recombinant FcnB was incubated in TBS buffer in the presence of 
EDTA the signal was reduced.   
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Figure 45: Binding of recombinant FcnB to GlcNAc in a dose-dependent manner.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated GlcNAc by 
using the monoclonal rat anti-mouse FcnB antibody IA4 (black bar). Binding was abolished by the 
presence of EDTA in the binding buffer (white bar). Data are given as mean ± SD of 3 independent 
technical replicates. Using the Mann-Whitney-test the inhibition by EDTA was found to be significant 
with p < 0.001. 
 
3.3.5 Binding to fetuin 
 
With regard to the fact that human M-ficolin has been shown to bind to fetuin, also its 
mouse homologue, FcnB, was tested for binding to fetuin. The assay was performed 
in the same way as described above.  
Fetuin was used for coating of the plastic and binding of recombinant FcnB to fetuin 
was determined by ELISA. Recombinant FcnB was also able to bound to fetuin. 
However, signals for the binding were reduced, when FcnB was incubated in a TBS 
buffer containing EDTA (see Fig. 46). 
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Figure 46: Binding of recombinant FcnB to fetuin.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated fetuin by using 
the monoclonal rat anti-mouse FcnB antibody IA4 (black bar). The binding of FcnB to fetuin was not 
found to be abolished, but reduced by the presence of EDTA in the binding buffer (white bar). Data 
are given as mean ± SD of 3 independent technical replicates.  
3.3.6 Binding to chitin 
 
Ficolins serve in the innate immune system as pattern recognition molecules by 
binding to pathogen surfaces. One type of attacking pathogens are fungi. A 
molecular constituent of the fungal cell wall is chitin. Therefore, recombinant FcnB 
was tested for binding to chitin-coated beads. The assay was performed in the same 
way as described above. Chitin-coated beads were used and the binding of 
recombinant FcnB was determined by ELISA. The data confirmed again the binding 
of FcnB to AcBSA, but not to BSA (see Fig. 47). Recombinant FcnB bound to chitin-
coated beads, revealing chitin as an additional ligand for FcnB. 
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Figure 47: Binding of recombinant FcnB to chitin.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated AcBSA, chitin 
or BSA by using the monoclonal rat anti-mouse FcnB antibody IA4. Data are given as mean ± SD of 3 
independent technical replicates.  
 
3.3.7 Binding to DNA from E. coli 
 
During the last years experiments demonstrated binding of ficolins to apoptotic cells 
(recently also published in Schmid, Hunold et al. 2011 by our group for FcnB) and 
help in the clearance of dying cells. One assumed ligand in binding to these 
apoptotic cells is DNA. Therefore, DNA was prepared from E. coli and used as ligand 
in binding assays.  
The assay was performed in the same way as described above. DNA from E. coli 
was coated in a final concentration of 10µg/ml and FcnB binding was determined by 
ELISA. The data reveal binding of FcnB to AcBSA in a dose-dependent manner. 
BSA served as a negative control (see Fig. 48).  
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Figure 48: Binding of recombinant FcnB to AcBSA and to DNA from E. coli.  
Recombinant FcnB at different concentrations was analyzed for the binding to coated AcBSA, DNA 
from E. coli (10µg/ml) or BSA by using the monoclonal rat anti-mouse FcnB antibody IA4. Data are 
given as mean ± SD of 3 independent technical replicates.  
 
3.3.7.1 Inhibition of FcnB binding to AcBSA by DNA 
 
Ficolins have been shown to bind to dying host cells. It is thought that DNA serves 
as a possible ligand. To test whether recombinant FcnB binds to DNA, inhibition 
assays were performed with DNA. The ELISA was performed using AcBSA for 
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coating. Recombinant FcnB was pre-incubated for 4h with buffer containing DNA 
from E. coli. Pre-incubation with DNA was shown to inhibit the binding of FcnB to 
AcBSA in the ELISA in a dose-dependent manner. The results also demonstrate 
again that binding of FcnB to AcBSA was inhibited in the presence of EDTA plus 
acetate. This leads also to the conclusion that DNA is a ligand for recombinant FcnB 
and competes with the binding of recombinant FcnB to AcBSA (see Fig. 49).  
 
 
 
Figure 49: Binding inhibition of recombinant FcnB to AcBSA by DNA.  
Recombinant FcnB was either pre-incubated with different concentrations of DNA (E. coli) or directly 
added to the plate either in a calcium-containing buffer or in the presence of EDTA/acetate. DNA 
reduced the binding of recombinant FcnB to AcBSA dose-dependently. Binding of FcnB to AcBSA 
was found to be calcium-dependent. Results are given as mean ± SD of 3 independent technical 
replicates. 
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3.3.8 Binding to bacteria 
 
3.3.8.1 Binding to S. aureus 
 
Direct binding of FcnB to bacteria was tested by adding a constant amount of FcnB 
to different strains of S. aureus to allow for binding. After removal of the bacteria the 
amount of FcnB left in the supernatant was determined by TRIFMA using 
biotinylated antibodies specific for FcnB. Only S. aureus strain T-5 reproducibly 
absorbed FcnB from the supernatant (see Fig. 50). 15 % of 5µg/ml recombinant 
FcnB used for binding was absorbed by the bacteria. This means that around 0.75 
µg FcnB were bound by 108 S. aureus T-5.  
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Figure: 50: Binding of recombinant FcnB to various strains of S. aureus.  
A constant amount of recombinant FcnB (5µg/ml) was used for the absorption by different strains of 
S. aureus. Each bar represents the mean percentage of unbound FcnB from independent single 
experiments. The amount of recombinant FcnB without bacteria was set to 100%.  
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3.3.8.2 Binding to Group B Streptococcus (GBS) 
 
As with S. aureus, it was tested whether different serotypes of Group B 
Streptococcus would absorb FcnB from the medium. 
The binding experiments revealed binding of FcnB to nearly all tested GBS strains, 
except GBS B848/64 and GBS VIII. The binding of recombinant FcnB to GBS 
serotype B848/64 was expected to be negative, because this strain is the only tested 
non-capsulated GBS strain. It has been found previously that also other ficolins did 
not bind to capsulated strains. With the exception of GBS B848/64 and VIII all other 
Streptococci removed about 20% of the offered FcnB, which means that about 1µg 
FcnB was bound by 108 GBS (see Fig. 51). 
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Figure: 51: Binding of recombinant FcnB to various strains of GBS.  
A constant amount of recombinant FcnB (5µg/ml) was used for the absorption by different strains of 
GBS. Each bar represents the mean percentage of unbound FcnB from one independent single 
experiment. The amount of recombinant FcnB without bacteria was set to 100%.  
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3.4 Recombinant FcnB and complement activation 
 
To investigate the capacity of recombinant FcnB to activate the lectin pathway, FcnB 
was tested for the interaction with recombinant human MASP-2 and the ability to 
lead to C4-deposition due to the activation of MASP-2.  
 
3.4.1 Interaction of FcnB with MASP-2 
 
Recombinantly FcnB, bound to AcBSA, was tested for the interaction with 
recombinant human MASP-2 (kindly provided by Prof. Jensenius, Aarhus, Denmark).  
The data revealed binding of FcnB to recombinant human MASP-2 in a dose-
dependent manner. The signals were lower compared to those observed with 
recombinant human M-Ficolin. Recombinant mouse Ficolin A (FcnA) bound to 
recombinant human MASP-2 with a similar signal intensity as recombinant FcnB. 
Binding of all ficolins to AcBSA and subsequent binding of MASP-2 were calcium-
dependent (see Fig. 52). 
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Figure 52: Binding of human and mouse ficolins to MASP-2.  
Recombinant human M-ficolin and recombinant mouse ficolins (FcnA and FcnB) were tested for 
binding to recombinant human MASP-2 in TRIFMA analysis. The binding of MASP-2 to the ficolin was 
either performed in a calcium-containing buffer or in the presence of EDTA. All tested ficolins were 
found to bind to MASP-2 in a ficolin-dose-dependent manner. Further, the interaction between MASP-
2 and ficolin was found to be calcium-dependent. The interaction between the ficolin and MASP-2 is 
abolished when EDTA is present in the binding buffer (striped bars). Results are given as mean ± SD 
of 3 technical replicates. This experiment was repeated at least 2 times. Statistical analyses were 
performed using Two-way ANOVA. 
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3.4.2 Activation of the lectin pathway by FcnB 
 
MASP-2 cleaves complement factors C4 and C2 to form the complement convertase 
C3 (complex of C4bC2a). and generates the cleavage products C4a and C4b. These 
by-products can be measured by the C4-deposition assays to verify complement 
activation. To investigate, if FcnB is able to activate the lectin pathway of the 
complement system, C4 deposition assays were performed. Recombinant human M-
ficolin or recombinant mouse FcnB were added to plates coated with AcBSA before 
recombinant human MASP-2 was added. The addition of recombinant C4 protein 
leads to cleavage of C4 when MASP-2 is activated by the interaction with the 
corresponding ficolin and C4-deposition can be measured. Results of the C4-
deposition measured by TRIFMA revealed that both ficolins, recombinant human M-
ficolin and recombinant mouse FcnB, were able to lead to C4 deposition (see Fig. 52 
A). In the two experiments performed recombinant human M-ficolin seemed to be 
more effective compared to recombinant mouse FcnB. No C4-deposition was 
observed, when ficolins were added to BSA-coated plates (see Fig. 52 B). 
 
 
 
Figure 53: C4-deposition after the binding of ficolin and MASP-2.  
Recombinant human M-Ficolin or mouse FcnB (at the indicated concentrations), recombinant human 
MASP-2 SUT (500ng/ml), and C4 (1.6µg/ml) were added to the AcBSA or BSA coated plastic. C4-
deposition was measured by TRIFMA. Data in (A) represent single values of one experiment with one 
replicate and in (B) data are given as mean ± SD of 3 independent technical replicates.  
 
To verify binding and activation of recombinant human MASP-2 to recombinant 
mouse FcnB in TRIFMA, it was analyzed whether the binding can be inhibited. 
Formation of the complex of MASP-2 and FcnB on AcBSA coated plastic and the 
subsequent cleavage of C4 was calcium-dependent (see Fig. 54). 
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Figure 54: Calcium-dependency of C4-deposition by FcnB.  
Recombinant mouse FcnB (at the indicated concentrations), recombinant human MASP-2 SUT 
(500ng/ml), and C4 (1.6µg/ml) were added to AcBSA coated plastic. C4-deposition was measured by 
TRIFMA. The experiment was performed either in calcium-containing buffer (green bars) or in the 
presence of EDTA (red bars). The data represent one single experiment with one replicate.  
 
Since recombinant FcnB was demonstrated to bind to S. aureus serotype T-5, it was 
tested whether FcnB bound to S. aureus T-5 can also induce complement activation. 
For this purpose, the bacteria were used to allow for the binding of recombinant 
FcnB and the MASP-2 interaction and C4-deposition was tested by TRIFMA.  
The complex of recombinant FcnB with recombinant human MASP-2 was 
significantly shown to form complexes on S. aureus serotype T-5 and enabled C4-
deposition. In contrast, no C4-deposition was observed on S. aureus serotype T-3 or 
T-9. Recombinant FcnB was found not to bind to these serotypes as already seen in 
previous TRIFMA experiments (see Fig. 55). 
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Figure 55: C4-deposition on different S. aureus serotypes.  
Recombinant mouse FcnB (at different concentrations), recombinant human MASP-2 SUT (1µg/ml), 
and C4 (1.6µg/ml) were added to coated S. aureus serotype T-5 (green bars), T-3 (yellow bars) or T-9 
(red bars) and the C4-deposition was measured by TRIFMA. Bacteria were coated at a concentration 
of 108 bacteria/ml. Data represent one single experiment.  
 
In previous experiments, FcnB has been shown to bind to different strains of Group 
B Streptococcus. Therefore it was investigated whether FcnB is able to induce C4 
deposition on these bacteria. A selection of strains, which has been shown to 
strongly bind to FcnB, was analyzed in a C4-deposition assay. Even though the 
signals were not very high, it seemed that FcnB bound to GBS strain II, strain III and 
strain IV and initiated C4-deposition, however, the background signals when the 
assay was performed with GBS strain 1a were very high (see Fig. 56).  
 
 
 
Figure 56: C4-deposition on different GBS serotypes.  
Recombinant mouse FcnB (at indicated concentrations), recombinant human MASP-2 SUT (1µg/ml), 
and C4 (1.6µg/ml) were added to coated GBS serotype 1a, serotype II, serotype III and serotype IV 
and C4-deposition was measured by TRIFMA. The bacteria were coated in a concentration of 108 
bacteria/ml. Data represent mean ± SD of 3 independent technical replicates. 
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3.5 Generation of monoclonal rat anti-mouse FcnB antibodies 
 
3.5.1 Immunization of rats 
 
For the generation of rat anti-mouse FcnB antibodies, three rats with different 
genetic background were immunized in parallel with recombinant mouse FcnB 
produced in DS-2 cells. The recombinant protein was tagged with a V5-His-tag. This 
tag enabled an easy purification over corresponding affinity columns, but at the same 
time increased the risk to generate antibodies against the tag. 
 
The sera of the three rats were tested by ELISA for their specific production of IgG 
after immunization against recombinant mouse FcnB. The ELISA demonstrated that 
the IgG production of all three rat sera was specific for the immunized antigen. The 
pre-immunization-sera did not show any signal when no antigen but coating buffer 
alone was present in the well. All three sera showed similar OD signals against the 
coated recombinant mouse FcnB protein when tested at the same dilution 
demonstrating a similar immune response by the three rats (see Fig. 57). 
 
 
 
Figure 57: Antigen-specific titer after the first immunization.  
Recombinant FcnB (2µg/ml) was coated to plastic and the antisera of the rats (at a 1:1000 dilution) 
were tested for their interaction with FcnB by ELISA. The BLANK indicates that no FcnB was applied. 
Results are given as mean ± SD from 3 independent technical replicates with sera from rat ACI (red 
bar), rat Wistar (blue bar) and rat F344 (green bar). 
 
 
When different concentrations of FcnB had been applied to the membrane, the anti-
sera revealed a very weak non-specific binding of the pre-immunization-sera to FcnB 
in a dot blot. From the three antisera generated, the antiserum of rat ACI was found 
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to be best in recognizing FcnB in the dot blot assay. It showed detection of FcnB in a 
dose-dependent manner detecting 2.5 ng of FcnB at a 1:10.000 dilution of the anti-
serum. The antisera did not bind to BSA, which served as a negative control (see 
Fig. 58). 
The antiserum of rat Wistar showed detection of the antigen in a dose-dependent 
manner detecting 20 ng of FcnB at a 1:10.000 dilution of the antiserum. Also, as 
seen for the rat ACI, the antiserum from rat Wistar did not non-specific bind to BSA 
(see Fig. 58). 
The antiserum of rat F344 showed the weakest detection signals to FcnB, compared 
to the other antisera. The antiserum from rat F344 recognized only 20 ng/ml of FcnB 
at a 1:10.000 dilution of the anti-serum (see Fig. 58). 
 
 
 
Figure 58: Detection of FcnB by antisera in a dot blot assay.  
Different amounts (as indicated) of FcnB were spotted onto nitrocellulose-membrane and exposed to 
different dilutions (as indicated) of the pre-immune- and antisera of a ACI (A), Wistar (B), and F344 
(C) rat, respectively. 
 
To further determine the specificity of the antisera, recognition of recombinant FcnB 
was analyzed in Western Blot analysis. The Western blot showed that the antisera of 
the Wistar and ACI rat recognized the recombinant protein (see Fig. 59). At least 
they detected the monomer of FcnB, running at 35 kDa. The antiserum of the F344 
rat did not recognize FcnB in the Western blot.  
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Figure 59: Detection of FcnB in a Western blot assay.  
Recombinant FcnB (5µg/ml) was applied to a 10% SDS PAGE and the protein was separated under 
non-reducing conditions. After blotting the membrane was exposed to the pre-immune- and the 
antisera of the different rats.   
 
When the antisera were tested after the first boost by ELISA, the data revealed a 
strong, specific response for all three antisera. The antiserum of the ACI rat showed 
nearly identical signals as directly after the immunization. The responses of the 
Wistar rat and the F344 rat showed higher signals after the boost. The antiserum of 
the ACI rat was positive at a dilution 1:64.000 (see Fig. 60). 
 
 
 
Figure 60: Anti-FcnB titer after the first boost.  
Recombinant FcnB (2µg/ml) was coated to plastic and the antisera of the rats (diluted in a logarithmic 
manner) were tested for their interaction with FcnB by ELISA. Results are given as mean ± SD from 3 
independent technical replicates with sera from rat ACI (red bar), rat Wistar (blue bar) and rat F344 
(green bar). 
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After the second boost the antibody response of the ACI and the Wistar rat were 
further enhanced. The reaction of the antiserum of the F344 rat was not changed 
after the third injection with the antigen. Strong antibody titers were now obtained 
with the antisera of the ACI and the Wistar rat (see Fig. 61).  
 
 
 
Figure 61: Anti-FcnB titer after the second boost.  
Recombinant FcnB (2µg/ml) was coated to plastic and the antisera of the rats (diluted in a logarithmic 
manner) were tested for their interaction with FcnB by ELISA. Results are given as mean ± SD from 3 
independent technical replicates with sera from rat ACI (red bar), rat Wistar (blue bar) and rat F344 
(green bar). 
 
Although all three rats had responded to the immunization with recombinant FcnB, 
the ACI and the Wistar rats had higher antibody titers after the first and the second 
boost; a third boost did not significantly improve the antibody titer in the F344 rat 
(see Fig. 62). 
 
 
 
Figure 62: Anti-FcnB titer after the third boost.  
Recombinant FcnB (2µg/ml) was coated to plastic and the antisera of the F344 rat (diluted in a 
logarithmic manner) was tested for the interaction with FcnB by ELISA. Data present single values of 
one experiment.  
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The specificity of the antigen response of all three rat anti-sera were tested to 
determine whether their reaction was raised against the FcnB or against the V5-His-
tag. Due to the fact that the rats were immunized with the recombinant protein 
carrying a highly immunogenic tag, it was necessary to exclude such reactions. 
Therefore ELISA plates were coated with another protein, which also contained the 
same tag. In this case the protein consisted of the tagged extracellular domain of the 
TNF receptor type 2 (TNFR2). The antisera from all three rats reacted strongly with 
the FcnB-V5-His-tag. The antiserum of the F344 rat showed a lower FcnB response. 
The antisera of both the ACI and the Wistar rat showed cross-reactivity with the V5-
His-tagged control protein. This demonstrated that both anti-sera contain also 
antibodies raised against the tag. But still the response towards the recombinant 
mouse FcnB was more than three-fold higher (see Fig. 63). 
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Figure 63: ELISA for cross-reaction of the anti-sera with the V5-His-tag.  
Recombinant FcnB (2µg/ml) or the control protein (2µg/ml TNFR2 ECD-V5-His) were coated on 
plastic and the antisera (1:500. Log 2 diluted) of the rats were applied in the ELISA for the detection of 
antigen-specific antibodies. Data are given as mean ± SD of three independent technical replicates. 
 
In order to further test for cross-reaction all three antisera were tested in a dot blot 
assay for recognition of recombinant mouse FcnA. The anti-sera of the ACI rat and 
the Wistar rat showed a specific response only to FcnB, but no cross-reaction with 
FcnA (see Fig. 64). The anti-serum of the F344 rat was not tested because it had 
only a weak ELISA titer. 
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Figure 64: Cross-reaction of the anti-FcnB antisera with FcnA by Dot blot analysis.  
Recombinant FcnA and FcnB (at indicated concentrations) were coated to nitrocellulose and the 
antisera of ACI rat or Wistar rat (diluted 1:1000) were tested for their interaction with FcnA and FcnB 
by Dot blot analysis.  
3.5.2 Generation of monoclonal rat anti-mouse FcnB antibodies 
 
For the generation of monoclonal rat anti-mouse FcnB antibodies spleen cells of the 
corresponding rat immunized with recombinant FcnB-V5-His-tagged protein were 
fused with myeloma cells. The resulting clones were tested for their ability to 
recognize recombinant FcnB. Positive clones were subcloned and further analyzed. 
All generated monoclonal rat anti-mouse FcnB antibodies are listed in the table 
below. 
 
Antibody Rat Isotype Fusion 
2F1 B6 B6 Wistar IgG2a Oct 2009 
2F1 B6 E2 Wistar IgG2a Oct 2009 
2F1 C7 G4 Wistar IgG2a Oct 2009 
16D3 D6 Wistar IgG2a Oct 2009 
16G3 C2 Wistar IgG2a Oct 2009 
11A1 A10 ACI IgG2a Sept 2009 
11A1 B11 ACI IgG2a Sept 2009 
11A1 C7 A5 ACI IgG2a Sept 2009 
 
Tab. 9: Overview of generated monoclonal rat anti-mouse FcnB antibodies. 
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3.5.3 Isotype determination of the monoclonal rat anti-mouse FcnB antibodies 
 
In order to determine to which antibody subclass the respective monoclonal rat anti-
mouse FcnB antibody belongs, an isotype-ELISA was performed. The ELISA data 
demonstrate that all generated monoclonal anti FcnB antibodies were of the IgG2b 
isotype (see Fig. 65). 
 
 
 
Figure 65: Isotype determination of the monoclonal rat anti-mouse FcnB antibodies. 
Recombinant FcnB (5µg/ml) was coated to plastic and anti-mouse FcnB antibodies were added for 
the detection of FcnB by ELISA. Different secondary goat-anti rat IgG and IgM (as indicated) 
antibodies were used for the determination of the isotype of the corresponding anti-FcnB antibody. 
Data are given as values from one single experiment with one replicate. 
 
3.5.4 Establishment of a sandwich-ELISA 
 
By testing each antibody against the others the epitope of the respective antibody 
should be identified. In this way antibodies should be determined that are useful to 
act as “capture” or as ”detection” reagent. Therefore, all monoclonal antibodies 
needed to be biotinylated. Non-biotinylated antibodies were used as “capture” 
antibodies and biotinylated antibodies were used for ”detection” of bound FcnB (see 
Fig. 66). Signals-to-noise ratios were calculated to identify proper antibody 
combinations. After analysis of all combinations of unlabeled and biotinylated rat 
anti-mouse FcnB monoclonal antibodies, 2F1C7 G4 and 16G3 C2 were selected as 
antibodies for coating (”capture” antibodies) and 11A1C7A5 and 11A1B11B8 were 
selected for ”detection”. Also a good choice for detection was the 16D3 antibody 
even if it has to be kept in mind that the background signals are very high when 
using this antibody as a ”capture” antibody.  
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Figure 66: Sandwich-ELISA establishment.  
All combinations of unlabeled and biotinylated rat anti-mouse FcnB monoclonal antibodies were 
tested against FcnB. Thereby the unlabeled rat anti-mouse FcnB antibodies (1µg/ml) were coated to 
plastic, FcnB (2µg/ml) was added and the detection of FcnB was performed using the corresponding 
biotinylated rat anti-mouse FcnB antibodies (1µg/ml). 
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3.5.5 Detection of recombinant mouse FcnB in Western Blot  
 
To test whether the generated monoclonal rat anti-mouse FcnB antibodies detect the 
recombinant protein in Western blot analysis and to further characterize the anti-
FcnB monoclonal antibodies, Western blot analyses were performed.  
As seen in the following figures (Fig. 67 an 68), all anti-FcnB monoclonal antibodies 
recognized at least the monomer of FcnB (35 kDa) when separated on the gel under 
reducing conditions but also higher oligomeric forms especially when separated 
under non-reducing conditions. The monoclonal antibodies differed in their 
recognition pattern with some detecting preferentially the lower oligomers whereas 
others recognized higher oligomeric forms of FcnB. 
 
 
 
Figure 67: Western Blot analysis for recombinant FcnB under non-reducing conditions.  
Recombinant FcnB (5µg/ml) was loaded onto a 10% SDS-PAGE and the run was performed under 
non-reducing conditions. After the run the protein was blotted onto nitrocellulose and FcnB was 
detected using the monoclonal rat anti-mouse FcnB antibodies as indicated (5µg/ml). 
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Figure 68: Western Blot analysis for recombinant FcnB under reducing conditions.  
Recombinant FcnB (5µg/ml) was loaded onto a 10% SDS-PAGE and the run was performed under 
reducing conditions. After the run the protein was blotted onto nitrocellulose and FcnB was detected 
using the monoclonal rat anti-mouse FcnB antibodies as indicated (5µg/ml). 
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3.6 Detection of native FcnB  
3.6.1 Detection of mouse FcnB in Western blot 
 
After having determined the mRNA expression levels of FcnB in different cell types, 
the respective cell lysates were analyzed in Western blot assays to test for FcnB on 
the protein level by detection with the monoclonal antibodies.  
BMDM were generated and cell lysates of LPS-stimulated or non-stimulated cells 
were prepared. Native FcnB was detected at an apparent molecular weight of about 
55 kDa. FcnB seemed to be constitutively expressed in BMDM. Stimulation with LPS 
did not further enhance the expression (mice 1, see Fig. 69 A). In contrast, FcnB 
expression in BMDM of another mice seemed to be induced by stimulation with LPS 
(mice 2, see Fig. 69 B). 
 
 
Figure 69: Detection of native FcnB in protein lysates from BMDM.  
BMDM were either stimulated with LPS (E. coli, 100ng/ml) for indicated times or left non-stimulated 
and cell lysates were prepared. The cell lysates from two different mice (A and B) were separated 
onto a 10% SDS-PAGE under reducing conditions and after blotting exposed to the monoclonal rat 
anti-mouse FcnB antibody (A) (IA4, 5µg/ml). β-actin (B) was used as a control for equal loading.  
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Lysates of PMN isolated from the bone marrow were also analyzed by Western blot. 
Also in lysates of primary PMN native FcnB was detected by the specific anti-FcnB 
antibody IA4. However, the apparent molecular weight after separation on a SDS-
PAGE under reducing conditions was about 35 kDa similar to the molecular weight 
seen with the recombinant FcnB (see Fig. 70). 
 
 
 
Figure 70: Detection of native FcnB in protein lysates from PMN.  
PMN were isolated from the bone marrow and protein lysates were prepared. The cell lysates were 
loaded at different concentrations (as indicated) onto a 10% SDS-PAGE and separated under 
reducing conditions. After blotting the samples were exposed to the monoclonal rat anti-mouse FcnB 
antibody (IA4, 5µg/ml). β-actin was used as a control for equal loading. 
 
Protein lysates from PMN were analyzed by using all generated anti-FcnB 
monoclonal antibodies for detection of native FcnB in Western blot. All monoclonal 
antibodies detected the monomer of FcnB. Therefore, all monoclonal antibodies are 
useful for the detection of native FcnB (see Fig. 71). 
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Figure 71: Detection of native FcnB in PMN (by all monoclonal anti-FcnB antibodies).  
PMN isolated from the bone marrow were separated on 10% SDS-PAGE under reducing conditions 
and exposed to all anti-FcnB monoclonal antibodies for detection. Staining for β-actin was used to 
control equal loading.  
 
3.6.2 Detection of mouse FcnB in serum 
 
To investigate whether mouse FcnB is present in serum, serum samples from 
different mouse strains were analyzed by TRIFMA (the samples were obtained from 
Prof. Jensenius laboratory, Aarhus, Denmark). With the positive control of 
recombinant mouse FcnB-V5-His protein a nice dilution curve was obtained. Serum 
of Balb/c mice seemed to contain a high concentration of FcnB. In contrast, no FcnB 
was detected in the sera of all other tested mouse strains (see Fig. 72).  
 
 
 
Figure 72: Detection of mouse FcnB in serum.  
Sera from different mouse strains were analyzed for FcnB by TRIFMA. Sera (at indicated dilutions) 
were added to AcBSA coated plates and bound FcnB was detected using a biotinylated monoclonal 
rat anti-FcnB antibody (1µg/ml 11A1 C7-Bio). Recombinant FcnB (at indicated concentrations) was 
used as a positive control. Data are given as mean ± SD of 3 independent technical replicates.   
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To confirm and further characterize this finding, the TRIFMA was performed with the 
serum from Balb/c mice in different buffers.  
The results verified the previous finding, that FcnB was detectable in serum of Balb/c 
mice. When binding was performed in EDTA-containing buffer, the signals were 
significantly reduced, demonstrating that the binding was calcium-dependent (see 
Fig. 73).  
 
 
 
Figure 73: Calcium-dependent binding of serum-FcnB to AcBSA by TRIFMA.  
Serum from Balb/c mice was analyzed for FcnB by TRIFMA. The serum (at indicated dilutions) was 
added to AcBSA coated plastic and incubated either in calcium-containing buffer, in glucose-
containing buffer, in GlcNAc-containing buffer, or in the presence of EDTA. Bound FcnB was detected 
using a biotinylated monoclonal rat anti-FcnB antibody (1µg/ml 11A1 C7-Bio). Recombinant FcnB (at 
indicated concentrations) was used as a positive control. Data are given as single values of one 
experiment. 
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3.7 Localization of FcnB in primary cells  
 
RT-PCR analysis had demonstrated that cells of the myeloid linage expressed FcnB 
and Western blot analysis had shown that FcnB protein was present in the cell 
lysates. For the role of FcnB in the innate immune system it is not only necessary to 
identify the producers of the lectin but also to know its localization. 
For these studies PMN isolated from bone marrow were analyzed by confocal 
microscopy. The experiments were done in the Institute of Medical Immunology, 
Buenos Aires, Argentina (in collaboration with Dr. Analiá Trevani and Dr. Gabriela 
Salamoné).   
The PMN were stimulated with PMA to induce NET formation. The NET structures 
were stained with specific antibodies against mouse elastase, mouse nucleosome 
and DAPI was used to identify DNA. FcnB was detected with the biotinylated 
monoclonal rat anti-FcnB antibody 11A1 C7. Non-stimulated cells served as a 
negative control, since NET were formed only after stimulation. Confocal microscopy 
demonstrated that NET were induced by PMA stimulation after 16h (see Fig. 74). 
NET were characterized by positive staining with the anti nucleosome antibody. 
Overlay of the anti-nucleosome staining and the DAPI staining revealed that DNA 
and nucleosomes co-localized, which is typical for NET structures. Specific staining 
for FcnB showed the presence of FcnB within some PMN, but was not detected on 
the NET structures. The staining with the monoclonal rat anti-mouse FcnB antibody 
11A1 C7 was specific. No signals were obtained with the corresponding isotype 
control. 
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Figure 74: NET formation by PMN.  
PMN were isolated from Balb/c bone marrow and stimulated for 16h with PMA. The staining was 
performed using antibodies against mouse nucleosome and against FcnB (1µg/ml 11A1 C7-bio). 
ToPro3 was used for DNA staining. Single stainings and overlays are shown. (A) Anti-FcnB 11A1C7-
Bio, (B) anti-mouse nucleosome, (C) DNA-staining with ToPro3, (D) White field, (E) Overlay of DNA 
and FcnB (F) Overlay of nucleosome and FcnB G) Overlay of nucleosome and DNA, and (H) the 
overlay of nucleosome, DNA and FcnB. Magnification: 40x. 
 
To further investigate the localization of FcnB, PMN were analyzed by confocal 
microscopy for the presence of FcnB inside of the cells. The results demonstrate the 
presence of FcnB inside stimulated PMN (see Fig. 75).  
 
 
 
Figure 75: Detection of FcnB inside of PMN.  
PMN were isolated from Balb/c bone marrow and stimulated for 16h with PMA. The staining was 
performed using the anti-FcnB 11A1 C7-bio (1µg/ml). ToPro3 was used for DNA staining. Single 
stainings and overlays are shown. (A) Anti-FcnB 11A1C7-Bio, (B) White field, (C) Overlay of DNA-
staining with ToPro3 and FcnB. Magnification: 40x. 
 
Co-localization studies with different lysosomal-specific antibodies were performed. 
FcnB was found to co-localize with structures recognized by a LysoRed antibody. 
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This antibody stains lysosomal structures. Thus, the FcnB protein seems to co-
localize with the lysosomes (see Fig. 76).  
 
 
Figure 76: Co-localization of FcnB with LysoRED inside of PMN.  
PMN were isolated from the bone marrow of Balb/c mice and stimulated with PMA for 16h. FcnB was 
stained by the monoclonal rat anti-mouse FcnB antibody 11A1 C7-biotinylated (1µg/ml). DNA was 
stained with ToPro3 and LysoRED was used for the detection of the lysosomal structures. 
Corresponding isotype controls are shown in (A) for FcnB and in (B) for LysoRED. DNA staining is 
shown in (C) and (G). Single stainings are shown in (E) for FcnB and in (F) for LysoRED. The 
corresponding overlays are shown in (I) for FcnB and LysoRED, (J) for DNA and LysoRED, (K) for 
FcnB and DNA and (L) for FcnB, DNA and LysoRED. White field pictures of the PMN are shown in 
(D) and (H). Magnification: 40x. 
 
To support the localization of FcnB in lysosomal structures inside of PMN, additional 
confocal microscopy analysis was performed using an antibody for the detection of 
the lysosomes. In this case, a FITC-labeled LAMP-1 antibody was used to identify 
lysosomal structures. Again, the results showed that FcnB was found inside of 
stimulated bone marrow-derived PMN. FcnB was identified in lysosomes and stained 
together with LAMP-1-FITC, indicating the presence of FcnB in lysosomal structures 
(see Fig. 77). This suggests a possible role of FcnB inside PMN. 
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Figure 77: Co-localization of FcnB with LAMP-1 inside of PMN. 
 PMN were isolated from the bone marrow of Balb/c mice and stimulated with PMA for 16h. 
Corresponding isotype controls are shown in (A) for Lamp-1-FITC, (B) for FcnB. Further are shown in 
(C) DNA staining with ToPro3, in (D) Overview white field, in (E) LAMP-1-FITC, in (F) FcnB (1µg/ml 
11A1 C7-biotinylated), in (G) DNA staining, in (H) Overview white field, and in  (I) overlay of LAMP-1-
FITC and FcnB. Magnification: 40x. 
 
To study the role of FcnB in PMN stimulated with living Pseudomonas aeruginosa 
(FITC-labeled) additional confocal-microscopy experiments were performed. The 
results demonstrated again FcnB inside PMN. Interestingly, FcnB-positive cells 
seemed to be surrounded by the FITC-labeled bacteria (see Fig. 78). However, no 
NET formation was induced by P. aeruginosa. 
 
 
 
Figure 78: Detection of FcnB inside of PMN stimulated with P. aeruginosa.  
PMN were isolated from the bone marrow of Balb/c mice and stimulated with P. aeruginosa for 16h.  
Shown are in (A) FITC-labeled bacteria Pseudomonas aeruginosa, in (B) FcnB (1µg/ml 11A1 C7-
biotinylated), in (C) DNA staining by ToPro3, in (D) Overview white field, in (E) Overlay of DNA and 
FITC-labeled P. aeruginosa, in (F) Overlay of DNA and FcnB, in (G) Overlay of FcnB and FITC-
labeled P. aeruginosa and in (H) Overlay of FITC-labeled P. aeruginosa, FcnB and DNA. 
Magnification: 40x. 
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4. Discussion 
 
The innate immune system contributes a first line of defense mechanisms by which it 
recognizes invading pathogens and initiates inflammatory responses to eliminate 
them (Janeway and Medzhitov, 2002). Therefore receptors and recognition 
molecules are necessary to sense dangerous signals and to detect pathogen-
associated-molecular-patterns (PAMPs). Up to now, several families of pattern-
recognition molecules are identified and studied. Part of these families are the well-
characterized TLRs, but also the lectins and collectins (Holmskov et al 2003). After 
binding to various pattern-associated structures these molecules help to trigger anti-
microbial responses. One potent constituent of the innate immunity is contributed by 
the complement system. This system consists of a cascade of proteolytic enzymes 
that finally leads to the formation of a membrane attack complex that in turn results 
in the lysis of the pathogen. Three pathways are known to initiate the complement 
system: the classical, the alternative and the lectin pathway. Pattern-recognition 
molecules such as the collectin MBL or the ficolins activate the lectin pathway. The 
aim of the present work was to characterize the pattern recognition molecule FcnB of 
the mouse.  
 
4.1. Expression of FcnB 
 
The first ficolins that were described were isolated from the porcine uterus and 
named ficolin α and ficolin β (Ichijo et al., 1993). Ficolin α was found to be present in 
serum whereas ficolin β was identified to be expressed in the bone marrow (Ohashi 
and Erickson,1998) and to be secreted by PMNs (Brooks et al., 2003). This led to 
the classification of serum-type ficolins and non-serum-type ficolins. Many 
expression studies were done to identify the producer cells of the human ficolins.  
During this work the expression of mouse FcnB was analyzed using RT-PCR 
analysis. Previous studies by Ohashi and Erickson in the year 1998 demonstrated 
the expression of mouse FcnB in the bone marrow and in the spleen (Ohashi and 
Erickson et al., 1998). It was shown that the cells expressing the mouse FcnB mRNA 
belong to the myeloid cell lineage (Liu et al., 2005a; Endo et al., 2010). These 
findings were confirmed by this thesis. To investigate the role of mouse Ficolin B in 
the immune system, it was necessary to analyze and determine the cell type of the 
mRNA expression. The identification of mouse FcnB producer cells or the general 
identification of its sources are possible hints for its function. 
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Results from this thesis demonstrate that bone marrow-derived dendritic cells 
(BMDC) and bone marrow-derived macrophages (BMDM), as well as PMN were 
found to express FcnB. RT-PCR analysis demonstrated high expression levels of 
FcnB mRNA within the first days of cell culture of BMDM and BMDC. The expression 
decreased during differentiation leads to the assumption that the protein is 
expressed in immature cells and down-regulated during differentiation into mature 
macrophages. The expression of FcnB during the in vitro differentiation of BMDC 
from progenitor cells to mature dendritic cells peaked strongly around day 4 in non-
stimulated cells and similarly declined during further differentiation. Neutrophils, 
generated in vitro from ERHoxb8 progenitor cells (Wang et al., 2006) facilitated the 
investigation of FcnB expression in PMN. RT- PCR results revealed that FcnB was 
present during the differentiation in Hoxb8-neutrophils peaking around day 3 of 
culture.  
 
Due to the assumption that ficolins serve as pattern recognition molecule the 
expression was suspected to be enhanced after stimulation. Stimulation studies with 
various stimuli revealed that LPS as well as PMA/Ionomycine were potent 
stimulators for FcnB expression by Hoxb8-neutrophils. Also, the results lead to the 
conclusion that FcnB belongs to a group of proteins, where a rapid induction of the 
expression is important, due to the fact that the expression was increased within only 
30min of stimulation. CpG and heat-aggregated IgG had no effect on FcnB 
expression.  
LPS, as a component of the gram-negative bacteria cell wall, is a potent stimulus 
and often used for induction of mRNA expression. Therefore, LPS was expected to 
trigger FcnB expression, due to the fact that LPS is present in the cell wall of all 
Gram-negative bacteria and Ficolins serve as pattern recognition molecules for the 
detection of bacteria. CpG was used to analyze whether stimulation of the TLR-9 
affects FcnB expression. Aggregated IgG was chosen for stimulation, because it is 
known to bind to Fc-receptors. Myeloid cells contain Fc-receptors on their surface. 
Therefore, it was assumed that a challenge of these Fc-receptors leads to induction 
of FcnB expression. PMA/Ionomycine is generally used for stimulation of PMN. In 
native PMN stimulation with LPS revealed a further increase of the FcnB expression 
while no reproducible and significant enhancement of FcnB expression was induced 
in neither BMDM nor BMDC. This can be explained by the fact that bone marrow 
progenitor cells are fully differentiated macrophages or dendritic cells, respectively, 
at the end of the culture. Additional activation stimulates these cells but does not 
change their maturation, thus, does not affect their differentiation status. 
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In vitro generated PMN, isolated from the bone marrow were investigated for their 
FcnB expression. RT-PCR experiments demonstrated expression of FcnB 
exclusively by CD11b+ Ly6C+ Ly6G+ PMN. In contrast, no expression was observed 
within the immature monocytic cell population, characterized by CD11b+ Ly6C- 
Ly6G+. Thus, these data identified native PMN as source of FcnB among immature 
myeloid cells. The same expression patterns as seen for PMN from the bone marrow 
were also seen for PMN isolated from the spleen. 
 
The expression of FcnB was investigated in mice, showing a permanent cellular 
environment of inflammation. These mice are deficient for the TNF receptor type 2 
(TNFR2), which functions by the neutralization of soluble TNF (Tumor-necrosis-
factor). Therefore, the lack of this receptor leads to constantly higher amounts of 
TNF within the body.  
A comparison of FcnB expression levels in wild type and TNFR2-deficient mice 
revealed higher expression levels of FcnB even in non-stimulated BMDC from 
TNFR2-deficient mice. The analysis of BMDC subpopulations on day 4 clearly 
demonstrated that mainly immature myeloid cells (CD11b+ Ly6G+ Ly6C+) produced 
FcnB mRNA. The higher FcnB expression levels found in mice with a constant 
inflammation suggests a role of FcnB under inflammatory conditions.  
The mRNA of the human orthologue to mouse FcnB, M-ficolin, was found to be 
expressed by monocytes from the peripheral blood, in the lung, in the spleen, and 
also by type II alveolar epithelial cells (Liu et al., 2005; Liu et al., 2005b). In this 
thesis the data showed that immature macrophages and dendritic cells as well as 
PMN express mouse FcnB. While inflammatory stimuli can clearly enhance the FcnB 
expression in PMN no further enhancement was observed in mature macrophages 
or dendritic cells from bone marrow cultures of wild type mice. However, enhanced 
FcnB expression was also seen in dendritic cells derived from mice that lack TNFR2. 
To sum up, immature myeloid cells expressed FcnB mRNA as already shown by Liu 
et al. (Liu et al., 2005). They also found that mouse FcnB is expressed in the bone 
marrow, the spleen, and also in the embryonic liver (Liu et al., 2005). 
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4.2 Detection of native FcnB 
 
Monoclonal rat anti-mouse FcnB antibodies were generated by immunization of 
three rats with different genetic background with DS-2-expressed recombinant 
mouse FcnB-V5-His. Since the antiserum of the ACI rat and the Wistar rat showed 
the strongest antigen-specific-responses the spleen cells of these rats were used for 
fusion with myeloma cells. Eight monoclonal antibodies specific for FcnB were 
generated, all of which were of the IgG2b isotype. The generated monoclonal 
antibodies were functionally tested for detection of ligand-bound FcnB. Also, for a 
second assay system (sandwich-ELISA) different monoclonal antibodies were 
identified for “catching” and for “detection”. All generated monoclonal antibodies 
recognized FcnB in ELISA, in TRIFMA, in dot blot and in Western blot. Additionally, 
all eight monoclonal antibodies recognized the FcnB monomeric form appearing at 
around 35 kDa on Western blot under reducing conditions as well as higher 
oligomeric forms under non-reduced conditions. Interestingly, it was found, that one 
monoclonal antibody, generated in a previous immunization (rat anti-mouse FcnB 
antibody IA4; generated by Dr. Valeria Runza) seemed to recognize preferently the 
lower oligomers of FcnB (monomer, dimer, trimer), whereas all new monoclonal 
antibodies were able to detect also higher oligomers including pentamers, hexamers 
and heptamers. None of the monoclonal antibodies showed cross-reactivity with 
recombinant mouse FcnA. 
Since mouse FcnB mRNA was identified to be expressed by myeloid cells, or more 
precise predominantly by immature cells of the myeloid lineage, lysates from various 
cell subpopulations of the myeloid cell lineage were analyzed by Western blot. 
Native FcnB was identified on the protein level in lysates of PMN as well as of 
BMDM from day 7 of differentiation. Differences between lysates from different mice 
became obvious: sometimes FcnB protein expression seemed to be inducible by 
LPS stimulation, whereas in cells from other mice, the protein production of FcnB 
seemed to be constant even in non-stimulated cells. A possible explanation for this 
may be that there was an ongoing inflammation in some mice. Also in BMDC 
generated from a mouse line showing a persistent inflammatory cellular environment 
(TNFR2-deficient mice) the expression of FcnB was higher compared to BMDC 
generated from wild type mice. 
Like its human homologue M-ficolin, the mouse FcnB was also demonstrated to be 
associated with cells of the myeloid cell lineage (Liu et al., 2005). Human M-ficolin 
was shown to be expressed on the surface and in granules of monocytes and 
granulocytes (The et al., 2000; Frederiksen et al., 2005; Rorvig et al., 2009; Zhang et 
al., 2010). Therefore, it was discussed whether M-ficolin serves as a phagocytic 
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receptor (The et al., 2000). In 2006 Runza et al. analyzed peritoneal exudate 
macrophages and found that FcnB was expressed in mature macrophages which is 
similar to the finding of Liu et al. in 2005 (Runza et al., 2006). Intracellular immuno-
stainings in permeabilized peritoneal macrophages revealed that FcnB is localized 
inside of these cells, that the amount enhanced after LPS stimulation, and that FcnB 
is co-localized with Lamp-1, which is associated with lysosomal membranes (Runza 
et al., 2006). The results from the present work that immature myeloid cells 
predominantly express the mouse lectin supplements these findings. In the present 
work another cell type of the myeloid cell lineage – the PMN - were investigated for 
the presence of native mouse FcnB by confocal microscopy. Using the FcnB-specific 
monoclonal antibodies native mouse FcnB was detected inside primary PMN and co-
localized with the lysosomal markers Lamp-1 and LysoRed. The human M-ficolin has 
also been found to be localized inside of the cytoplasm of PMN (Liu et al. 2005a). 
These findings further indicate a role of FcnB inside of these cells and could indicate 
that these lectins might act as intracellular scavenger receptors (Runza et al., 2008). 
A new interesting finding was the ability of PMN to generate extracellular traps to 
catch and destroy bacteria, the so-called NET (neutrophil extracellular traps). 
Thereby also complement could be involved. When the question came up, whether 
FcnB is present within these NET structures. Investigations of PMN by confocal 
microscopy revealed the presence of FcnB inside PMN after stimulation with PMA 
but FcnB was not found to be involved in the NET structures.  
Another question whether mouse FcnB is stored within these cells and whether it is 
released was tackled by further experiments. For a long time, there was a strict 
separation between serum-type and non-serum-type ficolins. In the case of the 
human M-ficolin the assumption existed that M-ficolin is not found in serum (Liu et 
al., 2005b) until new approaches with higher sensitivity revealed that M-ficolin is also 
found as a soluble protein in serum (Wittenborn et al., 2010; Honoré et al., 2008; 
Kjaer et al., 2011). Mouse FcnB was also investigated for its presence in serum but it 
was not detected (Ohashi et al., 1998; Liu et al., 2005a). When sera from different 
mouse strains were tested in this work by TRIFMA using specific monoclonal 
antibodies FcnB was detected in serum from Balb/c mice. The binding of this native 
FcnB from Balb/c serum to AcBSA was shown to be calcium-dependent. Sera of all 
other tested mouse strains were found to be negative. Interestingly, the 
demonstration of FcnB protein by confocal microscopy inside PMN was also 
successfully performed with cells from Balb/c mice. A possible explanation might be 
that this mouse strain produces exceptionally high amounts of FcnB. This might 
explain why no FcnB had been detected in serum in the studies performed by 
Ohashi et al. in 1998. Those experiments had been done with serum of C57BL/6 
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mice, which was also found to be negative for FcnB in this thesis. The reason why 
Balb/c mice seem to differ to C57BL/6 mice regarding their FcnB presence remains 
unclear to this date. Remarkable is that also the levels of MBL-A are higher in Balb/c 
mice compared to C57BL/6 mice whereas MBL-C levels are equal (Liu et al., 2001). 
 
On protein level human M-ficolin was detected in peripheral blood monocytes (Lu et 
al., 1996b; Endo et al., 1996; The et al., 2000) localized inside of secretory, 
cytoplasmic granules of PMN and monocytes (Liu et al., 2005). The porcine ficolin β 
was also identified to be membrane-associated and to be present in the cytoplasmic 
compounds of PMN (Brooks et al., 2003). Using the newly generated monoclonal 
antibodies specific for mouse FcnB previous results from our group (Runza et al., 
2006) 2006) were supported by demonstrating the presence of FcnB in lysates of 
PMN and bone marrow-derived macrophages and dendritic cells. Similar to mRNA 
expression, inflammatory stimulation seemed to increase the protein production. In 
native PMN from Balb/c mice FcnB was localized in lysosomal granules similarly as 
previously found for peritoneal macrophages (Runza et al., 2006). In addition, FcnB 
was detected in serum from Balb/c mice. 
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4.3. Binding-specificities of FcnB 
 
Ficolins are known to bind as pattern recognition molecules to various compounds. 
Their fibrinogen-like domain affords the binding specificity to different ligands, 
preferently N-acetylated compounds (Endo et al., 2010). Many carbohydrate binding-
specificities of ficolins were demonstrated to be calcium-dependent due to the 
presence of a calcium-binding site within fibrinogen-like domain. Common ligands 
found for all ficolins are AcBSA and GlcNAc. Using the newly generated anti-FcnB 
monoclonal antibodies also mouse FcnB was found during this thesis to bind to 
these ligands in a calcium-dependent manner. Controversial studies were reported 
for the human L-ficolin whether this interaction with GlcNAc is calcium-dependent 
(Matsushita et al., 1996; Endo et al., 2006) or calcium-independent (Ohashi and 
Erickson, 1997; Le et al., 1997). 
One binding specificity of mouse FcnB demonstrated here is the recognition of 
fetuin, which has sialic acid as a constituent. This is in common with its human 
orthologue M-Ficolin, (Endo et al., 2006). This interaction appeared only marginally 
to be calcium-dependent but still could be reduced by EDTA in case of the mouse 
FcnB. Liu et al., reported in 2011 that M-ficolin bound to fetuin but there was no 
further investigation whether this interaction is calcium-dependent (Liu et al., 2005; 
Endo et al., 2006; Liu et al., 2011). 
Recent data described that the binding of M-ficolin to Pentraxin 3, another pattern 
recognition molecule, is calcium-independent (Gout et al., 2011; Ma et al., 2009). 
Ficolins and MBL function in the recognition of dying host cells and facilitate thereby 
their clearance. This has recently been described for mouse FcnB by our group 
(Schmid, Hunold et al., 2011). 
In this regard, human L-ficolin was described to bind to DNA (Jensen et al 2006). 
During this thesis this ability was also verified for mouse FcnB. The interaction of 
recombinant mouse FcnB with DNA was further demonstrated by inhibition of the 
binding of FcnB to AcBSA by DNA in a dose-dependent manner. 
For the first time it was demonstrated in the present work that recombinant mouse 
FcnB was able to bind to chitin. Chitin is a highly acetylated polymer of GlcNAc and 
is mainly found in the cell walls of fungi. The ability of mouse FcnB to recognize 
chitin leads to the assumption that the mouse FcnB might serve as a pattern 
recognition molecule during fungal infections. Binding to chitin was also 
demonstrated for the human M-ficolin (Jepsen et al., 2010, Danish Society of 
Immunology Annual Meeting, May 25, 2010, unpublished data). 
In addition, recombinant mouse FcnB was also tested by TRIFMA for its binding 
ability towards various serotypes of Staphylococcus aureus and Streptococcus 
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Agalactiae (Group B Streptococcus, GBS). Bacteria of the Group B Streptococcus 
are pathogenic causing infections. They are also Gram-positive, coccal 
microorganisms. Surface patterns as exhibited by this group of bacteria are 
recognized by various recognition molecules, among others by ficolins.  
FcnB was demonstrated to bind to nearly all tested serotypes of GBS (11 out of 13) 
except the serotypes GBS B848/64 and GBS VIII. An expectation was that FcnB 
might not bind to the non-capsulated serotype B848/64, due to the fact that ficolins 
are predicted to recognize structures within the capsule.  
Also the human M-ficolin was demonstrated to bind to GBS with the only exception 
of the non-capsulated strain GBS B848/64 (Kjaer et al., 2011). That human M-ficolin 
as well as its mouse orthologue FcnB were able to recognize nearly all tested GBS 
serotypes might be explained by the fact that sialic acid is a terminal side-chain 
residue within the capsule of the GBS (Wessels et al., 1997; Miyake et al., 2004; 
Kjaer et al., 2011). Both ficolins were demonstrated to bind this ligand. 
The observation that FcnB was not able to bind to the GBS serotype VIII was also 
interesting because also the human M-ficolin exhibited a lower binding ability to this 
strain compared to all other investigated serotypes. This was argued by a different 
accessibility of the terminal sialic acid residue in this serotype (Kjaer et al., 2011). 
Interactions between the FcnB and bacteria of Staphylococcus aureus strains were 
also analyzed. S. aureus, is a microorganism with a coccal form. It belongs to the 
group of Gram-positive bacteria. Infections with this specific type of staphyloccocus 
often lead to diseases, ranging from being harmful to life threatening.  
Only binding of FcnB to the S. aureus serotype T-5, but no binding to any other S. 
aureus serotype was observed in this thesis. Among all capsular serotypes that have 
been described so far, most isolates of S. aureus belong to the capsule type 5 or 8 
(Karakawa and Vann, 1982; Arbeit et al., 1984; Hochkeppel et al., 1987; 
Sompolinsky et al., 1985; Thakker et al., 1998). Thereby the capsule type 5 S. 
aureus is also more virulent for mice compared to type 8 S. aureus due to a higher 
production of capsular polysaccharide (Thakker et al., 1998; Watts et al., 2005). Also 
the S. aureus serotyp 5 capsular polysaccaride (T-5) showed a greater degree of N-
acetylation and this might be a ligand for FcnB (Watts et al., 2005). 
No binding to any tested S. aureus serotype was observed for the human M-Ficolin 
(Kjaer et al., 2011). Liu et al. demonstrated binding of M-ficolin to a clinical S. aureus 
isolate (Liu et al., 2005). However, it is necessary to mention that the M-ficolin 
binding studies differed in the way of the bacterial preparation and also in the type of 
the S. aureus that was used for the experiments. Thus, FcnB might be able to serve 
as a pattern recognition molecule during S. aureus infection.  
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Summarizing, mouse FcnB shares many binding properties with its human and rat 
orthologues (Girija et al 2011; Gout et al 2010) and might act as a potent pattern 
recognition molecule by recognizing sialic acid (present in the glycoprotein fetuin) 
DNA (potentially a target in dying cells), and chitin (potentially a target in fungi). The 
fact that FcnB binds to DNA might be of importance concerning the finding that PMN 
have stored FcnB and produce NET structures upon stimulation which contain DNA. 
Furthermore, recombinant FcnB bound to various strains of GBS and to serotype T-5 
of S. aureus.  
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4.4 Complement activation by mouse FcnB 
 
Ficolins trigger the complement activation via the lectin pathway due to complex 
formation with MASPs (Matsushita and Fujita, 1992; Matshushita et al., 2000; Liu et 
al., 2005a; Endo et al., 2010; Girija et al., 2007).  
While various studies were published concerning complement activation by the 
human ficolins, mouse FcnB and its role in the lectin pathway is only poorly 
characterized (Girija et al., 2007). The only investigations in this regard were done by 
the Japanese group around Fujita and Endo (Endo et al., 2005).  
Therefore, one aim of this work was to investigate the role of mouse FcnB in 
complement activation using newly generated tools.  
Complex formations of recombinant mouse FcnA with recombinant mouse MASP-2 
was demonstrated by Endo et al. 2005, while previous studies by the same group 
had shown that recombinant mouse FcnB, also produced by insect cells, failed to 
form complexes with MASP-2 or MAp19 (Endo et al., 2005). In contrast, rat FcnB 
was shown to activate MASP-2 and subsequently initiate the lectin pathway of the 
complement system (Girija et al., 2011). Since mouse FcnB failed to activate the 
lectin pathway of the complement system (Endo et al., 2005) the putative MASP-
binding sites were analyzed in human and in other mammalian ficolins (Wallis et al., 
2011). The results revealed that all ficolins except the mouse FcnB contain an 
aliphatic/hydrophobic amino acid residue within the putative MASP-2 binding site, 
which is located inside the collagen-like region. In contrast, in mouse FcnB this 
amino acid is replaced by a glutamate residue (see Fig. 79) (Wallis et al., 2011). In 
substitution experiments with recombinant rat FcnB by Wallis et al. the mouse FcnB 
residue in this position was replaced by the rat FcnB amino acid which led again to 
activation of the complement system supporting the importance of this amino acid 
shift in the mouse FcnB for complement activation (Wallis et al., 2011).  
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Figure 79: Sequence alignments of the collagen-like domains of ficolins.  
The putative MASP-binding motif (grey shaded) is included within the collagen-like region of the 
ficolin. (Modified after Girija et al. 2007). 
 
However, Endo et al. reasoned that also mouse FcnB should be able to activate the 
lectin pathway because also mouse FcnB seems to be endowed with the required 
amino acid residues for the interaction with MASP-2 (Endo et al. 2005). This is 
conflicting with their former mentioned finding that their recombinant mouse FcnB 
failed to form complexes with MASP-2 (Endo et al. 2005). In this thesis it was clearly 
demonstrated that our S2-expressed mouse FcnB not only bound to recombinant 
human MASP-2 but was also able to activate the lectin pathway of the complement 
system by cleaving human C4 to C4b in a C4 deposition assay by TRIFMA. This was 
shown when FcnB was bound to AcBSA or when it was bound to various bacteria. 
These controversial findings concerning the ability of mouse FcnB to activate the 
complement system by our group and the group of Endo is potentially due to the 
multimeric structure of the used protein. In literature it is discussed that the 
oligomerization of the ficolin is required to be functionally active (Endo et al. 2005). 
Endo et al reported that their recombinant mouse FcnB only forms trimers (Endo et 
al. 2005). We demonstrate in this work clearly that our recombinant protein when 
freshly produced by insect cells exist in oligomers up to 200 kDa and higher 
assuming the formation of hexamers (210 kDa), heptamers (245 kDa) and octamers 
(280 kDa). In Fig. 80 a comparison of the DS-2-expressed mouse FcnB from our 
group as well as FcnB published by the Japanese group is shown after gel 
separation. 
We observed with our recombinant FcnB that it was not stable over time and 
degraded. Higher oligomers of ficolin, however, are necessary for the function of 
those molecules. 
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A)          B) 
                 
 
Figure 80: Oligomeric structure comparison of DS-2-expressed recombinant mouse FcnB.  
Multimerization of recombinant in insect cells produced mouse FcnB (A) under non-reduced 
conditions by our group and (B) under reduced conditions (left) and under non-reduced conditions 
(right) by the group of Endo (Endo et al. 2005).  
  
In summary in this thesis it was demonstrated for the first time that mouse FcnB is 
able to form complexes with MASP-2 and subsequently cleaves C4. Contradictory 
results regarding to the role of mouse FcnB within the complement system are 
probably due to the different oligomerization forms of the used FcnB. Further it was 
remarkable that recombinant mouse FcnB was able to interact with recombinant 
human MASP-2 leading to the assumption that assays using recombinant mouse 
MASP-2 instead of the human orthologue might result in even more efficient C4-
deposition. Sequence homologies between the human and the mouse MASP-2 
revealed at least 83% similarity in their amino acid sequences. 
Recently also a mutated FcnB was produced in our group. Thereby the 
corresponding glutamic amino acid within the putative MASP-2 binding site was 
changed to a alanine, like it is found in rat FcnB. Further experiments with the wild 
type and the mutant FcnB are necessary to determine if this mutant FcnB is more 
effective in complement activation or if the lower efficiency in activating the lectin 
pathway by mouse FcnB compared to its human and rat orthologue is possible due 
to a different role of FcnB in the innate immune system, beside the complement 
activation. 
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5. Summary 
 
The innate immune system contributes day by day to the elimination of invading 
pathogens. The lectin pathway of the complement system is initiated when 
mannose-binding-lectin (MBL) or ficolins interact with MASP-2.  
The aim of the present work was to characterize the mouse FcnB and define its 
function in the innate immune system and especially its role in the complement 
activation. 
Results from this thesis revealed that immature macrophages and dendritic cells as 
well as PMN express mouse FcnB (immature myeloid cells). While inflammatory 
stimuli can clearly enhance the FcnB expression in PMN no further enhancement 
was observed in mature macrophages or dendritic cells from bone marrow cultures 
of wild type mice, but was also seen in dendritic cells derived from mice that lack 
TNFR2.  
Previous results from our group (Runza et al., 2006) were supported by 
demonstrating the presence of FcnB on protein level in lysates of PMN, bone 
marrow-derived macrophages and dendritic cells, using newly generated monoclonal 
antibodies specific for mouse FcnB. In native PMN from Balb/c mice FcnB was 
localized in lysosomal granules similarly as previously found for peritoneal 
macrophages (Runza et al., 2006). In addition, in serum from Balb/c mice FcnB was 
detected. 
Further, binding properties of FcnB to various ligands were investiagted in this 
thesis. Our results indicate that FcnB might act as a potent pattern recognition 
molecule by recognizing sialic acid (present in the glycoprotein fetuin), DNA 
(potentially a target in dying cells) and chitin (potentially a target in fungi). The fact 
that FcnB binds to DNA shown in this thesis might be of importance concerning the 
finding that PMN have stored FcnB and produce NET structures upon stimulation, 
which contain DNA. Furthermore, recombinant FcnB bound to various strains of GBS 
and to serotype T-5 of S. aureus.  
One major function of ficolins is their interaction with MASP-2 what subsequently 
leads to the activation of the lectin pathway. In this thesis it was demonstrated for the 
first time that also mouse FcnB is able to activate the lectin pathway. Contradictory 
results regarding the role of mouse FcnB within the complement system are probably 
due to different oligomerization forms of the used FcnB.  
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All results obtained during this work lead to the conclusion that mouse FcnB plays a 
role in the innate immune system, serving as a pattern recognition molecule for the 
detection of microorganisms and activating the complement system by binding to 
MASP-2, like the other ficolins or MBL. 
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